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Introduction
1.1 Traumatic brain injury
Traumatic brain injury (TBI) is an important public health care problem in the western world. It is one 
of the most common causes of death in young adults and it can affect people’s lives enormously.
TBI is generally defined as an injury to the brain caused by an external physical force.  Often, the 
term ‘head injury’ is used synonymously with TBI. Since ‘head injury’ may refer to injury of the 
skull only, in this thesis the term ‘traumatic brain injury’ is used. 
Symptoms of TBI can be various, depending on the extent of damage to the brain. Specific 
characteristics of TBI, however, are the presence of amnesia and/or a loss of consciousness 
after the injury. In mild TBI, post-traumatic amnesia is an indicator of the severity of the 
injury; in patients with more severe injuries depth and duration of this post-traumatic loss of 
consciousness is a better indicator of the severity. In patients with more severe injuries the level 
of consciousness can be depressed for weeks or months. 
TBI evolves over time1,2. The sudden and often profound mechanical damage that occurs at the time 
of injury is considered the primary damage. This primary damage initiates a complex sequence 
of events, causing secondary damage. Such events may be the development of a haematoma 
in the intracranial compartment or result from pathophysiological mechanisms. Secondary 
damage can be further exacerbated by systemic insults, such as hypoxia and hypotension. 
1.2 Prevalence, etiology and impact
In the USA at least 5 million people (2% of the population) currently live with disabilities 
resulting from TBI, and each year at least 1,4 million sustain a TBI3. Of these, about 50.000 die, 85 
per 100.000 persons are hospitalized and 390 per 100.000 inhabitants are treated and released 
from an emergency department4. In the Netherlands, each year about 60 per 100.000 inhabitants 
require hospitalization and around 90 per 100.000 persons with an age of 20 years or older visit 
the emergency room of a hospital because of a TBI5,6. In 2002 around 950 (6 per 100.000) Dutch 
persons died because of a TBI7.  
The risk of experiencing a TBI is not equally divided among all age groups. Adolescents, young 
adults and persons older than 70 years have the highest risk of TBI (Figure 1). 
In the Netherlands, most persons who visited the emergency room of a hospital because of a TBI 
were injured by a traffic accident (42%). Other main causes of TBI were a fall (35%), an accident at 
home (5%), a sports accident (9%), an accident at work (4%) and a suicide attempt (5%)5.  
The societal costs of TBI can be substantial. In the United States the joint direct and indirect costs 
of TBI are estimated at $56,3 billion in 19958. In the Netherlands, around 9.600 patients were 
admitted to a hospital because of a TBI in 19995,6. The financial burden of direct medical costs 
due to TBI in the Netherlands was calculated to be � 72 million in 1999. These costs exclude the 
number of lost working days (more than 17.000 days). 
1.3 Consequences
The consequences of a TBI on the life of a TBI victim and family can be substantial. Dependent 
on the severity of the TBI, a TBI victim may – sometimes temporarily – suffer from problems 
with cognition (concentration, memory, judgment, mood), movement abilities (strength, 
coordination and balance), sensation (tactile sensation and special senses such as vision) and 
emotional stability3. Social consequences of TBI can also be considerable, including increased 
risk of suicide, divorce, chronic unemployment and economic strain. These consequences are 
tragic, not only to the TBI victims, but also to their relatives. Family members report depression, 
social isolation and anger, and the family life is often disrupted. The social consequences of TBI 
are illustrated by the story of Marco, a TBI victim, who permitted us to describe the impact that 
TBI had on his life (www.nietaangeborenhersenletsel.tk).
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Figure 1. Number of TBI related visits to an emergency department (ED) per 1��� persons per 
age category in the Netherlands in 1���5 
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Personal story of Marco
The accident happened in ��uly 1���. While driving on my scooter, I was hit by a car and 
landed with my head against a house. By ambulance I was brought to a general hospital, 
where I stayed for one day. Subsequently I was transported to the Dijkzigt Hospital in 
Rotterdam. There, I have been in coma for two weeks. In total I have spent four weeks 
in the Dijkzigt Hospital. Afterwards, I have been taken to several rehabilitation centers, 
where I stayed for two months in total. Finally, when I was allowed to go home again, 
I followed daily therapy in a rehabilitation center near my house. 
After the accident, I had to learn everything again�� talking, sitting, walking, and going 
to the toilet by myself, really everything. This was very hard for me and I often wished 
I had never woken up again. I know this sounds cruel, but this is how I felt at that 
moment. Nevertheless, I am very glad that my family and previous girlfriend helped 
me to live further. Happily I am physically more or less healthy again�� I only experience 
some problems with my memory. 
After about two years I went back to my former employer (I used to be a cook at a 
rather high level in the catering industry). I liked working again very much, since I had 
something to do. Together with the GAK and a reintegration company I set up a plan 
to return completely to my old profession. Everything went well, but as soon as I was 
absent for some time, e.g. for a holiday, I had to start all over again. I did not know what 
to do. Since the catering industry was too hectic for me, I started looking for another 
job, together with a work reintegration company. This wasn’t easy, since I had to think 
of my wishes and capabilities. I had (and have) problems with my memory, so not every 
job was and is suitable. Maybe I had to receive a new training. At that time I suffered 
from�� tiredness, forgetting names or things easily, speaking not audibly, feeling angry 
or offended easily, being unable to practice my profession. Before the accident I had 
many friends, but I lost most of them, although nowadays I don’t consider them as my 
real friends. 
I found it really hard to contact ‘unfamiliar’ people, people I did not know before. 
�eople cannot immediately see that I suffer(ed) from TBI, so they often treat me rudely 
or start pestering me. Therefore, I advice other TBI victims to overcome their initial 
hesitation and tell everybody what happened. By telling people they are given the 
opportunity to respond adequately. �eople act differently when they know, although 
some people also start patronizing. 
After performing a test to choose a profession, it appeared that I loved to work with 
computers. Therefore, I started a new training in S�W-�. After having followed this 
training I started working for a foundation. Basically, everything went well, but I still 
experienced too much problems, e.g. with my memory. Now, I am looking for a job that 
I like and that I can handle. I think this will be computerwork.  
1.4 Classification of TBI 
A TBI can be classified according to several aspects, such as mechanism, clinical severity and 
morphology. 
Mechanically, TBI can be classified into closed and penetrating TBI. A closed TBI occurs when a 
blunt object strikes the head or when brain damage results from acute acceleration/ deceleration 
or rotational forces. A compound skull fracture may be present in closed TBI. A penetrating TBI 
occurs when an object, such as a bullet, pierces the skull and enters the brain tissue. 
Both types have a different pathology. Penetrating TBI primarily results in direct damage to the 
cerebral tissue and hemorrhaging from the penetrating object. In closed TBI the resulting brain 
injury may be focal (restricted to one area of the brain) or diffuse (involving different areas of 
the brain). 
To evaluate clinical severity, various grading systems have been developed. The most often 
used system is the Glasgow Coma Scale (GCS)9, which is composed of three parameters, i.e. eye 
opening, motor response and verbal response (Table 1). 
For purposes of classification the scores of the three parameters can be added up, yielding a total 
score between 3 and 15. This total score summarizes the patients’ level of consciousness and 
is used for purposes of classification. At the bedside, however, the individual GCS parameters 
are considered more informative than the total GCS. According to the total GCS, about 80% 
of the TBI patients receiving medical attention can be categorized as mild (GCS 13-15), 10% as 
moderate (GCS 9-12) and 10% as severe (GCS 3-8) at the time of injury10. 
Table 1. Glasgow Coma Scale (GCS)
Eye opening Spontaneously 4
To verbal command �
To pain �
No response 1
Best motor response Obeying commands �
Localizing 5
Flexion withdrawal 4
Abnormal flexion �
Extension �
No response 1
Verbal response Oriented 5
Confused conversation 4
Inappropriate words �
Incomprehensible sounds �
No response 1
Total �-15
12
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The extent of damage can be assessed morphologically with a computed tomography scan (CT 
scan). The CT scan creates a series of cross-sectional X-ray images of the head and brain and can 
show bone fractures, as well as the presence of lesions, contusions and brain tissue swelling. 
Abnormalities on the CT scan are often morphologically categorized according to the presence 
or absence of a ‘mass lesion’ or according to the Marshall CT-classification11 (Table 2). After the 
initial assessment and treatment of the TBI, magnetic resonance imaging (MRI) may be used to 
detect more subtle changes in the brain tissue. 
1.5 Grading outcome
Different scales to grade outcome after TBI are available. One of the most widely used outcome 
scales is the Glasgow Outcome Scale (GOS)12. This is a five level classification scale that assesses 
overall outcome after TBI (Table 3). The scale is often dichotomized into two groups: favorable 
and unfavorable outcome. Favorable outcome includes the categories ‘moderate disability’ 
and ‘good recovery’, while unfavorable outcome includes ‘death’, ‘vegetative state’ and ‘severe 
disability’. Soon after the injury, individual patients move frequently from one GOS category to 
another, but from six months onwards the GOS seems to stabilize13. 
1.6 Prognosis and rationale of this thesis
The outlook for patients with a mild TBI is generally a good recovery, while patients with a 
severe TBI have a substantial risk to die. Predicting outcome for very good or very severe patients 
is therefore rather easy. However, for most severe and moderate TBI patients the outcome is 
not so easy to predict, while such predictions would be helpful. For example, they may support 
clinical decision-making and provide realistic and evidence-based expectations to relatives 
(counseling) and caregivers. Outcome predictions may also be applied to classify patients 
according to prognostic risk, which may be useful to compare outcome between patient series 
from different centers or to study treatment results over time. Furthermore, the design and 
analysis of randomized clinical trials (RCTs) may be improved; prognostic risks may be used to 
define enrollment criteria and for risk-stratification to estimate covariate-adjusted treatment 
effect14-19.
 
Individual outcome predictions can be obtained by prognostic models, created by multivariable 
analysis of patient data, including multiple clinical risk factors (predictors), such as age and GCS. 
By filling in these factors for a specific patient, the model can provide an individual probability 
of an outcome, e.g. the likelihood that the patient will die during the next six months20,21. 
In the past, several multivariable models have been developed with the purpose to predict 
outcome for TBI patients. The methods used for model development, however, are often 
inconsistent or even contradictory, e.g. with regard to the selected predictors and the way 
predictors are included in the model. This may limit the value and potential application of 
the previously developed models. Proper evaluation of prognostic models in TBI requires an 
understanding of issues affecting the design, conduct, analysis, reporting and validation of such 
models. In addition, many models that predict long-term outcome after TBI have been developed 
on relatively small cohorts from one single place or region, so that their applicability – i.e. their 
performance on more recent patients or patients from different centers – is questionable. Also 
the validity of prognostic models in TBI has seldom been evaluated in independent patients. 
These restraints limit the confidence we may have in previously developed prognostic models 
in TBI.
Next to predicting outcome more accurately, it may be useful to predict the need of specialized 
intensive care. Nowadays a high proportion of the severe and moderate TBI patients are first 
transported to a general hospital and later to a level I trauma center (secondary referral). This 
secondary referral may delay the institution of appropriate therapy and increase the risk of 
adverse events and systemic insults during inter-hospital transport. A more efficient triage may 
be aided by early identification of patients in need of specialized intensive care. This may be 
facilitated by the use of prognostic modeling.
Table 2. Diagnostic categories of types of abnormalities visualized on computed tomography 
(CT) scanning
Category Definition
Diffuse injury I No visible intracranial pathology seen on CT scan
Diffuse injury II Cisterns are present with midline shift �-5 mm and/or�� 
– lesion densities present,
– no high- or mixed-density lesion > �5 cc, 
– may include bone fragments and foreign bodies
Diffuse injury III Cisterns compressed or absent with midline shift �-5 mm, no high- 
or mixed-density lesion > �5 cc
Diffuse injury IV Midline shift > 5 mm, no high- or mixed-density lesion > �5 cc
Evacuated mass lesion Any lesion surgically evacuated
Non-evacuated mass lesion High- or mixed-density lesion > �5 cc, not surgically evacuated
Table 3. Glasgow Outcome Scale (GOS)
Score Description
Death
Vegetative state Awake, but not aware
Severe disability Conscious, but disabled
Moderate disability Disabled, but independent
Good recovery Resumption of normal life, even though there may be minor 
neurological or psychological deficits. 
14
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1.7 Objectives of this thesis
This thesis studies the prognosis of patients with a severe or moderate TBI, with a focus on 
predicting long-term mortality and unfavorable outcome, using baseline demographic, clinical 
and CT characteristics. We have the following objectives:
1. To study methodological developments in prognostic modeling in TBI.
 We aim to derive guidelines for model development and validation in TBI, based on a review 
of methodological aspects in previously published prognostic studies in TBI.
2. To develop and validate prognostic models that predict long-term outcome for 
patients with severe or moderate TBI. 
 We use baseline demographic, clinical and CT characteristics to predict six-month 
mortality and unfavorable outcome. The models are validated on the study population 
(internal validation) and on several other TBI cohorts of substantial size (external 
validation). Furthermore, we compared the external performance of our models to that 
of four previously developed prognostic models. 
3. To predict the need of specialized intensive care.
 We investigate the feasibility of predicting the risk of potential operable lesions and the 
risk of raised intracranial pressure. Both outcome measures are indicators of the need of 
specialized intensive care. 
1.8 Patient series
To address the objectives we use five patient series; two multi-center series of patients included 
in randomized controlled trials (RCTs) in TBI, two relatively unselected multi-center series of 
patients and one patient series collected in a single center in the Netherlands (Table 4). 
Multi-center trials: 
• The Tirilazad trials consist of patients included in the International and the North American 
multi-center (phase III) RCTs on the drug Tirilazad Mesylate22 in TBI23. The International 
Tirilazad trial (n=1120) was conducted in 40 centers in Europe, Israel and Australia from 1992 
to 1994 and the North American Tirilazad trial (n=1149) in 36 centers in the USA and Canada 
from 1991 to 1994. Both trials enrolled patients aged 15-65 years, with a severe or moderate 
closed TBI. Patients with an absent motor score or with a moderate TBI and a normal CT scan 
(Diffuse Injury I) were excluded. All patients were admitted to a neurosurgical unit within 
four hours after injury. Recommendations for patient management were similar across the 
centers. 
• The Selfotel trial consists of patients included in the International Selfotel trial (n=427), 
a phase III RCT, investigating the competitive NMDA-glutamate antagonist Selfotel24. The 
trial was conducted in Europe, Canada, Australia and Argentina between 1994 and 1995. 
Enrollment criteria were: age 16 – 65 years, closed TBI with a GCS of 4 to 8, presence of 
abnormalities on the CT scan and at least one reactive pupil. Recommendations for patient 
management were similar across the centers.
Relatively unselected multi-center series of patients:
• The survey by the European Brain Injury Consortium (EBIC) included 796 patients with 
severe or moderate TBI25, consecutively collected between February and April 1995 from 
67 European centers in which the six months outcome (GOS) assessment was routinely 
performed. Patients were admitted within 24 hours after the injury.
• The National Traumatic Coma Data Bank (TCDB) contains data on 746 patients with closed 
severe TBI admitted to four centers in the United States26. Data acquisition occurred from 
1984 to 1988. Patients were included if they deteriorated to a condition meeting enrollment 
criteria within 48 hours after the injury.
Single-center series of patients:
• The ErasmusMC cohort consists of 275 patients with mainly severe or moderate TBI, admitted 
to the trauma center of the Erasmus MC, Rotterdam, the Netherlands, between 2000 and 
2003. 
Table 4. Overview of the patient series used in this thesis
Series N Period data 
collection
Region* No of 
centers
TBI severity# Thesis 
chapter
Multi-center trials 
Tirilazad trial ���� 1��1-1��4 Eur, Aus, N-Am �� sev, mod � - �
Selfotel trial 4�� 1��4-1��5 Eur, Aus, N-Am, S-Am 5� sev �
Unselected multi-center series
EBIC survey‡ ��� 1��5 Eur �� sev, mod �, �
TCDB‡ �4� 1���4-1����� N-Am 4 sev �, �
Single-center series
ErasmusMC ��5 ����-���� NL 1 mainly sev, 
mod
��
* Eur = Europe, Aus = Australia, N-Am = North-America, S-Am = South-America, NL = the Netherlands
# sev = severe, mod = moderate
‡ EBIC = European Brain Injury Consortium, TCDB = Traumatic Coma Data Bank
16
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1.9 Outline of this thesis
Chapter 2 addresses objective 1. In this chapter we review earlier developed prognostic models 
in TBI in order to gain insight into methodological developments in prognostic modeling in 
TBI. This insight is used as a background to our modeling efforts. Furthermore, we propose 
guidelines to develop and validate prognostic models in TBI. 
The chapters 3 till 7 describe five studies to predict long-term mortality and unfavorable 
outcome (objective 2), using baseline demographic, clinical and CT characteristics. The patients 
included in the Tirilazad trials were central to address this research question. Chapter 3 studies 
the characteristics of the Tirilazad patients. In this chapter we also study regional differences in 
patient characteristics, case management and outcome, which may cause variation in outcome 
prediction, independent of demographical and clinical patient characteristics. In chapter 4 and 
5 the optimal way to include well-known and important predictors of outcome are studied. 
Chapter 4 examines the predictor age and chapter 5 studies the prognostic performance of 
the Marshall CT-classification in comparison with alternative easily applicable classification 
including CT characteristics. The purpose of chapter 6 was to develop prognostic models 
that estimates six-month outcome after severe or moderate TBI. These models are validated 
internally and externally on several other TBI cohorts. Chapter 7 describes the external validity 
of prognostic models considered in chapter 2 and 5. We relate the external validity of the models 
developed by us to the external validity of four previously developed models that used baseline 
demographic, clinical and CT characteristics to predict outcome at six months or later after 
severe or moderate TBI. 
Chapter 8 describes an explorative study for characteristics that predict the need for specialized 
intensive care (objective 3). This need was expressed in the risk of potentially operable lesions 
and the risk on raised intracranial pressure (ICP). We developed prognostic models to estimate 
these risks. 
In chapter 9, the main findings of the preceding chapters are summarized and discussed. Finally, 
conclusions and recommendations for further research are given. 
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Systematic review of previously developed models
Abstract
Context
Early prediction of outcome after traumatic brain injury (TBI) is important for several purposes. 
We aimed to review previous TBI studies to gain insight into methodological developments in 
prognostic modeling in TBI. 
Methods
We searched the National Library of Medicine’s PubMed database for relevant publications from 
1966 till July 2004. Studies were selected if they developed a prognostic model with the purpose 
to be used in clinical practice to predict the Glasgow Outcome Score (GOS) – or a categorization 
of it – for patients with severe or moderate TBI. 
Results
We selected 26 papers. Twenty-two studies developed models on relatively small patient series 
(n < 500) or on patient series originating from one single place or region. The type and number 
of candidate predictors varied considerably, with mostly 8 to 20 candidate predictors per model. 
Most studies used a stepwise selection procedure with a p-value < 0.05 to select predictors, which 
resulted in a median of 4 selected predictors. The most frequently used statistical technique was 
(logistic) regression analysis. The handling of missing values was often not reported (18 studies) 
or, if reported, patients with missing values were omitted from the study population. For most 
models only the apparent performance was examined. Seven studies assessed internal validity, 
usually by splitting the development dataset in a derivation- and test-set. External validation 
occurred by computer simulation (1 study) or on more recent patients from the same setting (3 
studies). No models were validated on patients from another place. 
Conclusion
This systematic review highlighted limitations in the development and validation of models that 
predict outcome after TBI. Adherence to modern insights in prognostic research is required to 
improve the validity of outcome predictions. Guidelines for developing and validating prognostic 
models are proposed, which if followed should contribute to improve the quality of prognostic 
modeling and validation in future studies.
Introduction
Outcome prediction after TBI is important for communication with relatives and caregivers, 
for resource allocation and clinical decision-making, and may further be used for classifying 
patients according to prognostic risk and for stratification in clinical trials. Outcome prediction 
is usually not accurately possible with one single risk factor. Multiple risk factors need to 
be considered jointly, preferably in a prognostic model. Such models are usually created by 
multivariable analysis, including several risk factors (predictors), such as age or Glasgow Coma 
Scale (GCS)1. By filling in these factors for a specific patient, the model can provide an individual 
probability of a certain outcome, e.g. the likelihood that the patient will die during the next six 
months. 
Predicting outcome after TBI has been the object of intensive research. In 1976 Jennett et al.2 
explored the possibility of predicting outcome in individual TBI patients by using a prognostic 
model, and many others followed them. Although their work moved this field towards a more 
realistic statistical base and away from clinical guesswork, prognostic models in TBI have not 
had a widespread impact on the clinical management of TBI patients. Partly, this may be caused 
by the fact that clinicians are not familiar with prognostic modeling, but – probably more 
important – the validity of prognostic TBI models has not been demonstrated clearly. Clinicians 
may also feel reluctant to use outcome predictions for clinical decision-making, e.g. treatment 
limiting decisions. 
In this study, we systematically review previous TBI studies to gain insight into methodological 
developments in prognostic modeling in TBI. We also evaluate the quality of the used development 
and validation methods by comparison with recently developed methodological standards. We 
conclude with a proposal for guidelines on sensible development and validation strategies for 
prognostic modeling in TBI.
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Methods
We searched for relevant medical publications, using the National Library of Medicine’s PubMed 
to access the MEDLINE database (period: 1966 – 2004). Tracking citations in the reference lists of 
the selected papers retrieved additional papers. For PubMed the following key words were used: 
‘prognosis’ or ‘prediction’, ‘model’ or ‘prediction rule’, ‘mortality’ or ‘outcome’ or ‘Glasgow 
Outcome Score’(GOS) and ‘head injury’ or ‘traumatic brain injury’. Studies were selected if they 
complied with the following criteria: 
1) a prognostic model was developed, using multiple clinical characteristics to predict 
outcome of patients with severe or moderate TBI; 
2) the model predicted GOS or a (dichotomized) categorization of it, such as mortality;
3) the model was developed with the purpose to be used in clinical practice; 
4) the study was published in the English language. 
A data extraction form was designed to collect the required information. We focused on five 
subjects, i.e. study population (number of patients, inclusion criteria, period data collection, 
place data collection), predictors (number and type of candidate predictors, number and type 
of selected predictors, coding of the predictors, time-point assessment predictors), outcome 
(coding of the GOS, time-point assessment outcome), model development (type of model, way of 
selecting predictors, handling missing predictor values, used performance measures) and model 
validation (type of validation(s), number and origin of patients used for external validation). One 
reviewer (C.H.) extracted all the data. For articles reporting more than one prognostic model, 
preference was given to the most extensive model that fulfilled the criteria mentioned above.  
Statistical terms, relevant for prognostic modeling and used in this study, are explained in the 
Glossary.
Results
Of more than 100 studies initially considered, 262-27 were selected for detailed assessment of 
development and validation aspects. Below, we present the methodology of these 26 studies 
according to five subjects, i.e. patient series used for developing the model, (candidate) predictors, 
predicted outcome measure, statistical techniques used to develop the model and validation 
aspects. In several studies more than one model was presented. 
Study population
Many studies (11 of the 26) developed models on patient data collected more than 20 years ago 
(end of data collection < 1985) (Table 1). Twenty-two of the 26 publications developed models 
on relatively small patient series (< 500 patients). The largest study population consisted of 799 
patients20. Furthermore, study populations often originated from one single place or region; 
only 4 patient samples originated from multiple centers and only 2 from multiple countries. 
The study populations always consisted of patient series, collected in hospitals (cohorts), but the 
inclusion criteria varied considerably. For instance, Quigley et al.21 selected only patients with a 
GCS ≤ 5, while Andrews et al.26 selected all patients with a GCS ≤ 12, or a GCS > 12, provided that 
the Injury Severity Score was above 15. 
Predictors
The number of candidate predictors for inclusion into a prognostic model varied considerably 
among the models and could be very large; up to 82 candidate predictors were considered20. 
Mostly, the number of candidate predictors varied between 8 and 21.  
Also the number of chosen predictors varied considerably among the previously developed models 
(Table 2). For several models, such as the models developed by Narayan et al.7 and Schreiber et 
al.25, selection was based on univariable p-values of the predictors. For other models all candidate 
predictors were included into the model without further selection, which sometimes resulted 
in many included predictors, e.g. 12 predictors in the model by Stablein et al.5. Most studies 
(n=16) used a forward or backward stepwise selection procedure to select predictors. During this 
procedure a p-value of 0.05 or, incidentally, a p-value of 0.10 (model by Combes et al.19) was used. 
The median number of selected predictors was four. Some model developers included more 
complex characteristics. For instance, Narayan et al.7 included motor evoked potentials.  
Several predictors were included in nearly all models (Table 3). Age is one of them; 22 studies 
included this predictor. Other predictors that were often included are the GCS, or one or more 
of its components (all studies), pupillary reactivity (17 studies) and computerized tomography 
(CT) scan abnormalities (17 studies). The coding of predictors varied among studies. For instance, 
Stewart et al.3 included age as a dichotomous variable (below or above 55 years) while Signorini 
et al.23 included age as a piecewise transformation, that is, no effect of age until 50 years and a 
continuous linear effect above this age.
– continues on page 30 –
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Additionally, predictors were often measured at different time-points, e.g. before admission to 
a neurosurgical unit or after three days (Table 2). Fourteen models used predictors that were 
assessed at the place of injury or at admission to the hospital. For three models predictors were 
assessed relatively late, i.e. between 7 to 28 days after injury. 
Outcome
Inherent to the criteria used for selecting papers for this review, all TBI models predicted 
mortality, the GOS28 or a categorization of the GOS. Nineteen studies dichotomized the GOS, 
although different dichotomizations were used. As shown in table 1 the time of assessing the 
outcome measure varied from ‘discharge’ or 48 hours to 24 months post-injury. 
Model development
Several statistical techniques were used to develop prognostic TBI models (Table 2). Before 1990 
several models have been developed with discriminant analysis. Later on, this technique was 
replaced by (logistic) regression analysis. Next to (logistic) regression (15 studies), models were 
also constructed with recursive partitioning (tree) (n = 2). Incidentally, other methods, such as 
neural networks20, were used to develop a model. 
Most statistical techniques cannot accommodate missing values. Often, the articles did not 
mention how patients with missing data were handled. If mentioned (6 studies), patients with 
missing data were omitted, so that the models were developed on patients with known values 
for all considered predictors (Table 2).
To assess performance, many measures were used. In the past, performance of TBI models has 
often been expressed in the accuracy rate or – its complement – the error rate (Table 2). Other 
often-used measures were sensitivity, specificity, false positive rate and false negative rate. The 
area under the receiver operating characteristic curve (AUC) and, incidentally, a goodness-of-fit 
test were used to determine performance of more recent models.
Model validation
For most models only the apparent performance was examined. Seven studies assessed internal 
validity, usually by splitting the development dataset. For instance, Choi et al.12 used 2/3 of the 
patients to develop the model, and the left 1/3 of the patients to assess its internal validity. 
Only the models by Choi et al.8, Gibson et al.14, Signorini et al.23 and Pillai et al.27 were externally 
validated. External validation occurred by computer simulation8 or on more recent patients 
from the same setting14,23,27. No models were validated on patients from another place. 
Discussion
Study population
Several models were developed on patient series collected more than 20 years ago. These models 
may be not useful, since diagnostic and therapeutic management have changed considerably 
since that time. For instance, the CT scan has taken a central role in current clinical practice. 
Furthermore, most models were developed on relatively small patient series. Consequently, the 
precision to quantify a prognostic model was rather small and generalizability of the developed 
model may be limited. The fact that the study population often originated from one single place 
or region may also limit generalizability of the model. 
Predictors
Overfitting
The number and type of chosen predictors varied considerably among the previously developed 
models. Five studies included all candidate predictors (Table 3). Since -in the field of TBI- many 
candidate predictor variables have been suggested, including all of them may be attractive. From 
a prognostic point of view, however, including many predictors may not be very sensible. Some 
candidate predictors may be strongly correlated with each other, so that part of them adds 
little prognostic value. Furthermore, including too many potential predictors may introduce 
overfitting, such as occurred in the model developed by Signorini et al.23,29. At validation of the 
model by Signorini et al.23 on a more recent group of patients than the study population, the 
Hosmer-Lemeshow statistic showed a significant lack of calibration (p<0.0001), with an overly 
pessimistic prediction in the patients with a poor prognosis but also a too optimistic prediction 
for patients with a better prognosis. This phenomenon is typical for ‘overfitting’. Overfitting can 
be limited by several procedures. One of them is that, as a rough estimate, no more than m/10 
predictor degrees of freedom (df) should be analyzed to construct a multiple regression model, 
where m is the number of events (for example, deaths)30,31. For instance, in the study population 
used by Signorini et al.23 87 patients died within 1 year. Consequently, less than 87/10 = 8.7 df 
could be examined in the analysis without risk of overfitting (see Appendix). 
Definition
Next, it is important that candidate predictors can be defined precisely and that their value is not 
substantially influenced by any treatment or therapy. Variables as age and cause of injury are 
unambiguous. A problem with the CT classification, however, is that it differentiates between 
patients with evacuated and patients with non-evacuated mass lesions. Many have argued that this 
reflects a clinical decision and does not in itself constitute a CT parameter, and in clinical practice 
this has led to confusion. Furthermore, TBI patients are more and more frequently paralyzed and 
intubated, by which especially the verbal- and eye score of the GCS become not interpretable. 
Consequently, these predictors should preferably not be included in prognostic TBI models. 
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Predictors were often measured at different time-points (Table 2). This hampers comparison of 
the performance of the different models, since measurements performed at a later time may be 
expected to correlate better with the outcome4. Which time-point is appropriate depends on the 
aim of the model. 
Furthermore, complex predictors, such as motor evoked potentials7, may have substantial 
predictive power, but are not always practical and easily obtainable in emergency situations. 
Outcome
All TBI models considered here predict mortality or (a categorization of) the GOS. Both outcome 
measures are relatively easy to define and measure, and represent clinically relevant endpoints. 
Mortality is unambiguous, but for the GOS some degree of inter-observer variability has been 
reported32. This inter-observer variability may partially be diminished by using a structured 
interview during assessment33. 
The time of assessing the outcome measure varied considerably, i.e. from ‘discharge’ to 24 
months post-injury. Early outcome measures are less stable, making several prognostic models 
clinically less relevant. From 6 months onwards GOS measurements are considered constant34. 
Model development
Statistical techniques
Several statistical techniques were used to develop prognostic TBI models, such as discriminant 
analysis, logistic regression analysis, neural networks and recursive partitioning. 
Compared to discriminant analysis logistic regression analysis requires fewer assumptions in 
theory (independent variables do not need to be normally distributed, linearly related, or have 
equal within-group variances), is more statistically robust in practice, handles categorical as 
well as continuous variables and has coefficients which many find easier to interpret. Next to 
logistic regression, recently developed models were also constructed with recursive partitioning 
(2 models) and, occasionally, neural networks (1 model) (Table 2). Although logistic regression, 
recursive partitioning and neural networks each have their own advantages and drawbacks, 
their performance is generally similar35-38. 
Selection and inclusion of predictors
Many TBI models that were developed with stepwise selection techniques used a p-value of ≤ 
0.05 to select predictors. Such a p-value is stringent and may lead to the exclusion of many -also 
informative- characteristics, especially in small development samples. Higher p-values, for instance 
p-values of 0.20 or 0.50, have been advocated to increase the external validity of the model39. 
Also the way predictor variables, e.g. age, are included in the models varied greatly. From a 
prognostic point of view, coding of predictor variables should be as detailed as possible, since 
categorization of predictors often leads to loss of information. On the other hand, categorization 
of predictor variables may diminish complexity of the model and improve implementation in 
clinical practice. 
Missing values
Missing predictor values form a common problem in prognostic studies. They can introduce 
bias, depending on the missing data mechanism and the adopted missing data approach. In 
TBI models patients with missing predictor values were mostly omitted, so that the models 
were developed on complete cases only. Such an approach assumes that the missingness in the 
predictors is not associated with the outcome40. This assumption, however, is often not realistic. 
Furthermore, patients with missing values usually miss only one or a few of the predictor values, 
so that dropping incomplete patients leads to a waste of precious information available in the 
other predictor variables and the outcome31,41. 
Patients with initially missing predictors can be preserved for analysis by considering the missing 
data as a separate category42, by single imputation43, in which a single value is substituted for 
each missing value, and by multiple imputation44,45, where several independently completed 
data sets are obtained. 
Performance measures
Before a model can be used in clinical practice, its performance needs to be appropriate. Three 
aspects of validity can be distinguished; clinical usefulness, calibration and discrimination. Most 
of the reported performance measures, i.e. accuracy rate, error rate, sensitivity, specificity, false 
positive rate, false negative rate, determine the clinical usefulness of a model. The accuracy rate 
and the error rate have been used to assess performance of most, and especially older, TBI models. 
Currently, the accuracy rate is generally considered inappropriate for validation purposes, because 
this rate is greatly influenced by the outcome distribution of the patient series. For instance, in a 
representative TBI patient population with an average mortality of 20 percent, the accuracy rate 
will already be 80 percent if all patients would be labeled as survivors. In patient series with such a 
skewed outcome distribution, high accuracy rates are typical. An exception is the model by Lannoo 
et al.24; this model reported a high accuracy rate (93%) while the mortality rate was 51%.
Nowadays, the performance of prognostic models is often expressed with respect to calibration and 
discrimination. In contrast to measures of clinical usefulness, calibration and discrimination measures 
evaluate the performance of a prediction model over the whole range of predicted probabilities.
Although the performance of most models was sufficient to high, this performance was often 
assessed only at apparent validation, sometimes even on part of the study population.
Model validation
The purpose of a prognostic model is to provide valid outcome predictions to new patients. 
Therefore, it is essential that the validity of a model is assessed. Before a model can be 
implemented safely in clinical practice, all different types of validation – apparent, internal and 
especially external validation – need to be satisfactory.  
For most models only the apparent validation was examined (Table 1). The major drawback of 
assessing only this type of validation, however, is that the assessment will always be optimistic, 
since both development (estimation of regression coefficients, selection of predictors) and 
testing are performed on the same patients. 
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For few models the internal validity was assessed, usually by splitting the dataset. The major 
disadvantage of data splitting, however, is that only part of the patients is used for model 
development and only part for model validation. Statistically more efficient techniques, that 
uses all available patients for model development while also the internal validity can be assessed, 
are re-sampling methods, such as bootstrapping31,39,46. 
External validation of models is essential to support general applicability47. When simply 
tested on the development patients, the (apparent) performance may be excellent. However, 
when testing on new patients the performance of the model may be considerably poorer48. 
Surprisingly, only four model developers8,14,23,27 performed an external validation of their model. 
External validation occurred, however, only on more recent patients from the same setting, 
while – besides time aspects – also place aspects may affect the external validity of a prognostic 
model. For instance, other medical centers may treat patients with different characteristics, 
such as more severe patients. A model that is valid for patients from one single place (specific 
‘case-mix’) is not automatically valid for patients from another place. Therefore, a model should 
preferably be repeatedly validated on various patient series, differing in time and place. 
Quality of used development and validation methods in TBI modeling
This review has highlighted important limitations in the methods used to develop and 
validate previous prognostic models in TBI. Many studies were limited by old, small and 
relatively homogeneous study populations and the way predictors were obtained and selected. 
Furthermore, rather crude statistical methods were used. In the majority of the studies the 
extent of missing predictor values was not reported and, if reported, patients with missing 
values were omitted. Additionally, validation was often only performed on the study population 
itself and the performance was only seldom tested on new patients from another time and not 
on patients from another place. 
Partly the methodological deficiencies can be explained by the fact that most models have been 
developed many years ago. Especially in the last decade knowledge about methodological aspects 
of prognostic modeling, such as bootstrapping, has considerably increased30,31. 
Before a prognostic model is widely accepted and applied clinically, we believe attention should 
be paid to a number of checkpoints. In table 4 we propose guidelines for good prognostic 
modeling and validation. These guidelines are based on the findings described in this article, 
but also on other modeling studies30,49-54 and on practical considerations. 
In conclusion, it is evident that quality in the development and validation methods used for 
prognostic modeling in TBI can be improved, especially with respect to procedures for predictor 
selection, dealing with missing predictor values, and validation. The proposed guidelines for 
developing and validating a prognostic model, if followed, should contribute to improve the 
quality of prognostic models and valid outcome predictions in future patients.  
Table 4. Guidelines for developing and validating prognostic models in TBI
Study population • large and well-defined cohort of consecutive patients
• heterogeneous, i.e. including a clinically broad spectrum of patients from 
multiple centers 
• representative for current clinical practice
Predictors • plausible, based on previous studies and expert opinion
• precisely defined (in order to minimize inter-observer variability)
• readily available or easily obtainable 
Outcome • relevant for clinical practice
• precisely defined
• measurable with minor observer variability 
Model development • use of appropriate statistical techniques to model prediction-outcome 
relationships and to deal with missing predictor values
• use of sensible performance measures, evaluating calibration and 
discrimination aspects
• presentation in a readily applicable format
Model validation • internal validation
• external validation on patients managed by different protocols or at 
different times and places 
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Glossary
Accuracy rate and error rate
The accuracy rate is defined as the proportion of patients with a certain outcome that was 
predicted correctly, whereas the error rate is equal to 1 minus the accuracy rate. 
Area under the receiver operating curve 
The area under the receiver-operating curve (AUC) is often used to quantify the discriminative 
ability of a prognostic model, developed with logistic regression analysis. The receiver-operating 
curve is a plot of the sensitivity versus the false positive rate (or 1-specificity), evaluated at 
consecutive threshold values of the predicted probability. The AUC evaluates whether those 
patients with higher predicted risk are more likely to have a poor outcome (mortality/unfavorable 
outcome) among all possible pairs of patients with different outcomes. A model with an AUC 
of 0.50 has no discriminative power at all (such as a coin flip), and an AUC of 1.0 reflects perfect 
discrimination30,31.
Bootstrap validation
Bootstrap validation involves drawing samples of patients with replacement from the 
development sample. Each sample can be considered as if one is repeating the data collection 
with the same number of patients and under identical circumstances as the original. Regression 
models were estimated in each of the bootstrap samples and evaluated on the original sample. 
The average difference in performance indicated the optimism (overfitting)30,31. Subsequently, 
the coefficients can be corrected (shrunk) for predictive purposes. In this way, nearly unbiased 
predictions of the outcome can be obtained for future but similar patients30,31,39. 
Calibration
Calibration (or reliability) refers to the agreement between the observed outcome frequencies in 
the data and the predicted probabilities of the model. For example, if a group of patients (with 
certain characteristics) are predicted to have a 10% chance of mortality, the actually observed 
mortality of this group should on average be 10%. 
Clinical usefulness
Clinical usefulness refers to the ability of the model to improve the decision making process. 
For instance, determining which patients have such a high risk of developing raised intracranial 
pressure or a potentially operable lesion that they need to be admitted to a specialized 
neurosurgical trauma center. 
Discriminant analysis
Discriminant analysis is a technique for classifying a set of observations, e.g. a patient population, 
into predefined groups (classes). The purpose is to determine the class of an observation (patient) 
based on a set of characteristics (predictors). The basic idea underlying discriminant analysis is 
to determine whether groups differ with regard to the mean(s) of the predictor(s), and then to 
use these predictors to prognosticate group membership58. Accordingly, an attempt is made to 
maximize between group variance while minimizing within group variance. 
 Appendix
Letter regarding the model developed by Signorini et al.23; Predicting survival using simple clinical 
variables: a case study in traumatic brain injury
Signorini et al.23 developed a prognostic model to predict survival at 1 year for patients with 
traumatic brain injury. A strong point is that this model uses variables, which are easy and 
cheap to measure. A thorough statistical analysis was performed, including tests for goodness-
of-fit and checks for influential observations. The model was also validated externally in a more 
recent group of patients. However, during the external validation the Hosmer-Lemeshow statistic 
showed a significant lack of calibration (p < 0.0001). This implies that the model does not give 
accurate predictions of the survival of ‘new’ patients. The lack of calibration is especially due to 
an overly pessimistic prediction in the patients with a poor prognosis but also to a too optimistic 
prediction for patients with a better prognosis (Figure 2)23. This is typical for ‘overfitting’—that 
is, that a model tends to predict too extreme probabilities in new patients. Overfitting can be 
limited by several procedures. One of them is that, as a rough estimate, no more than m/10 
predictor degrees of freedom (df) should be analyzed to construct a multiple regression model, 
where m is the number of events (for example, deaths)30. As 87 patients died within 1 year, 87/10 
= 8.7 df could be examined during the course of analysis without risk of overfitting. In the paper 
6 df were used by the final multivariate prognostic model. However, age was fitted as a piecewise 
linear variable after using a generalized additive model, requiring an unknown number of df, 
but always more than one. Furthermore, we assume that easy to achieve variables such as sex (1 
df) and cause of injury (3 df) were considered but dropped during model construction. Also some 
of the candidate variables originate from combined variables when, after initial assessment, 
it seemed that some categories could be collapsed. Altogether this means that probably much 
more than 8.7 df were examined. The overfitting could have been corrected by multiplying each 
regression coefficient in the model with a shrinkage factor. This factor can be estimated by a 
heuristic formula55, by cross validation, or by a bootstrap re-sampling procedure. This can be 
done with the Design library56, which was already used by the authors. The shrinkage factor 
is close to unity when there is no overfitting. When the selection of predictors is unstable or 
predictors have small effects, a lower shrinkage factor might be found— for example, 0.8. We 
regret that the model is presented as giving ‘reasonable accurate predictions of long term 
survival’, especially because the external validation showed a significant lack of calibration. 
Correction with a shrinkage factor would have resulted in a recalibration of the probability 
of survival in the nomogram presented in the paper (Figure 3)23 and in the formula used in a 
subsequent paper57. We hope that modern modeling techniques will increasingly be applied in 
clinical prediction problems such as traumatic brain injury, such that prognostic models are 
developed that reliably support the physician in clinical decision-making.
C.W.P.M. Hukkelhoven
M.J.C. Eijkemans
E.W. Steyerberg
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Discrimination
Discrimination refers to the model’s ability to separate patients with different outcomes. A good 
discriminating model for mortality will predict high probabilities for patients who die and low 
probabilities for patients who survive. Discrimination is often quantified by the area under the 
receiver operating characteristic curve (AUC). 
False positive rate and false negative rate, sensitivity and specificity
The false positive rate is the proportion of patients who are actually negative (e.g. survive), but who 
are classified by the model as positive (e.g. outcome death), whereas the false negative rate is the 
proportion of patients who are who are actually positive, but predicted as negative (Figure 1). 
Sensitivity refers to the proportion of patients with the outcome (e.g. favorable outcome) who 
are correctly classified by the model as having the outcome. Specificity refers to the proportion 
of patients without the outcome who are correctly classified by the model as not having the 
outcome (Figure 1).
Figure 1. Calculation of false positive rate, false negative rate, sensitivity and specificity
Outcome
Yes No
Outcome
Prediction
Yes a b False positive = b/ (b + d) 
False negative = c/ (a + c)
No c d Sensitivity = a/ (a + c)
Specificity = d/ (b + d)
Goodness-of-fit test
Goodness-of-fit tests are used to test the calibration of a prognostic model. An example of such a 
test is the Hosmer-Lemeshow goodness-of-fit test for logistic regression analysis59, which assesses 
agreement between predicted and observed risks over the full range of predicted probabilities. 
Patients are often grouped per decile of predicted risk to perform the test, which means that 
each group contains 10% of the patients.
Imputation, single and multiple
Single and multiple imputation approaches assume that the missingness of data is related to 
the observed data (the other predictors), but does not depend on unobserved data or values of 
the predictors itself. A simple method of single imputation is to use the median or mean of the 
predictor for the missing values, while a more complex method is to estimate the missing values 
by using regression models including the values of the other predictors. However, if a large 
proportion of the values is missing, single imputation may overstate the available sample size, 
leading to an underestimation of the variance and hence too narrow confidence intervals and 
more significant p-values45. Multiple imputation may then be a statistically better approach44. 
On the other hand, if only a small part of the predictors is missing, multiple imputation will give 
similar results to single imputation. 
Logistic regression
Logistic regression is a frequently used statistical method in prognostic research. It relates one 
or more characteristics (predictors) of patients (X = {X1 … Xk}) to an outcome (Y) by multiplying 
the characteristic(s) with regression coefficients (β = {βi … βk}). These regression coefficients 
represent the strength of the association between a patient characteristic and the outcome. 
The outcome variable is also called the dependent variable and the predictors the independent 
variables. 
In logistic regression analysis the outcome variable is generally dichotomous, that is, the 
outcome variable can take the value 1 with a probability of outcome p, or the value 0 with a 
probability of other outcome 1-p. 
The relationship between the predictor and outcome variable is defined by the logistic regression 
function, which is the logit transformation of the probability of the outcome given predictor X 
(p(X)):
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where α = the intercept of the model (constant), βi the array of regression coefficients and Xi 
the array of patient characteristics (predictors).
An alternative form of the logistic regression equation is:
	 Logit [p(X)] = log [p(X)/(1-p(X))] = α + β1X1 + β2X2 + … + βkXk
where α, βi and Xi defined as above.
A logistic regression model is usually estimated with maximum likelihood methods, assuming 
that the outcome Y follows a binomial distribution.
Neural networks
Artificial neural networks are mathematical structures designed to mimic the information 
processing functions of a network of neurons in the brain60,61. The network is composed of a 
large number of interconnected units (neurons) working in parallel. 
The most common neural network model is the multilayer perceptron (Figure 2). In this type of 
network, the neurons are arranged in a layered configuration containing an input layer, usually 
one ‘hidden’ layer, and an output layer. The values of input variables (e.g. patient characteristics) 
are imported into the network via the input layer and multiplied with the weights of the 
connections. These multiplied values constitute the input of the next (hidden) layer, from where 
the process is continued to produce the output variables (e.g. risk of mortality) in the output 
layer.	
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Figure 2. Multilayer perception
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A neural network does not use any preliminary information about the links between the input 
and output variables; the relationships between input and output variables are determined by 
the data. Neural networks learn by example; the errors from the initial prediction of the first 
record (e.g. patient) are fed back into the network and the weights are adjusted to minimize the 
error the second time around, and so on for many iterations. The process from input to output 
layer is repeated many times. The hidden layer makes the network more flexible by enabling it 
to recognize more patterns, compared to a logistic regression model. A neural network without 
a hidden layer and with one output variable is equivalent to a logistic regression model.
Recursive partitioning
Recursive partitioning62 is a method to construct binary trees. The method is based on statistically 
optimal splitting (partitioning) of the patients into pairs of smaller subgroups. Splits are based on 
cut-off levels of the predictors, which produce maximum separation among two subgroups and 
a minimum variability with these subgroups with respect to the outcome. The predictor causing 
the largest separation is situated at the top of the tree, followed by the predictor causing the next 
largest separation, and so on. For instance, in the tree developed by Choi et al.15, the patients are 
first split on the basis of their pupillary response; patients with a bilaterally normal response are 
separated from patients having unilaterally or bilaterally absent responses. Thus, the predictor 
pupillary response causes largest separation when dividing the population into two subgroups. 
Splitting continues until the subgroups reach a minimum size or until no improvement can 
be obtained. As the full tree developed may be too complex it is usually pruned using cross-
validation to prevent overfitting. Prediction of outcome for a patient is accomplished by simply 
running that patient down the prediction tree, according to the values of the predictors. 
Overfitting
Overfitting can be defined as the tendency of models to perform very well on the development 
population, but to predict too extreme probabilities in new patients. Overfitting can be (partly) 
corrected by multiplying each regression coefficient in the model with a shrinkage factor. 
This factor can be estimated by a heuristic formula55, by cross validation, or by a bootstrap 
resampling procedure. The latter can, for instance, be performed easily with the Design library56. 
The shrinkage factor is close to unity when there is no overfitting. 
Stepwise selection 
In stepwise selection candidate predictors are added (forward stepwise selection) or deleted 
(backward stepwise selection) to assess their additional prognostic value. A candidate predictor 
is usually selected if its additional prognostic value is statistically significant.
Validity
Various types of validity are distinguished; 
a) apparent validity, in which model validity is assessed on exactly the same patients as 
used to develop the model, 
b) internal validity, in which model validity is assessed on patients similar to those from 
the development population, for example by using bootstrapping, 
c) external validity, in which model validity is assessed in patients from another setting, 
time or place.
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Abstract
Object
Regional differences have been shown in patient characteristics and case management within 
multiple unselected series of patients suffering from traumatic brain injury (TBI). One might 
expect that such regional heterogeneity would be small in a more selected population of a 
randomized clinical trial. The goal of this study was to examine what regional differences in 
patient characteristics, case management, and outcomes exist between continents and among 
countries within a patient population included in a randomized clinical trial. 
Methods
Data were extracted from two concurrently conducted randomized clinical trials of the drug 
tirilazad; the designs of these studies were similar. The studies included 1701 patients with 
severe and 476 patients with moderate TBI. Differences were primarily investigated between 
studies performed in Europe and North America, but also among European regions and between 
Canada and the United States. Associations among regions and outcomes (6-month mortality 
rates and Glasgow Outcome Scale scores) were studied using multivariable logistic regression 
analysis.
Results
Comparisons between continents and among regions within Europe showed differences in 
the distribution of patient ages, causes of injury, and several clinical characteristics (motor 
score, pupillary reactivity, hypoxia, hypotension, intracranial pressure [ICP]), and findings on 
computerized tomography scans. Secondary referrals occurred 2.5 times more frequently in 
Europe. Within Europe secondary referral was mainly associated with an increased proportion 
of patients with mass lesions (46% in the European Study compared with 40% in the North 
American Study). Therapy for lowering ICP was more frequently applied in North America. 
After adjustments for case-mix and management, mortality and unfavorable outcomes were 
significantly higher in Europe (odds ratios = 1.58 and 1.46, respectively). Significant differences 
in outcome between regions within Europe or within North America were not observed.
Conclusions
Despite the use of a strict study protocol, considerable differences in patient characteristics and 
case management exist between continents and among countries, reflecting variations in social, 
cultural, and organizational aspects. Outcomes of TBI may be worse in Europe compared with 
North America, but this finding requires further study.
Introduction
Traumatic brain injury is a heterogeneous disease that affects patients with wide ranges of 
clinical severity and varying clinical symptoms. General surveys1-3 and studies on unselected 
series4-6 have reported that differences in patient characteristics, demographics and management 
are partly caused by regional factors. 
Within more selected series, such as a randomized clinical trial, the population is more clearly 
defined by inclusion and exclusion criteria. Recommendations for basic case management and 
therapeutic approaches serve to minimize treatment variability. These factors may be expected 
to result in a more homogeneous patient population, in which regional differences in patient 
characteristics, management, and outcomes are diminished. Nevertheless, heterogeneity of the 
population has been proposed as one factor contributing to difficulties in demonstrating the 
efficacy of new therapeutic agents or approaches in the field of TBI7,8.
The purpose of the present study was to examine the contribution of regional factors to the 
possible heterogeneity of a patient population included in a randomized clinical trial. We studied 
regional differences in patient characteristics (demographics and clinical characteristics), causes 
of injury, case management (referral policy and treatment), and outcomes in 2177 patients 
included in the tirilazad trials conducted in patients with TBI9. Because these two trials were 
conducted within the same period of time (1991 – 1994) and according to largely similar 
protocols, they offer the opportunity to study differences between and within North America 
and Europe without the interference of external circumstances, such as variation in recruitment 
criteria, definitions of variables, or changes in case management over time. 
Clinical material and methods
Patient population
All patients included in this study had been enrolled in one of two multicenter prospective phase 
III randomized clinical trials on the use of the drug tirilazad for TBI. One trial was conducted 
in North America from 1991 to 1994 (NAS) and the other in Europe, Israel, and Australia from 
1992 to 1994 (ES). The inclusion and exclusion criteria were virtually identical. In both trials the 
patients who were enrolled were 15 to 65 years of age and had endured a severe (Glasgow Coma 
Scale [GCS] 4-8) or moderate (GCS 9-12) closed TBI. The proportion of patients with moderate 
TBIs was 15% in the study comprising Europe, Israel, and Australia, whereas this proportion 
was 30% in the North American trial. These proportions were attributed to requirements in the 
protocol and therefore were not a result of regional variation in the patient population. In the 
former study patients suffering from moderate TBI, in whom the computerized tomography 
(CT) scan revealed normal findings, were excluded, whereas the NAS patients, in whom the CT 
scan yielded a normal finding and the GCS motor score was 5 or 6, were only excluded if their 
blood alcohol level exceeded 0.2 g/dl. All patients were admitted to the neurosurgical trauma 
center within four hours after injury. Recommendations for case management, especially those 
for intracranial pressure (ICP)-lowering therapy, were similar across trials. Participating centers 
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included neurosurgical trauma centers involved in teaching and research related to trauma 
care. In both trials the efficacy of tirilazad mesylate, an aminosteroid medication that displays 
an anti-oxidant effect10, was studied against that of placebo. Details on the international tirilazad 
trial have been reported9. 
In neither trial was a significant difference between the tirilazad- and placebo-treated groups 
shown for the primary outcome measure (Glasgow Outcome Scale [GOS]11 score 6 months after 
injury). Therefore, data from both treatment groups were combined in the present analysis. 
Data extraction
Data pertaining to the first 24 hours after injury were extracted on the following items: patient 
demographics (age and sex); causes of injury; clinical characteristics (GCS score, hypoxia, 
hypotension, and pupillary reactivity – all determined before or at admission to the neurosurgical 
trauma center – and maximum ICP within the first 24 hours after injury. [Pupillary reactivity 
was differentiated as ‘both pupils reactive’, ‘one pupil reactive’ or ‘no pupillary reactivity’]); 
characteristic appearance of the CT scan (CT scan classification12, status of basal cisterns, and 
presence of a traumatic subarachnoid hemorrhage (SAH), mass lesion or a midline shift. [Because 
observer variation may occur in distinguishing between the CT scan classes of ‘mass lesion 
evacuated’ and ‘mass lesion not evacuated’, we combined both categories into the classification 
‘mass lesion’]; referral policy and early case management (use of ICP-lowering therapy and time 
intervals between injury and referral to the study center, acquisition of a CT scan, or performing 
a surgery); the number of patients included in each center; and outcomes, that is, mortality 
and unfavorable outcome (severe disability, vegetative state, or death according to the GOS) 6 
months after injury. A GOS measurement between 5 and 7 months after injury was considered 
to be a measurement at 6 months. For 16% of North American patients and 6.7% of European 
patients, the GOS was measured outside the time interval of 5 to 7 months after injury. For these 
patients outcome was imputed according to a specific algorithm, in which GOS values at other 
points in time were considered. This algorithm reduced the frequency of missing GOS scores 
to 9.6% in the North American population and 3.4% in the European population. The detailed 
algorithm is presented in the Appendix.
Regional differences
Regional differences in patient demographics, clinical characteristics, referral policy, and case 
management approach were studied between Europe and North America for both severe and 
moderate TBI. Patients enrolled in Australia and Israel were not included in the present analysis 
of intercontinental differences because of the relatively low numbers (64 patients in Australia 
and 28 in Israel). For analysis of differences among regions within Europe, the countries were 
grouped together by geographic location if the numbers of patients in individual countries were 
judged insufficient for a country-based analysis. Patients enrolled in Switzerland (23 patients) 
were excluded from this analysis because the policies in that country governing patient referral 
and treatment in cases of trauma as well as geographic circumstances precluded meaningful 
grouping with another country. Within North America, differences were studied between Canada 
and the United States (US). Regional comparisons of separate case management approaches for 
patients suffering from severe and moderate TBI were judged not to be meaningful because of 
small sample sizes. 
Statistical analysis
For a comparison of continuous variables between continents, we used Student t-tests and 
Wilcoxon tests; to compare differences among regions within Europe we applied analysis 
of variance or Kruskal-Wallis tests. For categorical variables, frequencies were analyzed in 
contingency tables with chi-square statistics. Probability values lower than 0.05 were considered 
statistically significant. Regional differences in the quality of bare follow-up data may lead to 
variations in the exclusion of patients who died after a certain period of time. To check this, the 
time interval between injury and death was compared between both continents. No difference 
was observed. 
Differences in outcomes at 6 months between the two continents and between the two countries 
within North America were studied using uni- and multivariable logistic regression analysis, with 
adjustment for variation in case mix (dissimilarity between patients in different regions, such 
as possible differences in age, motor score, pupillary reactivity, CT scan classification, hypoxia, 
hypotension, and proportion of patients with moderate TBI) and case management (time interval 
between injury and admission to study center, and application of sedation, paralysis, and ICP-
lowering therapy). Because center volume may be associated with patient outcome, we also 
adjusted for the number of patients included by each center. Values of missing confounders 
(2.6% of the required values) were imputed per patient, based on the values of the nonmissing 
confounders13,14. We used computer software for this analysis, i.e. Design and Hmisc library from 
S-plus (Version 2000; MathSoft Inc., Seattle, WA). The associations among regions within Europe 
and outcome 6 months after injury were tested with a likelihood ratio test. The robustness of the 
logistic regression analyses was confirmed by performing two sensitivity analyses; 1) repetition 
of regression analyses in which patients whose primary cause of death was not likely to be 
related to TBI were excluded; and 2) repetition of regression analyses in which patients whose 
CT scans revealed normal findings were excluded. Calculations were performed with the aid of 
a commercially available statistical computer software package (SAS Version 6.12; SAS Institute 
INC., Cary, NC). 
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Results
The study population included 2177 patients, 1701 patients with a severe TBI and 476 with a 
moderate TBI. Table 1 shows that the percentage of patients with severe TBI was lower in North 
America (72%) than in Europe (85%). 
Comparison of Europe and North America
Patient characteristics and causes of injury 
The characteristics of patients enrolled in the NAS and the ES are shown in Table 2. Patient 
ages (mean 32.8 years in North America and 33.7 years in Europe) and sex distributions (79% 
male patients in North America compared with 76% male patients in Europe) were similar in 
both studies. On both continents patients were most frequently injured in road traffic accidents 
(57% in North America compared with 61% in Europe [Table 3]); however, in North America 
accidents more frequently involved motor vehicles, whereas in Europe a larger proportion of 
traffic accidents involved bicycles and mopeds. Traumatic brain injuries caused by falls were 
more common in Europe (20% in the ES compared with 15% in the NAS), whereas assaults were 
more common in North America (11% in the NAS and 2.6% in the ES [Table 3]). The proportion of 
patients with secondary insults (hypoxia or hypotension) or the absence of pupillary reactivity 
was larger in North America than in Europe. The incidence of traumatic SAH and the status of 
the basal cisterns were similar between continents; however, in Europe mass lesions were noted 
more frequently (46% in the ES compared with 40% in the NAS [Table 2]). Likewise, midline shift 
greater than 5 mm was more common in Europe (23% in the ES and 17% in the NAS [Table 2]). 
Table 2. Characteristics of �1�� patients with severe or moderate TBI
Characteristic No. of Patients (%)
North America Europe
Total no. of patients 114� 1����
Demographics
Age in yrs (mean ± standard deviation) ��.�� ±1�.4 ��.� ±14.� 
Sex
  Male ��4 (��) ���1 (��)
  Female �45 (�1) �4� (�4)
Clinical features 
Motor score
  1 – � �5� (��) �4� (��)
  4 – 5 4���� (5�) 515 (5�)
  � �� (��) �� (�.�)
�upillary reactivity*
  Both reactive �41 (���) ���� (��)
  One Reactive 111 (1�) 15� (1�)
  No reaction 1��� (��) 11� (1�)
Hypotension* �4� (�1) 141 (14)
Hypoxia* ���� (���) 1�� (15)
IC� ≥ �� mm Hg within 1st �4 hrs postinjury* 4�� (5��) 4�� (�4)
Findings on admission CT scan 
Initial CT classification*
  Diffuse injury I �� (�.�) 1� (1.�)
  Diffuse injury II ���� (�4) ��� (��)
  Diffuse injury III 1�� (1�) 1�� (1�)
  Diffuse injury IV �5 (�.�) 4� (�.�)
  Mass lesion 454 (4�) 4�1 (4�)
Midline shift > 5 mm* 1��5 (1�) ��� (��)
Absent or compressed basal cisterns 4�5 (44) 4��5 (4��)
Traumatic SAH �1� (54) 544 (54)
*  p-value < �.�5 between continents
Table 1.  Distribution of patients with severe TBI by country
Region Total No. of patients with severe TBI (%)*
All �1�� 1��1 (���)
Continent
North America 114� ���� (��)
Europe 1���� ���5 (��5)
Country
US 1��� �41 (��)
Canada 11� ��5 (�1)
Norway �� 1� (���)
Sweden 5� 4�� (���)
Denmark 55 4� (���)
Finland �� 4� (���)
The Netherlands ��� �� (��)
Belgium 5�� 5� (���)
Germany 1�� 1�5 (��4)
Switzerland �� 1� (���)
France 1�� ��� (���)
Italy 1�� 14� (���)
�ortugal �� 1� (�5)
Spain �� ��� (���)
UK ��� �1 (��)
*  Severe TBI is defined as a GCS score of � to �� at admission
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These analyses were repeated separately for patients suffering from severe and moderate TBI. The 
aforementioned differences in patients’ characteristics between the two continents remained 
for both groups, except for pupillary reactivity, for which no differences were observed in the 
group of patients with moderate TBI. 
Case management
In Europe more patients were admitted to the study center following secondary referral (Table 
4). The median times between injury and arrival at the study center and between injury and 
examination of the CT scan were longer in Europe for patients with a primary referral (Table 4). 
Intracranial pressure was monitored in 66% of patients in North America and in 73% of patients 
in Europe. The guidelines for the protocol of the trials advised ICP monitoring in patients with 
a GCS score of 6 or less, as well as in patients in whom there was evidence of raised ICP on 
the CT scan (absent or compressed basal cisterns or mass lesion). Measurements of ICP were 
available in 80% of the patients in the NAS and 88% of the patients in the ES with these clinical 
characteristics. The method of ICP monitoring varied between continents: ventricular fluid 
pressure monitoring was used more commonly in North America (37%) than in Europe (24%). 
The approach to ICP-lowering management was significantly different between the continents, 
being on average more intensive in North America (Table 5). In both continents sedation was 
induced in more than 90% of the patients. In North America a larger proportion of patients 
received neuromuscular blocking agents (Table 5).
Patient outcomes
Mortality at 6 months post-TBI was higher in Europe than in North America (25% in the ES and 
20% in the NAS, p=0.002). Because this difference may be caused by the larger proportion of 
patients with moderate TBI in the NAS population, we adjusted for moderate and severe TBI. 
The separate analyses still showed a significantly greater probability that death would occur 
among patients in Europe (odds ratio [OR] = 1.24, p < 0.05; Table 6). The difference in mortality 
rates may also be explained by the demonstrated differences in patient characteristics, time 
intervals, and use of ICP-lowering medication. Characteristics indicating a more severe case mix 
in Europe were greater proportions of patients with mass lesions, midline shifts, and raised 
ICP. On the other hand, patients in the NAS more often displayed papillary abnormalities and 
an increased incidence of hypoxia and hypotension. After adjustment for variations in case mix 
and management, the observed difference in outcomes between both studies became even more 
pronounced (OR = 1.56, p = 0.007, Table 6). 
The difference in unfavorable outcome between the continents (43% in Europe compared with 
38% in North America) was 5%. After the difference was adjusted for severe and moderate TBI, 
it was not significant (OR = 1.04, p = 0.68; Table 6). After adjustment for variations in case mix 
and case management, including the proportion of patients with moderate TBI, the regional 
difference in unfavorable outcome became more clear and reached statistical significance (OR = 
1.46, p = 0.007). Subgroup analyses for patients with severe and moderate TBIs confirmed that 
outcomes were poorer in Europe compared with North America (all ORs > 1, Table 6).
Table 3.  Causes of injury in �1�� patients with severe or moderate TBI*
Cause of injury No. of Patients (%)
North America Europe
All causes 114� 1����
Traffic accident �51 (5�) ��5 (�1)
  Motor vehicle 511 (���) �45 (55)
  Motorcycle 11�� (1��) 11� (1�)
  Bicyle/moped �� (�.4) 1�� (��)
Fall 1�1 (15) ��1 (��)
Sports/recreation �� (1.�) �4 (�.�)
Assault 1�� (11) �� (�.�)
Other# 1��1 (1�) 151 (15)
*  p-value < �.�5 
# Other includes accidents at work and injuries within a building 
Table 4. Comparison of health care process parameters
Referral policy Median (Q1-Q3)*
Primary Referral Secondary Referral
North America Europe North America Europe
No. of patients# ���� (��%)‡ ���� (�1%)‡ 1�� (1�%)‡ 4�� (��%)‡
Time from injury to arrival  
at study center (mins)
��# (��-55) 5� (�5-��) 1�� (11�-1�5) 14� (115-1���)
Time from injury to acquisition 
of CT scan (mins)#
�5 (��-1�4) 1��� (��4-1��) 1��� (1�5-���) 1�� (��-1�4)
Time from injury to surgery 
(mins)
155 (1��-�1�) 1�� (1�5-���) �41 (1���-�1�) �15 (1���-��5)
* Q1 = first quartile�� Q� = third quartile
# p < �.�5 between continents
‡ �ercentage per continent  
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Table 6. Outcome � months postinjury in patients with severe or moderate TBI
Outcome Europe
(1���� patients)
North America
(114� patients)
Crude OR
(�5% CI) #
Adjusted OR*
(�5% CI) #
Severe and moderate
Mortality  �5� (�5%)  ��5 (��%)  1.�4 (1.�� – 1.5�)†  1.5� (1.1� – �.1�)
Unfavorable outcome ‡  4��� (4�%)  4�� (���%)  1.�4 (�.��� – 1.�5)†  1.4� (1.11 – 1.��)
Severe
Mortality  �4� (���%)  1�� (�4%)  1.�1 (�.�� – 1.51)  1.54 (1.�� – �.1��)
Unfavorable outcome ‡  4�1 (4�%)  �5� (4�%)  1.�� (�.��4 – 1.�4)  1.4�� (1.�� – �.��)
Moderate
Mortality  1� (11%)  �� (��.1%)  1.4� (�.��� – �.��4)  �.�� (�.���� – �.��)
Unfavorable outcome ‡  �� (1�%)  4�� (1�%)  1.1� (�.�� – 1.�5)  1.��� (�.�4 – �.��)
# CI = confidence interval
* Adjusted for severe or moderate TBI, causes of injury, age, clinical characteristics (motor score at 
admission, hypotension, hypoxia, CT classification, compressed or absent basal cisterns, midline 
shift > 5 mm, raised IC�, and type lesion), and case management (difference in time between injury 
and arrival at study center, IC�-lowering therapy, and number of patients per center). The effect of 
region on outcome is statistically significant (p-value < �.�5) if the �5% CI does not include the value 
one
† Adjusted for severe or moderate TBI
‡ Unfavorable outcome includes death, vegetative state, and severe disability according to the GOS
Comparison of regions within Europe
Patient characteristics and causes of injury
Comparisons among regions within Europe are summarized in Table 7. Road traffic accidents 
more frequently were the cause of injury in Italy, Portugal and Spain, and the Netherlands and 
Belgium. Falls as a cause of injury were more common in Germany and Finland. The mean age of 
patients varied from 30 years in France to 38 years in Germany (Table 8). Pupillary abnormalities 
were more frequently seen in Germany and the United Kingdom (UK). Hypoxia was more common 
in France and in the Netherlands and Belgium. The proportion of patients with intracranial 
hypertension was lowest in the UK (49%) and highest in the Netherlands and Belgium (73%). 
Patients with mass lesions were frequently observed in Germany (60%) and Italy (52%). 
Case management
The proportion of patients who were secondarily referred for treatment ranged from 25% in 
France to 58% in Italy. The median time between injury and arrival at the study center for patients 
primarily referred ranged from 36 minutes in Portugal and Spain to 100 minutes in France. For 
patients secondarily referred, the time to arrival at the study center ranged from 128 minutes in 
Italy to 180 minutes in France. The median time between injury and acquisition of a CT scan for 
primarily referred patients was lowest in Italy (82 minutes) and highest in France (139 minutes). In 
patients in the secondary referral group, the median time to acquisition of a CT scan was lowest 
in the Netherlands and Belgium (89 minutes) and highest in Portugal and Spain (176 minutes). Ta
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There was no clear difference among regions in the time between injury and the start of surgical 
procedures in patients who underwent surgery.
Patient outcomes
Table 8 shows that the mortality rate varied between 20 and 31 % within Europe and unfavorable 
outcomes varied between 36 en 56%. These differences did not prove to be statistically significant 
in either unadjusted or adjusted analyses (likelihood ratio test: p = 0.32 for death and p = 0.23 
for unfavorable outcome).  
Comparisons within North America
Patient characteristics and causes of injury
Ages of patients, causes of injury, and most clinical characteristics were similar for both Canada 
and the US. Only the occurrence of traumatic SAH was more frequent in patients from the US 
(56%) than from Canada (42%, Table 8). 
Case management
In Canada significantly more patients were admitted following secondary referral (35% in Canada 
compared with 12% in the US). The median time between injury and arrival at the study center 
was similar in Canada and the US, both for patients who were primarily referred (approximately 
40 minutes), and for patients who were secondarily referred (approximately 135 minutes). 
Among patients who were primarily referred, in Canada delays before CT scans were obtained 
were significantly longer than those in the US (median 128 minutes for Canada compared with 
93 minutes in the US; p < 0.05; data not shown); among patients who were secondarily referred, 
surgery was performed later (median 333 minutes post-TBI in Canada compared with 202 
minutes post-TBI in the US; p < 0.05, data not shown). 
Patient outcomes
The mortality rate was 21% in Canada and 19% in the US and the rates of unfavorable outcome 
were 37 and 38%, respectively. Differences in both outcome measures were not significant in 
either unadjusted or adjusted analyses (p = 0.68 for the mortality rate and p = 0.83 for the rate 
of unfavorable outcome in the unadjusted analysis). 
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Discussion
The present study shows that, despite strict inclusion and exclusion criteria and recommendations 
for case management, major regional variations may exist in a patient population included 
in a geographically diverse clinical trial. These differences relate to causes of injury, patient 
characteristics (demographics and clinical characteristics), case management (referral policy, 
time intervals, and therapy) and outcomes. The differences may pertain to social and cultural 
differences, as well as to aspects of local policies governing responses to trauma, both of which 
are outside the influence of investigators. Regional differences in measuring instruments or in 
clinical scoring may also add to the observed heterogeneity. 
Social and cultural differences, such as mode of transport, influence the causes of injuries that 
are sustained. In North America relatively more patients who were enrolled in the study were 
injured while driving a motor vehicle, which resulted in many high-velocity injuries. In Europe 
relatively more patients sustained a low-velocity injury, caused by a bicycle, moped, or fall. 
The cause of injury was associated with clinical characteristics: patients who sustained a high-
velocity injury had a higher incidence of abnormal pupils, hypoxia, and hypotension. Findings 
on the CT scan indicative of raised ICP (absent or compressed basal cisterns, midline shift, or 
mass lesions) were more common in patients injured as the result of a fall or a bicycle accident 
(data not shown). These patterns are in accordance with those of previous reports6,15,16. As the 
cause of injury, falls were more frequent in Europe, particularly in Finland and Germany (Tables 
3 and 7). Patients who sustained injuries from falls were commonly older and had a higher 
incidence of obliteration of basal cisterns, midline shifts, and mass lesions were detected on CT 
scans in these patients (data not shown). These clinical characteristics were related to outcome. 
Consequently, social and cultural differences influence the composition of the population under 
study (case mix) and relate to outcome.
Likewise, varying approaches to basic TBI management, as demonstrated between North America 
and Europe for ICP-lowering therapy, may be considered evidence of a cultural difference in 
attitude: ICP-lowering medication was less frequently administered in Europe than in North 
America to patients in whom ICP was 20 mm Hg or higher, thus demonstrating that a more 
conservative approach was taken in Europe (Table 2). A limiting factor of the present study is 
that ICP-lowering therapy was only recorded after initiation of ICP monitoring. It is conceivable 
that therapy may have been instituted before initiation of monitoring, thus affecting the 
observed ICP. If in North America relatively many patients received therapy before the start of 
monitoring, this would lower their observed ICP. In this case the ‘real’ ICP of North American 
patients would be higher, thus decreasing the observed difference in the frequency of ICP-
lowering therapy. Both in North America and in Europe ICP-lowering medication was also given 
to patients in whom the ICP was lower than 20 mm Hg, although the study protocol and also 
more recent North American evidence-based guidelines for severe TBI management17 advise that 
ICP-lowering therapy be initiated only at a threshold of 20 to 25 mm Hg. 
Secondary referral occurred more frequently in Europe than in North America (Table 4). We 
performed an additional analysis of which patient characteristics and external factors were 
associated with secondary referral. Both in North America and Europe, the distance from the 
injury site to a neurosurgical trauma center was related to secondary referral. In North America 
patients who were secondarily referred more frequently had sustained injuries as motor vehicle 
occupants, reflecting a protocol for dealing with trauma in which policy dictates referral of 
patients with high-velocity injuries to a neurosurgical trauma center. In contrast, in Europe 
mass lesions were significantly more frequently seen in patients who were secondarily referred 
and, consequently, surgery was also performed in a higher percentage of patients. Hence, the 
European referral policy appears to be based more on abnormalities observed on the CT scan, 
resulting in the selection of patients with a higher incidence of mass lesions.
Secondary referral occurred also more often in Canada than in the US. The longer delays before 
CT scans were obtained or surgery was performed in Canada, compared with the US, are most 
likely caused by local in-hospital protocols for dealing with trauma, because the delays between 
injury and arrival at the study center were similar both for patients primarily and secondarily 
referred. 
Remarkably, outcomes in the European population were worse than in those in the North 
American population, with regard to death and, to a lesser extent, unfavorable outcomes (Table 
6). Several causes contributing to these differences in outcome need to be considered, such as 
regional variation in enrollment criteria, regional differences in case mix, and regional variation 
in management. Various adjustments, including those of major predictive variables18, were 
made with statistical models, but the difference in outcome could not be explained. Sensitivity 
analyses (excluding patients in whom there were normal findings on CT scans or patients whose 
deaths were not likely to have been related to TBI) provided results similar to the overall analysis. 
Care should be taken, however, before concluding that treatment results in North America are 
definitely better. Many other factors can also affect the difference. These include unknown 
confounders, traumas other than TBI, center effects, and perhaps to a lesser extent, regional 
differences in scoring or measuring instruments. In an extensive analysis of the National 
Acute Brain Injury Study of hypothermia, Clifton et al.19 demonstrated significant intercenter 
differences. Our results could not confirm this, however; in the multivariable analyses the 
number of patients included in each center had no significant relationship with outcome. 
In the present study we found no clear differences in outcomes among regions within Europe, 
or between Canada and the US. The lack of statistical significance may be caused by the small 
sample sizes in the different regions, which result in large confidence intervals and limited 
statistical power. 
In the recent past two large series contained patient data on TBI that were collected in different 
centers distributed over a continent, one series in Europe (the European Brain Injury Consortium 
survey, EBIC)6 and the other in the US (the Traumatic Coma Data Bank, TCDB)20,21. We used these 
more unselective series for a comparison with the present study. Differences among regions 
within Europe in the present study are similar to those reported in the EBIC survey6. In the EBIC 
survey, patients injured in Spain, the Netherlands, and Belgium were also younger, on average, 
and more frequently sustained injuries in road traffic accidents. Conversely, in Finland and 
Scandinavia, patients were older, and more frequently sustained injuries due to a fall. In the UK, 
France, Scandinavia, Portugal, and Spain secondary referrals were more frequent, but were not 
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always related to a higher incidence of surgical operations. Detailed comparisons of the EBIC 
survey and the present study are complicated, because different inclusion and exclusion criteria 
were used. For example, in the present study all patients older than 65 years were excluded, 
resulting in a lower mean age (34 years compared with 42 years in the EBIC survey). 
The TCDB20,21 only included patients with severe TBIs. When compared with patients who 
sustained severe TBI from the NAS, the population in the TCDB was somewhat younger (median 
age 30 years in the present study compared with 25 years in TCDB). Variations in causes of 
injury were more pronounced (75% traffic accidents and 5% assaults in the TCDB compared with 
61% traffic accidents and 11% assaults in the present study). The difference in the proportion 
of direct transfers was also remarkable, 61% in the TCDB compared with 90% in the present 
study. The observed differences may reflect changes occurring over time in mobility, society, or 
protocols for dealing with trauma. 
The distribution of patients in the various categories of CT classification differed among the 
EBIC, the TCDB, and the present study. It remains uncertain whether these differences are real 
or may be explained by variations in selection criteria and observer variation in scoring the CT 
scan classification.  
The observed regional differences can be seen to argue for blocked randomization in each center 
and for stratification of patients by prognostic risk. Such procedures will ensure a balanced 
treatment assignment, with respect to prognostic risk in each stratum. Prerandomization 
stratification by prognostic risk may be difficult to accomplish in emergency situations, however. 
Alternatively, covariate adjustment could be included in the final statistical analysis for predictive 
characteristics and regional effects. Such an adjustment will increase the statistical power of the 
study to detect a treatment effect22,23. Moreover, heterogeneity in the severity of injury in the 
patients can be reduced by limiting enrollment to patients with an intermediate prognosis, for 
example, between a 20 and 80% risk for unfavorable outcome. This leads to a focus on patients 
for whom treatment effects can be better determined8. Designing a randomized clinical trial in 
this way may limit the disturbing effects of heterogeneity and increase chances of showing the 
benefit of a new therapy7. 
Conclusions
We have shown that regional differences in patient characteristics, case management, and 
outcomes exist also in the context of a randomized clinical trial. This aspect merits additional 
attention to the design of such a study. The observed poorer outcome in Europe, compared with 
North America, is a remarkable finding and requires further study. 
Appendix 
Imputation of outcome at 6 months postinjury in both tirilazad trials.
Outcome assessment of GOS scores at 6 months was considered to be applicable if the assessments 
were performed between 5 and 7 months after the date of injury. For 164 patients, the GOS 
score was measured outside this time interval. In these cases imputation of outcome (favorable 
or unfavorable) was performed, in which we used assessments obtained at 3 or 12 months 
postinjury and gave each imputation a weight factor. We used the following algorithm: 
– If the GOS score is available for the period 7 to 8 months postinjury, impute that score for the 
6-month postinjury time point (weight=1).
– If the GOS score is still missing, but is available for the period 4 to 5 months postinjury, 
impute that score for the 6-month postinjury time point (weight=1). 
– If the GOS score is still missing, but is available for the period 2.5 to 3.5 months postinjury, 
then do one of the following:
1) If the GOS score at 2.5 to 3.5 months postinjury was ‘good recovery’, impute a score of 
unfavorable outcome for the 6-month postinjury time point (weight=1). 
2) If the GOS score at 2.5 to 3.5 months postinjury was ‘vegetative state’, impute a score of 
unfavorable outcome for the 6-month postinjury time point (weight=1).
3) If the GOS score at 2.5 to 3.5 months postinjury was ‘severe disability’, then do one of the 
following:
i) if the GOS score at 11 to 13 months is missing, give the GOS score at 6 months 
postinjury a favorable outcome value (weight=0.33) and an unfavorable outcome value 
(weight=0.67). 
ii) if the GOS score at 11 to 13 months is ‘good recovery’, give the GOS score at 6 months 
postinjury a favorable outcome value (weight=0.75) and an unfavorable outcome value 
(weight=0.25).
iii) if the GOS score at 11 to 13 months is ‘moderate disability’, give the GOS score at 
6 months postinjury a favorable outcome value (weight=0.5) and an unfavorable 
outcome value (weight=0.5).
– If the GOS score is still missing, but the outcome for the period at 11 to 13 months is ‘severe 
disability’, give the GOS score at 6 months an unfavorable outcome (weight=1).
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Comment on paper
To the editor: 
As European Principal Investigators and members of the Executive Committee of the Tirilazad 
Europe (Australia Study), we read with the interest the paper by Hukkelhoven, et al.24.
The issue of regional differences among patients enrolled in large multicenter studies is 
important and these authors are to be congratulated for the detailed description of the 
characteristics of a large database composed by combining information about patients recruited 
into two separate projects: European and American tirilazad trials9. Their findings confirm some 
of those previously reported concerning the demographic, clinical, and radiological profile of 
head-injured patients enrolled in clinical trials. 
An intriguing, and even unprecedented finding is the apparent difference in outcome in 
patients recruited from the different continents (Europe and the US) in which the two trials 
were performed, even after accounting for ‘variations in case mix and management.’ Previous 
prospective comparisons between populations of head-injured patients in Europe and North 
America did not show these differences. For example, Murray25 demonstrated that the outcomes 
in patients treated at a trauma center in California were almost identical to those predicted in 
patients treated in centers in the United Kingdom and The Netherlands. 
A number of issues must be addressed before considering that differences in approaches to case 
management, which may account for differences in observed outcome. These include questions 
about the comparability of patients recruited for the two trials, the convenience of case 
management approaches within the different continents, and inconsistencies of approaches to 
assessment of outcome. 
Comparability in the pattern and severity of brain damage is a fundamental prerequisite in the 
investigations of potential influences on outcome. Thus, at a comparable clinical level of severity, 
outcome is worse in a patient who has a mass lesion; however, patients recruited in Europe had 
a higher frequency of mass lesions than those in North America. Likewise, at a given clinical level 
of severity, outcome varies according to the time when the patient is assessed postinjury and the 
extent of resuscitation previously carried out. As a reflection of this, neurosurgical unit personnel 
who accept patients only as secondary referrals (after previous assessment and resuscitation in 
other hospitals) are likely to recruit patients already selected as having more serious injuries. Only 
10% of patients in North American centers were secondary referrals, whereas 39% of patients in 
European centers were referred secondarily (as much as 60% in some regions of Europe). 
Although complete information regarding time from injury to admission to the study center 
is unavailable for the two cohorts, it is clear that patients took longer to reach the European 
centers.
Therefore, it would be interesting to know the results of comparisons of outcome between 
these two categories of patients. Furthermore, comparability in the findings on each patient’s 
initial computerized tomography (CT) scan may still allow differences to emerge in association 
with the development of delayed worsening, including the possibility of the development of 
surgically significant mass lesions in a patient previously considered to have a diffuse injury26. A 
significant difference in the incidence of traumatic subarachnoid hemorrhage (SAH) a powerful 
indicator of poor prognosis) was demonstrated in patients directly admitted, compared with 
patients transferred from another hospital27. Center personnel accepting a large number of 
secondary referrals are likely to select more critically ill patients (with evolving mass lesions and 
traumatic SAH). 
Validity of the concept of a continent-specific approach to case management can be questioned. 
Thus, wide variations in practices among different centers in North America have been 
reported19,28, with only 16% of centers complying fully with published guidelines29. Similar 
variations have been reported among European countries and among centers within a country2. 
Intercenter differences apply even among centers taking part in sophisticated clinical trials19.
In the clinical trials involving tirilazad, researchers included patients with severe head injury 
as well as those considered to have moderate head injury. The identification of patients with 
moderate head injury is less firmly established, there is more variability in the translation of 
Glasgow Coma Scale (GCS) observations into a qualifying GCS score in this group, and there 
are varying approaches to preadmission assessment, intubation, resuscitation, and criteria for 
interhospital transfer likely to affect this group. These factors may have resulted in differences 
in the total populations included in the European and North American studies. 
The use of very intensive hyperventilation in 46% of patients with an intracranial pressure (ICP) 
below 20 mm Hg in North American centers is particularly curious. 
The possibility that more frequent use of ‘more aggressive’ therapy, particularly aimed at 
lowering ICP, is proposed as a possible reason for the difference in outcome. This is controversial. 
For instance, extreme hyperventilation (PCO2 ≤ 25 mm Hg) was used twice as frequently in 
patients treated in North American centers (including in patients with a normal ICP) even 
though there is evidence that this practice is associated with worsening of patient outcome. The 
avoidance of chronic, prolonged hyperventilation is regarded as a standard in the treatment of 
severely head injured patients in North America30. Researchers of other observational studies28,31 
have found the greater use of ICP monitoring or therapy not to be associated with substantially 
improved favorable outcomes. 
Reliable comparisons between results in cohorts of patients require that outcome is assessed 
using comparable methods, follow up is as complete as possible, and occurs at identical 
intervals after injury. Variations between different observers, related to experience and/or 
professional background, are well recognized. The impressionistic use of the Glasgow Outcome 
Scale, known to be associated with high rates of interobserver variation, has been superseded 
by a structured approach to score assignment32, but this approach was not used in the tirilazad 
studies. Although the proformas used to record outcome information were identical in the two 
trials, no advance steps were taken to ensure that they were applied and interpreted identically 
on the two continents. 
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In conclusion, we have significant reservations about the assertion that mortality and unfavorable 
outcomes were significantly higher in Europe. At the very least, this statement requires 
qualification with an acknowledgment that the observation may reflect differences in the type 
of patients recruited to the trials, in approaches to reporting outcome, and differences in case 
management. Finally, the debate about the merits of different approaches to the treatment of 
severely brain injured patients, which has festered for more than two decades, seems unlikely to 
be resolved by comparing outcomes of cohorts in different circumstances. We strongly endorse 
the view31 that randomized, prospective trials are required, first, to establish the principle that 
ICP lowering/ decompressive therapy is beneficial, and second, to evaluate the merits of different 
approaches.
Franco Servadei, M.D. 
Albino Bricolo, Ph.D.
Jacques Lagarrigue, M.D.
Ramiro Lobato, M.D.
Lennart Persson, Ph.D.
Members of the Executive Committee of the Tirilazad Europe–Australia Study
Author reply 
Dear Editor, 
We would like to thank the principle investigators and members of the Executive Committee of 
the Tirilazad Europe-Australian study for their constructive comments on our paper on regional 
differences in patient characteristics, case management and outcomes in traumatic brain injury24. 
In this paper we compared North America with Europe and found on average a better outcome 
in North American patients. Surprisingly, this continental difference in outcome remained after 
adjustment for a large set of potential confounders. In fact, the difference became even larger 
after adjustment, since the North American patients were more severe with respect to several 
confounders, such as the presence of hypoxia or hypotension. We did not wish to place too 
much emphasis on this finding, as the underlying reasons for this difference were unclear. The 
finding however is intriguing.
Outcome comparison between continents in a multivariable analysis has seldom been 
performed, which makes comparison of our findings with previously observed results difficult. 
In the past, Murray et al.25 compared six-month mortality between Glasgow and San Francisco 
in a multivariable analysis, but, in contrast to our results, no continental difference in the 
outcome was observed. However, this study25 was rather a comparison of two centers than of 
two continents and data were collected about 20 to 30 years ago, i.e. between 1970 and 1985. 
Servadei et al. wondered whether the continental difference in outcome is real. Regarding the low 
p-values corresponding with the adjusted odds ratios in Table 624, it is not very plausible that the 
difference is caused by chance. The data might however be biased for comparison of continents. 
Methods and/or time points of severity assessment and additional investigations may have 
varied structurally between continents, possibly affecting the estimated values of the severity 
parameters. Servadei et al. also suggested that the continental difference in outcome might be 
explained by a structural continental difference in outcome assessment. This is unlikely, since 
the difference in outcome is also observed for the unambiguous outcome mortality. 
Besides the possibility of bias, several other factors could have contributed to the continental 
difference in outcome. Among them were unknown clinical factors – not included as a 
confounder – , differences in management approach and center effects24. 
In our paper we adjusted for many potential confounders in order to estimate the ‘pure’ effect of 
continent on outcome. Data on many previously identified potential confounders were available. 
However, it is always possible that other important confounders were missed. Examples of such 
confounders are extracranial injuries, which were not consistently reported in the Tirilazad 
trials, or as yet unidentified confounders. 
Servadei et al. suggested the dissimilar distributed referrals as possible confounder. When 
adjusting for referral, all characteristics that correlate with referral policy – and that are not 
already adjusted for – are clustered under this referral-factor. Although we did not correct for 
referral in itself, we adjusted for difference in time between injury and arrival at the study center 
6
Chapter 3
6
Regional differences in TBI: experience from the tirilazad trials
in our paper. By this, the latter obviated both referral policy and duration of the transport by 
ambulance, which could also possibly worsen the clinical state of the patient. Further subgroup 
analyses, separate for patients with primary and secondary referral, learned that referral policy 
could not explain the outcome difference between Europe and North America (all ORs > 1.0, 
Table 9, analogous to Table 624). In fact, the outcome difference was even slightly larger (larger 
ORs) for primarily referred patients than for those secondarily referred. Separate analyses for 
severe and moderate TBI patients showed the same pattern (Table 9).  
Further, the present analyses included only characteristics measured at admission. Patients 
with a similar severity at admission may develop differently in time, thus contributing to the 
observed continental difference in outcome. 
Another possible factor contributing to the continental difference in outcome may be variation 
in management. The question arose whether the identified outcome difference may be a 
structural difference between continents or primarily a difference between centers with more 
centers performing favorably in North America. Wide variations in practices between different 
centers within North America and Europe have been reported2,6,19,28. The outcome difference 
being ‘center-specific’ instead of ‘continent-specific’ is possible, especially if inter-center-
variability in outcome would be larger than inter-continent-variability. Unfortunately, power 
was not large enough to study these inter-center-differences in a valid way – even not with our 
relatively large sample size. 
Regarding management, we adjusted for intensity of ICP therapy. Therefore the ICP management 
can not be the reason for the difference in outcome. We regret that some physicians may have 
interpreted our paper as if we were advocating a more aggressive therapy, as this was certainly 
not reported as such in our paper. In 1983 our group33 reported in this journal a clear difference 
in 1-year survival between two Dutch centers, with the higher survival rate at the center 
with the more conservative management regimen. However, other studies reported opposite 
findings28,34. We agree with Servadei et al. that randomized, prospective trials are required to 
offer convincing evidence whether intensive therapy, e.g. for lowering ICP, is beneficial. This, 
however, is a complicated issue as in general more severely injured patients will receive more 
intensive therapy30. 
Overall, the observed continental difference in outcome is an unexpected and intriguing result. 
This difference may be caused by coincidence and may have been overestimated in the tirilazad 
data. Other explanations include regional differences in scoring or measuring instruments, (yet) 
unknown clinical factors, regional differences in management approach and center effects. We 
hope our paper and the discussion presented here will challenge neurosurgeons to think further 
about this remarkable finding and to explore possibilities that may lead to improvement in 
outcome of TBI patients. 
 
Table . Comparison of mortality � months postinjury, patients with severe or moderate TBI
Referral North America Europe Crude OR Adjusted OR# 
n mortality n mortality (�5% CI) (�5% CI)
Severes and moderates
All referrals 1���� �5% 114� ��%  1.�4 (1.��–1.5�)*  1.5� (1.1�–�.1�)
  �rimary referral ���� ��% ���� ��%  1.�� (�.��–1.��)*  1.5� (1.1�–�.���)
  Secondary referral 4�� �4% 1�� ��%  1.�� (�.��–1.���)*  1.4� (�.���–�.��)
Severes
All referrals ���5 ���% ���� �4%  1.�1 (�.��–1.51)  1.54 (1.��–�.1��) 
  �rimary referral 54� ���% ���� �4%  1.�� (�.�5–1.5�)  1.5� (1.��–�.��)
  Secondary referral ��5 ��% 1��� ��%  1.�� (�.�5–1.��)  1.4� (�.��–�.�4)
Moderates
All referrals 15� 11% ��� ��%  1.4� (�.���–�.��4)  �.�� (�.����–�.��)
  �rimary referral ���� 1�% ���4 ��%  1.�� (�.��–�.�5)  �.41 (�.���–�.�4)
  Secondary referral �5 �% �� ��%  1.�� (�.��–5.1�)  1.��4 (�.��–1�.5)
* Adjusted for severe or moderate TBI
# Adjusted for severe or moderate TBI, cause of injury, age, clinical characteristics (motor score at 
admission, hypotension, hypoxia, CT classification, compressed or absent basal cisterns, midline 
shift > 5 mm, raised IC�, type lesion), management (difference in time between injury and arrival 
at study center, IC� lowering therapy, number of patients per center), referral policy
OR = Odds Ratio (Europe versus North America), �5% CI = �5% Confidence Interval. The effect of region 
on mortality is statistically significant (p-value < �.�5) if the �5% CI does not include the value one
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Abstract
Objective
Increasing age is associated with poorer outcome in patients with closed traumatic brain injury 
(TBI). It is uncertain whether critical age thresholds exist, however, and the strength of the 
association has yet to be investigated across large series. The authors studied the shape and 
strength of the relationship between age and outcome, that is, the 6-month mortality rate and 
unfavorable outcome based on the Glasgow Outcome Scale. 
Methods
The shape of the association was examined in four prospective series with individual patient 
data (2664 cases). All patients had a closed TBI and were of adult age (96% < 65 years). The 
strength of the association was investigated in a meta-analysis of the aforementioned individual 
patient data (2664 cases) and aggregate data (2948 cases) from TBI studies published between 
1980 and 2001 (total 5612 cases). Analyses were performed with univariable and multivariable 
logistic regression. 
Results
Proportions of mortality and unfavorable outcome increased with age: 21 and 39%, respectively, 
for patients younger than 35 years and 52 and 74%, respectively, for patients older than 55 years. 
The association between age and both mortality and unfavorable outcome was continuous and 
could be adequately described by a linear term and expressed even better statistically by a linear 
and a quadratic term. The use of age thresholds (best fitting threshold 39 years) in the analysis 
resulted in a considerable loss of information. The strength of the association, expressed as an 
odds ratio per 10 years of age, was 1.47 (95% confidence interval [CI] 1.34 – 1.63) for death and 
1.49 (95% CI 1.43 – 1.56) for unfavorable outcome in univariable analyses and 1.39 (95% CI 1.30 
– 1.50) and 1.46 (95% CI 1.36 – 1.56), respectively, in multivariable analyses. Thus, the odds for a 
poor outcome increased by 40 to 50% per 10 years of age. 
Conclusions
An older age is continuously associated with a worsening outcome after TBI; hence, it is 
disadvantageous to define the effect of age on outcome in a discrete manner when we aim to 
estimate prognosis or adjust for confounding variables. 
Introduction
Increasing age is associated with worse outcome in patients with systemic diseases such as 
cancer, coronary heart disease, and neurological diseases such as subarachnoid hemorrhage 
(SAH), traumatic brain injury (TBI), and dementia1-10. Traumatic brain injury is a major health and 
socioeconomic problem throughout the world and is the leading cause of death and disability 
in younger patients in more economically developed countries. It remains unclear how the 
association between patient age and outcome after closed TBI can be described best, however. 
In some studies researchers have treated outcome as a continuous function of age2,11,12, whereas 
others have identified age threshold values between 30 and 60 years of age3-5,13-17. 
In a study on early indicators in the management and prognosis of severe TBI, Chesnut et 
al.17, provided a detailed overview of published data on the association between patient age 
and outcome following TBI. These authors concluded that the probability of a poor outcome 
increased with patient age in a stepwise manner, suggesting an age threshold of 60 years. Note, 
however, that they recognized that this threshold might be an artifact of the age grouping used 
by various researchers in converting continuous data into categorical data. 
Establishing the association between patient age and outcome more precisely is important 
in being able to predict outcome and understand how to adjust for age in epidemiological 
studies. Obtaining more knowledge about the shape of this association may also help to explain 
the relationship itself. Furthermore, identifying threshold values may be relevant to clinical 
research, for example, for purposes of stratification in randomized clinical trials or prognostic 
modeling.  
The primary aim of this study was to describe the relationship between age and outcome in 
patients with TBI, which fit the data well and was simple (that is, low-dimensional) and easily 
communicated and applied in clinical practice. We also examined whether a meaningful age 
threshold value could be determined. Furthermore, we quantified the strength of the effect of 
patient age on outcome in a meta-analysis. 
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Clinical material and methods
Patient population
Two data sources were used in the present study: 1) individual patient data (2664 cases) from 
four different patient series; and 2) aggregate data (2948 cases) extracted from TBI outcome 
studies published between 1980 and 2001 (Table 1). Adults (patients > 14 years) with severe 
closed TBI (Glasgow Coma Scale [GCS] scores 3-8) were selected for analysis.  
The shape of the association between patient age and outcome was studied in the individual 
patient data by using both continuous age transformations and age as a threshold value (for 
example, an age ≥ 40 years compared with an age < 40 years). The strength of the association 
was considered in a meta-analysis that included both aggregate data and individual patient data. 
Outcome measures at 6 months postinjury were death and the Glasgow Outcome Scale [GOS] 
score18 dichotomized into unfavorable outcome (death, vegetative state, and severe disability) 
and favorable outcome (moderate disability and good recovery). 
Data collection
Individual patient data included populations from three multicenter phase III randomized 
clinical trials19-21 and one prospective series22 of patients with closed TBI. Six-month outcome 
data were available from 2500 patients. In 164 patients outcome had not been assessed at 6 
months postinjury, but could be assigned according to a specific algorithm that used GOS results 
obtained at other points in time19. 
We searched for relevant published studies by using the PubMed service to access the MEDLINE 
database of citations (period 1980-2001) with the key words: ‘age’, ‘outcome’, ‘head injury’ or 
‘traumatic brain injury’ and ‘relation’ or ‘association’. Additional papers were retrieved by 
tracking citations in the reference lists of the aforementioned reports. Studies published in the 
English language were selected if they included the following: 1) 35 or more adult patients 
with severe closed TBI; 2) frequency data on at least two age categories together with 6-month 
mortality data or 6-month unfavorable outcome data; and 3) patient data from Europe, Israel, 
North America, or Australia to ensure comparability with the data from the individual patient 
series. Of more than 100 studies initially considered, 111,3,5,15,23-29 met these criteria and constitute 
the aggregate data. Studies selected for the meta-analysis are listed in Table 1.
 
Shape of the association
The shape of the association between patient age and outcome was studied using the following 
age transformations:
1. A smoothing spline30-32. This is a very flexible way to describe an association, but cannot be 
expressed easily in a parametric formula. A penalty factor, which prevents wild oscillation of 
the spline, is based on the default nominal degrees of freedom. Because the smoothing spline 
represents maximal goodness-of-fit but cannot be expressed in a formula easily, it was used 
as a reference for the performance of other age transformations.  Ta
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Age and outcome
2. We also considered a variety of continuous transformations: linear (age), linear plus quadratic 
(age plus age2), linear plus cubic (age plus age3), square root (age0.5), logarithmic (log[age]), 
exponential (exp[age]) and reciprocal (age-1). We also analyzed a previously suggested piecewise 
transformation, that is, no effect of age until 50 years and a linear effect above this age4.
3. In addition, we determined age threshold values: all 60 threshold values between 15 and 76 
years of age were evaluated, thus including thresholds discussed in previous studies3-5,13-17. The 
95% confidence intervals [CIs] were constructed with profile log-likelihood methods33 around 
the best fitting (optimal) threshold. 
We included all transformations of age in logistic regression models, both univariably ones 
and those adjusted for potential confounders. The confounding variables considered were 
cause of injury, sex, geographical region, GCS, hypoxia, hypotension, pupillary reactivity, raised 
intracranial pressure [ICP] (defined as ICP ≥ 20 mm Hg), traumatic SAH, and CT scanning-based 
classification34. Interactions between the best fitting age transformation and the confounding 
variables were not statistically significant. 
Values of missing confounders (4.6% of all values) were assigned to each patient, based on 
correlations with existing confounders35,36. The fit of the models was expressed on the log-
likelihood scale of the model chi-square function (deviance)37. The higher the model chi-square, 
the better the model fits the data. The fit of the different age transformations was compared 
with the fit of the smoothing spline and with the fit of age as a continuous linear term. 
Strength of the association
The strength of the association was analyzed with univariable (aggregate data and individual 
patient data) and multivariable (individual patient data) logistic regression, including age as a 
continuous linear term. Results were expressed as odds ratios [ORs] for every 10 years of age. In 
the aggregate data, age was typically reported in categories with a range of values, for example, 
10 to 20 years or 15 to 25 years. Consequently, the association with age as a continuous linear 
term could not be estimated directly. By using the overall age distribution (mean age and 
standard deviation) in the study under consideration, however, we could validly assign a mean 
age to each age category38. If the overall age distribution was not reported, the age distribution 
from the combined data from the tirilazad trials19,20 was ascribed, matched to specific patient 
characteristics (for example, patients with epidural hematoma). 
All analyses were performed on available data sets separately as well as on pooled data sets. 
Because the association between patient age and death was statistically significantly different 
across the studies with aggregate data (test for heterogeneity, p = 0.0001), pooled effects were 
estimated using a random effects model39, including ‘study’ as a factor in the analyses. For 
all other associations, homogeneity in effects (p > 0.10)40 could be assumed and fixed effects 
methods were used. 
Calculations were performed using commercially available software (SAS, version 6.12; SAS 
Institute Inc., Cary, NC or S-plus, version 2000; Insightful Inc., Seattle, WA).
Results
In the four individual patient series, the mean rate of death varied from 23 to 40% and the 
mean rate of unfavorable outcome varied from 43 to 60%, with the highest proportions in the 
unselected series of the European Brain Injury Consortium [EBIC] (Table 1). Complete outcome 
data and the distribution of patients across age groups are listed in Table 2. Patient populations 
from the 11 studies gathered from the literature were diverse, some being relatively unselected 
and others highly selected (for example, patients with acute hematomas). Consequently, 
outcome varied considerably: 22 to 79% for mortality and 41 to 85% for unfavorable outcome. 
The proportion of several confounding variables, such as low GCS score, traumatic SAH, and 
mass lesions, increased with age (Table 3). In contrast, no age-related effects were observed for 
unreactive pupils, hypotension, and hypoxia. 
Shape of the association among individual patient data
Poor outcome increased with age (Table 2 and Figure 1); for example, the mortality rate increased 
from 21% at an age younger than 35 years to 72% at an age older than 65 years. For unfavorable 
outcome, these percentages were 39 and 85%, respectively. 
The smoothing splines look partly linear and partly quadratic (Figure 1). Adding a slightly more 
or less liberal penalty factor did not clearly alter the shape of the curve. For ages older than 65 
years, the splines were based on only 101 patients (4%), thus implying that the curve is uncertain 
Table 2.  Frequency of six-month outcome across age groups in four prospective series of 
patients with severe TBI 
Variable (%) Age Groups (yrs)
Total 15-�4 �5-�4 �5-44 45-54 55-�4 ≥ �5
Outcome* 
No. of patients ���4 ���� ���� 4�4 ��4 ��5 1�1
Mortality ��� �1 �1 ��� �� 4� ��
Unfavorable outcome 4�� ��� 41 5� �4 �� ��5
GOS score
No. of patients �5�� ���� ��� ��1 ��� �14 1��
Good Recovery �� 44 �5 �5 �� 1� 4
Moderate Disability 1� 1�� �� �� 14 14 11
Severe Disability 15 1� 1� 1� �� �1 �
Vegetative State 4 4 � 5 � 4 �
Death �� �� �� �� �� 45 ��
* If the �-month GOS score1�� was not available (1�4 cases), unfavorable outcome was assigned, based 
on GOS values at other points in time
0
Chapter 4
1
Age and outcome
above this age. Among survivors, the relative proportion of poor outcomes increased with age: 
severe disability and vegetative state occurred in just over 20% of the survivors at age 20 years 
and in approximately 50% of the survivors at age 60 years (Figure 1 and Table 2). 
Several continuous transformations of age resulted in a good fit: age as a linear variable reached 
90 and 96% of the optimum (the smoothing spline is the reference) for rates of mortality and 
unfavorable outcome, respectively. The linear plus quadratic (age plus age2) and linear plus cubic 
(age plus age3) transformations resulted in even better fits (Table 4), which were statistically 
significant for mortality in both the univariable and multivariable analyses and for unfavorable 
outcome in the multivariable analysis. The absolute differences in estimated probabilities of 
poor outcome in a comparison of linear and linear plus quadratic, and linear and linear plus 
cubic age transformations were small, however (Figure 1). The difference in the estimated 
mortality rate in a comparison of age linear and age linear plus age quadratic transformations 
was a maximal 3.3% at age 47 years. Unfavorable outcome results were similar (Figure 1). 
Table 3. Frequency of demographics, clinical characteristics, CT parameters, and �-month 
outcome across age groups in four prospective series of patients with severe TBI
Variable (%) Age Group (yrs)
Total 15-�4 �5-�4 �5-44 45-54 55-�4 ≥ �5
No. of patients ���4 ���� ���� 4�4 ��4 ��5 1�1
Demographics
High-velocity injury �� ��� �5 5� 45 �5 4�  
Male sex �� ��� ��� �� �� �5 ��
Clinical characteristics
GCS score �-5 ��� �� �5 4� �� 4� 5�
�upillary reactivity
  both reactive �4 �� �4 �� �� �� 44
  one reactive 1�� 14 1� �1 1� �� 1�
  both unreactive 1�� 1� 1� 1� �� �� 4�
Hypotension �� �5 �� �� �� �5 ��
Hypoxia �� �� �� �� ��� 4� �1
IC� ≥ �� mm Hg 54 55 5� 5� 5� 5� �5
CT scanning parameters
Traumatic SAH 5� 4� 5� 5� ��� �� ��
CT scanning classification*
  I or II �� 4� ��� �1 �� �� ��
  III or IV �1 �5 �� 1�� 1� 1� �.�
  V or VI 4� �� �� 4�� 5� 5� ��
* According to Marshall, et al., 1��1�4
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Figure 1. Graph demonstrating the univariable association between age and �-month outcome 
in ���4 patients with severe TBI. Age was described as a continuous linear term (age linear), an 
age linear plus quadratic term, and a smoothing spline. The vertical strokes at the base of the 
graph indicate the age distribution. For ease of interpretation, the probability scale is presented 
in this figure, rather than the logistical log-odds scale generally used in logistic regression models. 
A linear association on the log-odds scale corresponds to a sigmoid curve on the probability 
scale. Model parameters for age linear (age per 1� years) were as follows�� logit (mortality) = -�.1�� 
+ �.�4 × age and logit (unfavorable outcome) = -1.�4 + �.�� × age. Model parameters for age linear 
plus age quadratic (age per 1� years) were as follows�� logit (mortality) = -1.�� – �.1�� × age + �.�� 
× age� and logit (unfavorable outcome) = -�.�� + �.�� × age + �.�4 × age�
Figure 2. Graph displaying the univariable association between age and �-month outcome in 
���4 patients with severe TBI. Age was described as a discrete variable with a threshold at �� 
years. The vertical strokes at the base of the graph indicate the age distribution
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The fit of the linear, linear plus quadratic, and linear plus cubic age transformations was 
consistent in each individual study and remained constant after adjustment for confounding 
variables, indicating robustness of the findings. After adjustment, age linear resulted in 78% 
of the optimal goodness-of-fit for the mortality rate and 93% of the optimal fit for unfavorable 
outcome. Linear plus quadratic and linear plus cubic age transformations yielded 94 and 98% of 
the optimal goodness-of-fit for rates of mortality and unfavorable outcome, respectively. Other 
continuous transformations, such as age0.5, log(age), and the piecewise transformation4 (a linear 
effect above the age 50 years), performed worse. 
Optimal age thresholds could be identified accurately, that is, 39 years for both death (95% 
confidence interval [CI] 39-40 years) and unfavorable outcome (95% CI 39-39 years). These 
threshold transformations resulted in a maximal 73% (mortality) and 84% (unfavorable outcome) 
of the optimal fit (Table 3), however. The age threshold value at 39 years is graphically reflected 
in Figure 2.
 
Strength of the association 
Among the individual patient data, the odds ratios (ORs) were similar, that is, 1.30 to 1.46 for 
mortality and 1.33 to 1.49 for unfavorable outcome per 10 years of age (Figure 3). Meta-analyses 
of these data yielded a pooled OR of 1.37 (95% CI 1.30 - 1.46) for mortality and 1.43 (95% CI 1.35 
- 1.51) for unfavorable outcome. Thus, the effect of a 10-year increase in age was a multiplication 
of the odds for mortality with 1.37 and for unfavorable outcome with 1.43. In the individual 
patient data, we adjusted the age-outcome association for potential confounding variables, as 
shown in Table 2. The pooled adjusted ORs – 1.39 (95% CI 1.30 - 1.50) for mortality and 1.46 
(95% CI: 1.36 - 1.56) for unfavorable outcome – were very similar to the pooled unadjusted ORs. 
Given that the 95% CIs did not include the value 1, age was independent of other risk factors in 
patients with severe TBI.
In the aggregate data, the ORs varied considerably: mortality, 0.87 to 2.92; and unfavorable 
outcome, 1.47 to 2.64 per 10-year increase in age (Figure 3). The pooled ORs were 1.55 (95% CI 
1.32 - 1.86) for mortality (10 studies, 2376 cases) and 1.61 (95% CI 1.49 - 1.73) for unfavorable 
outcome (6 studies, 1982 cases) per 10 years of age. 
When combining aggregate and individual patient data, total ORs were 1.47 (95% CI 1.34 – 1.63) 
for mortality and 1.49 (95% CI 1.43 – 1.56) for unfavorable outcome (Figure 3, upper and lower). 
Figure 3. Graphs demonstrating a comparison of the strength of the effect of patient age 
on mortality (upper) and unfavorable outcome (lower) obtained from individual patient data 
and aggregate data. Solid squares denote the values for the estimated ORs. Horizontal lines 
extending to the right and left of the solid squares indicate the �5% CIs. The variation in the 
CIs is, for the most part, a function of the different sample sizes. Aggr. = aggregate�� ind. = 
individual�� Int. Tir. trial = Marshall, et al., 1���� and Hukkelhoven, et al., ������ NA. Tir. trial = 
Hukkelhoven, et al., ������ EBIC survey = Murray, et al., 1����� Selfotel trial = Morris, et al., 1����� 
OR = odds ratio�� CI = confidence interval  
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Discussion
We compared various age transformations to identify simple and accurate descriptions of the 
associations between age and mortality and age and unfavorable outcome in patients with severe 
TBI. We found that these associations were continuous. Statistically, age linear plus quadratic 
transformations fit significantly better than age linear ones. This was primarily caused by the 
slightly better fit in younger patients, who constituted a large part of the study population. 
Nonetheless, the absolute difference in the estimated probability of poor outcome comparing 
age linear and age linear plus quadratic transformations was at most a few percent, which 
we consider clinically unimportant; therefore, both age linear and age linear plus quadratic 
transformations are adequate descriptions of the association between patient age and six-month 
outcome following TBI. A linear relationship between age and outcome has also been reported 
in patients with aneurysmal SAH41,42. 
The smoothing splines (Figure 1) may also be interpreted as consisting of two linear parts. 
We found an optimal change point at 60 years for mortality and at 29 years for unfavorable 
outcome. These change points varied considerably across populations and contained broad CIs, 
however. Therefore, these piecewise linear transformations are less appropriate to describe 
the association between patient age and outcome. We also found a clear effect of age in those 
younger than 50 years, in contrast to a previous conclusion based on data in 372 patients4.
The use of age thresholds for describing the relationship between patient age and outcome 
resulted in a considerable loss of information and is therefore not recommended. Hence, our 
findings challenge the conclusions of authors who have published guidelines claiming that the 
association between patient age and outcome can be described in a stepwise manner17. The 
reason why authors of previous studies have identified age thresholds with many different 
values3-5,13-17 is probably a consequence of the statistical methods used. Arbitrary categorization 
of age and relatively small numbers of patients in specific age categories means that few patients 
can change proportion of poor outcome considerably.
 
Further, the value of the identified age threshold is determined by the distribution of age in 
the examined patient population. In the present study, with a close to linear association and a 
very large proportion of the patients between 15 and 65 years of age, thresholds were situated 
approximately midway, at 39 years, which was partly induced by the age distribution of the 
examined patient population. When separately analyzing the unselected population of the 
EBIC study, which contained a relatively greater number of older patients, threshold values 
included higher ages (that is, 59 years for mortality and 45 years for unfavorable outcome). 
It may be hypothesized that increased mortality at an older age is in part caused by an increased 
number of (possibly extracerebral) medical complications, which would be expected to increase 
late mortality. The median time to death did not differ between patients younger than and older 
than 50 years of age, however (p = 0.75, tirilazad data). Moreover, in both age groups the primary 
cause of death was cerebral, and no clear difference was noted in the frequency of extracerebral 
(systemic) causes of death. 
In accordance with several data from several other studies3,5,42 , we observed that the proportion 
of survivors with poor outcome (for example, severe disability or vegetative state) increased with 
age and that the proportion of patients with favorable outcomes declined. These results support 
the hypothesis that the adult brain has a decreased capacity for repair as it ages43, because of 
a decreasing number of functioning neurons and a greater exposure to minor repetitive (often 
subclinical) insults to the brain as age increases. In adults, however, diminished cognitive or 
behavioral function may be influenced beneficially by regeneration or plasticity of the brain44,45. 
Further investigation of the physiological and pathophysiological features in the aging brain is 
required to identify new medical interventions that perhaps could prevent the poorer outcome 
associated with advanced age. 
Several limitations of our analyses should be acknowledged. First, the individual patient data 
consisted mainly of selected populations from randomized clinical trials; therefore specific 
subgroups, such as patients with GCS motor score of 1 or an age older than 65 years, were 
underrepresented. Whether our findings may be extrapolated to these or other subgroups of 
patients with closed TBI is uncertain. Nonetheless, applying results to specific patient categories 
may be valid, given that statistical interactions between patient age and important confounding 
variables were not significant. Second, the less detailed study parameters – for example, the 
age categories – in the aggregate data may have led to less reliable ORs. The ORs of the pooled 
individual data did not differ considerably from the ORs of the pooled aggregate data, however. 
The ORs were generally 1.4 to 1.5 per 10 years of age and univariable and adjusted ORs were 
similar, although we cannot exclude possible effects of other confounding factors that were not 
(consistently) present in the data set, such as extracranial injuries4. 
Our study has a number of implications. First, a better estimate for the odds on poor outcome is 
obtained, that is, a 40 to 50% increase per 10 years of age, which is independent of the presence 
of risk factors. Furthermore, the existence of threshold values was not supported. Finally, the 
association between patient age and outcome after severe TBI is a continuous function, which 
can be adequately described by an age linear term or even statistically better by an age linear 
plus quadratic term. We therefore advise applying one of these transformations in future studies 
on adults with severe TBI for purposes of prognostic modeling or adjusting for confounding 
variables.
Acknowledgements
We gratefully acknowledge the permission granted by the principal investigators for accessing the data 
sets for purposes of the current study. We greatly appreciate all the work performed by the investigators 
and study personnel, without whose input the current analysis could not have been performed.  

Chapter 4

Age and outcome
References
1. Braakman R, Gelpke G, Habbema ��DF, Maas AIR, Minderhoud ��. Systematic selection of prognostic 
features in patients with severe head injury. Neurosurgery 1������������-���.
�. Choi S, Ward ��, Becker D. Chart for outcome prediction in severe head injury. �� Neurosurg 
1������5�(�)����4-���.
�. Gómez �, Lobato R, Boto G, De la Lama A, González �, de la Cruz ��. Age and outcome after severe 
head injury. Acta Neurochir (Wien) ������14������-���1.
4. Signorini D, Andrews �, ��ones �, Wardlaw ��, Miller ��. �redicting survival using simple clinical 
variables�� a case study in traumatic brain injury. �� Neurol Neurosurg �sychiatry 1�����������-�5.
5. Vollmer D, Torner ��, ��ane ��, et al. Age and outcome following traumatic coma�� why do older 
patients fare worse? �� Neurosurg 1��1���5��S��-S4�.
�. Laketta E. Age-associated cardiovascular changes in health�� impact on cardiovascular disease in 
older persons. Heart Fail Rev �����������-4�.
�. van Reekum R, Simard M, Cohen T. The prediction and prevention of Alzheimer’s disease - towards 
a research agenda. �� �sychiatry Neurosci 1������4��41�-4��.
��. Seeman T, Guralnik ��, Kaplan G, Knudson L, Cohen R. The Alameda County Study�� the health 
consequences of multiple morbidity in the elderly. �� Aging Health 1������1��5�-��.
�. Guralnik ��. Assessing the impact of comorbidity in the older population. Ann Epidemiol 1�����������-����.
1�. Yancik R, Wesley M, Ries L, Havlik R, Edwards R, Yates ��. Effect of age and comorbidity in 
postmenopausal breast cancer patients aged 55 years and older. ��AMA ���1�����5������5-����.
11. Narayan R, Greenberg R, Miller ��, et al. Improved confidence of outcome prediction in severe head 
injury. �� Neurosurg 1���1��54���51-���.
1�. Teasdale GM, Skene A, �arker L, ��ennett B. Age and outcome of severe head injury. Acta Neurochir 
Suppl (Wien) 1����������14�-14�.
1�. Overgaard ��, Hvid-Hansen O, Land A, et al. �rognosis after head injury based on early clinical 
examination. Lancet 1������(�����)����1-��5.
14. �iek ��, Chesnut R, Marshall LF, et al. Extracranial complications of severe head injury. �� Neurosurg 
1�����������1-���.
15. Resnick D, Marion D, Carlier �. Outcome analysis of patients with severe head injuries and 
prolonged intracranial hypertension. �� Trauma 1�����4�(�)��11���-1111.
1�. Waxman K, Sundine M, Young R. Is early prediction of outcome in severe head injury possible? 
Arch Surg 1��1��1����1���-1�4�.
1�. Chesnut R, Ghajar ��, Maas AIR, et al. Management and prognosis of severe traumatic brain 
injury. �art ��� early indicators of prognosis in severe traumatic brain injury. �� Neurotrauma 
������1�(�/�)��55�-���.
1��. ��ennett B, Bond M. Assessment of outcome after severe brain damage. A practical scale. Lancet 
1��5��1��4���-4��4.
1�. Hukkelhoven CW�M, Steyerberg EW, Farace E, Habbema ��DF, Marshall LF, Maas AIR. Regional 
differences in patient characteristics, management and outcome�� experience from the Tirilazad 
trials. �� Neurosurgery ����������54�-55�.
��. Marshall LF, Maas AIR, Marshall S, et al. A multicenter trial on the efficacy of using tirilazad 
mesylate in cases of head injury. �� Neurosurg 1�����������51�-5�5.
�1. Morris G, Bullock R, Marshall S, Marmarou A, Maas AIR, Marshall LF. Failure of the competitive N-
methyl-D-aspartate antagonist Selfotel (CGS 1��55) in the treatment of severe head injury�� result 
of two phase III clinical trials. The Selfotel investigators. �� Neurosurg 1������1�����-�4�.
��. Murray GD, Teasdale GM, Braakman R, et al. The European Brain Injury Consortium survey of 
head injuries. Acta Neurochir (Wien) 1�����141�����-���.
��. ��aggi ��, Obrist W, Gennarelli T, Langfitt T. Relationship of early cerebral blood flow and metabolism 
to outcome in acute head injury. �� Neurosurg 1���������1��-1���.
�4. Choi S, Muizelaar ��, Barnes T, Marmarou A, Brooks D, Young H. �rediction tree for severely head-
injured patients. �� Neurosurg 1��1���5���51-�55.
�5. Lobato R, Rivas ��, Cordobes F, et al. Acute epidural hematoma�� an analysis of factors influencing 
the outcome of patients undergoing surgery in coma. �� Neurosurg 1������������4��-5�.
��. Klauber M, Marshall LF, Barrett-Connor E, Bowers S. �rospective study of patients hospitalized 
with head injury in San Diego County, 1����. Neurosurgery 1���1��������-�41.
��. Gentleman D. Causes and effects of systemic complications among severely head injured patients 
transferred to a neurosurgical unit. Int Surg 1������������-���.
���. Gale ��, Dikmen S, Wyler A, Temkin N, McLean A. Head injury in the �acific Northwest. Neurosurgery 
1������1���4���-4�1.
��. Wilberger ��, Harris M, Diamond D. Acute subdural hematoma�� morbidity and mortality related to 
timing of operative intervention. �� Trauma 1�������(�)�����-���.
��. Royston �. A strategy for modelling the effect of a continuous covariate in medicine and 
epidemiology. Statist Med ������1���1���1-1��4�.
�1. Reinsch C. Smoothing by spline functions. Numer Math 1�����1���1��-1���.
��. Hastie T, Tibshirani R. Generalised additive models. London�� Chapman and Hall, 1���.
��. Hardy R, Thompson S. A likelihood approach to meta-analysis with random effects. Stat Med 
1�����15���1�-���.
�4. Marshall LF, Gautille T, Klauber M, et al. The outcome of severe closed head injury. �� Neurosurg 
1��1���5��S���-S��.
�5. Harrell FE, ��r., Lee KL, Mark DB. Multivariable prognostic models�� issues in developing models, evalua-
ting assumptions and adequacy, and measuring and reducing errors. Stat Med 1�����15(4)����1-���.
��. Little R. Regression with missing X’s�� a review. �� Am Stat Assoc 1����������1��� - 1���.
��. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford�� Oxford University �ress, 1���.
���. Steyerberg EW, Kievit ��, de Mol Van Otterloo ��, van Bockel ��, Eijkemans M��C, Habbema ��DF. 
�erioperative mortality of elective abdominal aortic aneurysm surgery. A clinical prediction rule 
based on literature and individual patient data. Arch Intern Med 1��5��155��1����-���4.
��. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1���������1��-1����.
4�. �etitti D. Approaches to heterogeneity in meta-analysis. Statist Med ���1���������5-����.
41. Kassell N, Torner ��, ��ane ��, Adams H, Kongable G. The International Cooperative Study on the 
Timing of Aneurysm Surgery. �art 1�� Overall management results. �� Neurosurgery 1���������1��-��.
4�. Lanzino G, Kassell N, Germanson T, et al. Age and outcome after aneurysmal subarachnoid 
hemorrhage�� why do older patients fare worse? �� Neurosurgery 1�������5��41�-41��.
4�. Carlsson C, Von Essen C, Lofgren ��. Factors affecting the clinical course of patients with severe 
head injuries. I. Influence of biological factors. II Significance of post-traumatic coma. �� Neurosurg 
1�����������4�-�4���� �4��-�51.
44. Marshall LF. Head injury�� past, present and future. �� Neurosurgery ������4���54�-5�1.
45. �eterson D. Stem cells in brain plasticity and repair. Curr Opin �harmacol ����������4-4�.
0
Chapter 4
5
Prediction of outcome in traumatic brain 
injury with CT characteristics:  
a comparison between the CT-classification 
and combinations of CT predictors
A.I.R. Maas, C.W.P.M. Hukkelhoven, L.F. Marshall, E.W. Steyerberg
Neurosurgery, in press
2
Chapter 5
3
 CT and outcome 
Abstract
Background and objective
The Marshall CT-classification identifies six groups of patients with Traumatic Brain Injury (TBI), 
based on morphologic abnormalities on the CT scan. This classification is increasingly used as a 
predictor of outcome. We aimed to examine the predictive value of the Marshall CT-classification 
in comparison with alternative CT models. 
Methods
The predictive value was investigated in the Tirilazad trials (n=2269). Alternative models were 
developed with logistic regression analysis and recursive partitioning. Six-month mortality was 
used as outcome measure. Internal validity was assessed with bootstrapping techniques and 
expressed as the area under the receiver-operating curve (AUC). 
Results
The Marshall CT-classification showed reasonable discrimination (AUC = 0.67), which could 
be improved by rearranging the underlying individual CT characteristics (AUC = 0.71). 
Performance could be further increased by adding intraventricular and traumatic subarachnoid 
hemorrhage and by a more detailed differentiation of mass lesions and basal cisterns (AUC = 0.77). 
Models developed with logistic regression analysis and recursive partitioning showed similar 
performance. For clinical application we propose a simple CT score, which permits a more clear 
differentiation of prognostic risk, particularly in patients with mass lesions. 
Conclusion
It is preferable to use combinations of individual CT predictors rather than the Marshall CT-
classification for prognostic purposes in TBI. Such models should include at least the following 
parameters: status of basal cisterns, shift, traumatic subarachnoid or intraventricular hemorrhage, 
and presence of different types of mass lesions. 
Introduction
Classification of traumatic brain injury (TBI) is necessary to accurately describe patient series 
and requires grouping of patients according to specific characteristics. In clinical practice, the 
clinical severity of TBI is generally classified as severe, moderate or mild according to the level 
of consciousness as measured with the Glasgow Coma Scale (GCS). The increased use of early 
sedation, intubation and ventilation in more severe patients has decreased the value of the full 
GCS for purposes of classification1-3. Alternatively, in more severe patients, TBI can be classified 
according to morphologic criteria based on CT or MRI investigations. Although MRI may be more 
sensitive for detecting small white matter lesions in a later phase after TBI, CT examination 
remains the investigation of choice in the acute phase4,5. 
Conventional classification of TBI with CT findings differentiates between focal and diffuse 
injuries6,7. In 1991 Marshall et al.8, following analysis of the Traumatic Coma Data Bank, proposed 
a CT-classification for grouping patients with TBI according to multiple CT characteristics. This 
CT-classification identifies six different groups of patients with TBI, based on the type and 
severity of several abnormalities on the CT scan. It differentiates between patients with and 
without mass lesions and permits a further discrimination of patients with diffuse injuries 
into four categories, taking into account signs of raised ICP (i.e. compressed or absent basal 
cisterns, midline shift). Since its introduction this CT-classification has become widely accepted 
for descriptive purposes, and is also increasingly being used as major predictor of outcome 
in TBI. Various studies have confirmed the predictive value of the CT-classification9-11, and the 
international guidelines on prognosis include the CT-classification as a major CT predictor 
based on class I evidence12. Whether the Marshall CT-classification is best suited for prediction 
or whether other combinations of CT parameters may be more appropriate for this specific 
purpose has not been investigated in detail. 
The aim of the present study was to examine the prognostic performance of the Marshall CT-
classification in comparison with other combinations of CT predictors in TBI, by re-weighting 
and refining the CT characteristics used to determine this classification and by including 
additional CT parameters.
Patients and methods
The Marshall CT-classification
The Marshall CT-classification is presented in Table 1. Discriminating features in this classification 
are 1) presence or absence of mass lesions, 2) presence or absence of intracranial abnormalities 3) 
CT signs of raised intracranial pressure (status of basal cisterns, shift), and 4) planned evacuation 
of mass lesions. 
To facilitate comparison with alternative classifications we translated the Marshall CT-
classification into a binary tree (Figure 1). 
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Patients
Our studies were conducted on the combined data sets of the International and North American 
Tirilazad trials (n=2269). Details on the Tirilazad trials have been reported elsewhere13,14. Inclusion 
and exclusion criteria of the two trials were similar. Both trials included patients between 15 
and 65 years of age with severe (GCS 3-8) or moderate (GCS 9-12) closed TBI. With respect to 
the CT characteristics the inclusion criteria varied slightly: the international study excluded 
moderate TBI patients with a normal CT scan, whereas the North American study excluded such 
patients only when the blood alcohol level exceeded 0,2 g/dl. Protocols and recommendations 
for management were comparable for both trials.
In both trials the efficacy of Tirilazad mesylate, an amino-steroid that displays an antioxidant 
effect, was studied against that of placebo. We combined data from placebo and treatment 
groups, since in neither trial a significant difference between the Tirilazad and the placebo 
treated group was shown for the primary outcome measure, i.e. mortality and unfavorable 
outcome on the Glasgow Outcome Scale.
Definitions of CT characteristics and outcome
We based our studies on data recorded for admission CT scans performed within the first 
4 hours after injury. Full data on CT characteristics on admission were available in 2249 patients. 
CT data were extracted on the following items:
- CT-classification
- presence of abnormalities
- presence and size of midline shift
- status of basal cisterns
- presence of intraventricular blood (IVH)
- presence of traumatic subarachnoid hemorrhage (tSAH)
- presence and type of mass lesions and expected evacuation of mass lesion
- single versus multiple non-mass lesions
The characteristics ‘any abnormalities’, ‘intraventricular blood’, ‘tSAH’ and ‘expected evacuation 
of mass lesions’ were available in the data sets as binary data and scored as present or absent, 
without further differentiation. The other CT characteristics were classified into several 
categories with increasing differentiation: midline shift was classified in two ways: (i) shift ≤ 5 
mm versus shift > 5 mm and (ii) no shift, shift of 1-5 mm, shift of 6-10 mm, or shift > 10 mm. The 
status of basal cisterns was categorized in two ways as (i) normal versus abnormal (compressed 
and absent) and (ii) normal versus compressed versus absent. Presence and type of mass lesions 
were categorized in 3 ways as (i), mass lesion present or absent (ii), absent mass lesion, epidural 
mass lesion, intradural (intracerebral plus subdural) mass lesion and (iii) absent mass lesion, 
epidural mass lesion (EDH), subdural mass lesion (SDH), intracerebral mass lesion.
For several patients values of some of the predictors were missing (4,8% of the required values). 
These values were statistically estimated with regression models including the other predictors 
and subsequently imputed15,16. This approach is considered preferable to complete case analysis, 
in which patients with missing values are excluded from analysis15.  The outcome measure was 
mortality at six months post-injury.
Figure 1  Marshall CT-classification presented in a tree structure
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Table 1 Diagnostic categories of types of abnormalities visualized on computed tomography 
(CT) scanning
Category Definition
Diffuse injury I no visible intracranial pathology seen on CT scan
Diffuse injury II cisterns are present with midline shift �-5 mm and/or�� 
- lesion densities present, 
- no high- or mixed-density lesion > �5 cc, 
- may include bone fragments and foreign bodies
Diffuse injury III cisterns compressed or absent with midline shift �-5 mm, no high- or 
mixed-density lesion > �5 cc
Diffuse injury IV midline shift > 5 mm, no high- or mixed-density lesion > �5 cc
Evacuated mass lesion any lesion surgically evacuated
Non-evacuated mass lesion high- or mixed-density lesion > �5 cc, not surgically evacuated
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Statistical analysis and performance of models
To test whether the arrangements of the CT characteristics within the Marshall CT-classification 
was reasonable for predictive purposes, we developed alternative models with the same 
variables. Subsequently, we investigated whether performance could be improved by adding CT 
characteristics or by separating already included characteristics into smaller categories. Each 
model was developed with two methods: recursive partitioning (CART)17 and logistic regression 
analysis. We chose these two approaches for different reason: logistic regression analysis is a 
standard statistical procedure, in which interactions and relative importance of predictors are 
considered. Results are generally robust, but the underlying methodology may remain unclear 
to non-statisticians. On the other hand recursive partitioning, in which prediction trees are 
created, has a greater clinical appeal, but carries some risk of overfitting, especially in more 
complex trees. To correct for this, the trees were pruned using cross validation.  
Modeling was performed with SAS software (version 6.12, SAS Institute INC., Cary, NC) and 
S-plus (version 2000, Insightful Corporation, Seattle, WA), using the RPART library. The RPART 
library (rpart2.zip) and manual (rpart2doc.zip) can be found at http://www.stats.ox.ac.uk/pub.
Swin.
Internal validity of the original CT-classification and alternative models was assessed with 
bootstrapping procedures. Internal validity assesses whether the models perform well for 
a population of patients similar to those for whom the model was developed. Bootstrapping 
involved taking samples 100 times with replacement from the development sample. Each sample 
can be considered as repeating the data collection with the same number of patients and under 
identical circumstances as the original. In each of the 100 bootstrap samples a regression model 
was estimated, and evaluated on the original sample, applying a shrinkage factor to correct for 
optimism15,18-20. In this way nearly unbiased predictions of outcome can be obtained for future 
but similar patients15,19,21.
 
Performance of the models was assessed with respect to discrimination, which can be quantified 
by the area under the receiver-operating curve (AUC). For a randomly chosen pair of patients, the 
AUC represents the probability that a patient who dies has a higher predictive probability for 
mortality. The higher the AUC, the better the model discriminates. A model with an AUC of 0.50 
has no discriminative power, while a model with an AUC of 1.0 reflects perfect discrimination.
Application in clinical practice
Presentation of a classification according to a prediction tree is readily understandable for a 
clinical audience. Interpretation of a logistic regression model is more complicated. To facilitate 
application of these models we created a score chart to estimate the outcome probability based on 
the values of the regression coefficient, which were re-scaled and rounded to whole numbers.   
Table 2 Distribution of CT parameters and mortality in the International and in the North 
American sample
CT parameters and outcome Total
(n=��4�)
International 
sample (n=111�)
North American
sample (n=11��)
 n  %  n  %  n  %
CT parameters
Abnormalities No 1�� ��% 5� 5% 1�1 11%
Yes ���� ��% 1��� �5% 1�1� ���%
Missing � � �
Traumatic SAH No 1��� 4�% 51� 4��% 511 4�%
Yes 11�1 5�% 5�� 5�% ��4 54%
Missing 4� �� ��
Intraventricular  
blood
No 1�4� ��% ���� ��% ����� ��%
Yes 4�� �1% ��5 �1% ���� �1%
Missing �� 14 1�
Basal cisterns Normal 11�4 54% 5�� 5�% �1�� 5�%
Compressed ��� ��% ��5 �4% ��4 ��%
Absent ��� 1�% 14� 1�% 15� 14%
Missing 5� 1�� ��
Midline shift None 14�� �4% �54 5�% ��� ��%
1 - 5 mm ��� 1�% ���� 1�% 154 14%
� - 1� mm ��� 11% 1�1 11% 11� 1�%
> 1� mm 1�� �% 11�� 11% �� �.5%
 Missing ��� 11 ��
Lesion No ��� 1�% 11� 11% �4� ��%
Yes 1���� ��4% ��5 ���% ���� ���%
One, not mass ��1 ��% 4�� ��% ��� ��%
Multiple, not 5��5 �1% ��� ��% �5� ��%
Mass lesion ��� ��% ��� ��% �5� 41%
Epidural* ��4 ���% 1�� �5% �5 �1%
Subdural* 41�� 5�% ��5 55% �1� 5�%
Intracerebral* 5��4 ���% ��� �5% ��� ���%
Missing �1 4 1�
CT-classification I 1�� ��% 5� 5% 1�1 11%
II ���� ��% 4�5 ���% 4��� ��%
III 4�� 1�% �1� ��% ��� 1��%
IV ���� 4% 4� 4% 4� 4%
V 5�� �4% ���� ��% �5� ��%
VI 1�� ��% ��1 �% 1�� 1�%
Missing � � �
Outcome
Mortality Yes 4�1 ��% ��� �4% ��1 1�%
No 1�5�� ���% ��4� ��% �1� ��1%
Missing � � �
* More than one (type of) mass lesion on the CT scan was possible
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Results
Individual CT characteristics and outcome
The distribution of CT characteristics and outcome is presented in Table 2. Mortality was lower 
in the North American patients (19%) than in the International patients (24%), partly reflecting 
a different distribution of severe versus moderate patients included in both trials. More than 
90% of the patients had abnormalities on the admission CT scan: 84% showed evidence of 
parenchymal or extracerebral lesions, 45% had abnormal basal cisterns, 53% tSAH and 21% had 
intraventricular blood. Mass lesions were present in 39% of the population, and of these 80% had 
an associated intracerebral lesion. 74% of all mass lesions were evacuated and of these 84% were 
evacuated within 4 hours of injury. 
Midline shift, basal cisterns, intraventricular blood and traumatic subarachnoid hemorrhage 
were identified as significant predictors of mortality (Table 3). In the multivariable analysis the 
full differentiation of lesions was not clearly associated with differences in mortality, but the 
differentiation between epidural and intradural lesions was highly relevant (Table 3, Table 4). 
Prognostic value of CT-classification versus alternative groupings of individual 
components
Figure 2 presents the classification of our patient population according to the Marshall CT-
classification in a prediction tree format with mortality figures per class. The percentage 
mortality in patients with no abnormalities (CT class 1) and in patients with diffuse injuries 
without radiological signs of raised ICP (CT class 2) was low (6.4 and 11% respectively). The 
highest mortality rate was observed in patients with absent or compressed basal cisterns and a 
midline shift larger than 5 mm (CT class 4): 44%. Mortality rates for patients with mass lesions 
were 30% for those with evacuated mass lesions and 34% for those with non-evacuated mass 
lesions. Analysis of the discriminatory properties of the Marshall CT-classification showed an 
AUC of 0.669. 
Figure 3 presents a prediction tree constructed with recursive partitioning, using the same 
characteristics and the same number of terminal nodes as used in the Marshall CT-classification. 
We found that a primary division according to status of the basal cisterns yields the strongest 
discrimination. Subsequently for patients with present basal cisterns a split on abnormalities 
and for patients with absent or compressed basal cisterns a split on shift > 5 mm caused 
the maximum reduction in heterogeneity. Discriminatory analysis showed an AUC 0.705, 
considerably higher than found for the original CT-classification. 
Alternative models with additional variables
We investigated whether models could be developed with better discriminative properties by 
adding additional CT predictors not originally included in the Marshall CT-classification or by 
further separation of already included CT characteristics.
– continues on page 103 –
Table 3  Multivariable analysis of CT characteristics, pooled Tirilazad patients
Characteristics Categorization Mortality OR (5% CI)*
Abnormalities No �.4% Reference
Yes ��% 1.� (�.5 – �.�)
Shift No shift 1�% Reference
� - 5 mm ��% 1.4 (1.� – 1.�)
� – 1� mm ��% 1.� (1.1 – �.4)
> 1� mm 4�% �.� (1.� – �.1)
Basal cisterns Normal 15% Reference
Compressed ��% �.� (1.5 – �.�)
Absent 55% 5.� (4.� – ��.�)
Intraventricular blood No 1�% Reference
Yes �1% �.� (1.5 – �.�)
TSAH No 1�% Reference
Yes ��% �.� (1.5 – �.5)
Lesions No 1�% Reference
Single non-mass 15% �.� (�.� – 1.4)
Multiple non-mass ��% 1.� (�.� – 1.�)
Epidural mass 1�% �.5 (�.4 – �.�)
Subdural mass 4�% 1.4 (�.� – �.1)
Intracerebral mass �5% 1.1 (�.� – 1.�)
* OR = Odds Ratio, �5% CI = �5% Confidence Interval 
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Table 4  Added discriminative value of  a) extra CT characteristics and b) further differentiation 
of  CT characteristics 
Models Discrimination (AUC*)
Logistic regression Recursive partitioning
Basic model # �.��� �.��5
Added CT characteristic
  Evacuation mass lesion �.�14 �.�1�
Dropped CT characteristics
  Any abnormalities �.��� �.��1
Added CT characteristics 
   Non-mass lesions (single or multiple) �.�14 �.�1�
   Blood (tSAH and/or intraventricular blood) �.��� �.���
Separation of already included CT characteristics
   Mass as epidural versus intradural �.��� �.�1�
   Mass as epidural vs subdural vs intracerebral �.��� �.��1
   Cisterns (normal, compressed, absent) �.��� �.���
   Shift (no, 1-5 mm, �-1� mm, > 1� mm) �.�1� �.�1�
All ‡ �.��� �.��4
* AUC = Area under the receiver operating curve
# The basic model contains all characteristics included in the Marshall CT-classification, except 
evacuation mass lesion
‡ All�� Characteristics of the basic model plus single non mass lesions, multiple non mass lesions, 
mass as epidural vs. subdural vs. intracerebral, cisterns as normal vs. compressed vs. absent, shift 
as 1-5 mm vs. �-1� mm vs. > 1� mm, blood as tSAH vs. intraventricular blood
Figure 2  Mortality for each category of the Marshall CT-classification, Tirilazad cohort 
(n=��4�)
Figure 3  Mortality for each category of the CT prediction tree constructed with recursive 
partitioning, using the same characteristics and the same number of terminal nodes as in 
the Marshall CT-classification. Construction occurred on the Tirilazad cohort (n=��4�)  
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The added benefit of additional parameters was assessed versus the basic model presented 
in Figure 3. Results are summarized in Table 4. The discriminative ability could be improved 
considerably by adding tSAH and intraventricular blood, and by further differentiating the basal 
cisterns, midline shift and mass lesions into several categories. Dropping the characteristic ‘any 
abnormalities’ had negligible influence on the AUC. No statistically significant interactions were 
observed between the selected characteristics (p = 0.42). 
The results of this multivariable analysis showed the potential for developing an alternative model 
with added characteristics. Including all discriminating variables in a logistic regression model 
yielded an AUC of 0.769, and of 0.794 in the prediction tree. Such a model is however complex and 
resulted in 15 terminal nodes in the prediction tree. Searching for an appropriate compromise 
between good discrimination and easy clinical applicability we chose a simpler model based on the 
following characteristics: midline shift (subdivided into 0-5 mm, > 5 mm), basal cisterns (subdivided 
into absent, compressed and present), mass lesion (subdivided into epidural and intradural), 
traumatic subarachnoid hemorrhage and/or intraventricular blood. The apparent validity of this 
model was 0.750 and on internal validation we obtained an AUC of 0.748. 
Clinical application
For clinical application we translated the logistic regression model into a score chart, with which 
the probability for mortality according to the CT characteristics can be estimated by adding the 
scores for individual patients (Table 5). We chose to add plus 1 to the sum score in order to make 
the grading numerically consistent with the grading of the motor score of the GCS and with 
the Marshall CT-classification. Table 6 shows the application of this score chart for classifying 
the study population according to prognostic risk. The difference in observed mortality rates 
between patients from the lowest and patients from the highest risk group is 61%, which is 
considerably larger than the maximal difference in mortality in the Marshall CT-classification 
(38%, Figure 2). Table 7 illustrates the better discrimination for prognostic risk assessment of 
the CT prediction score in comparison to the Marshall CT-classification, particularly in patients 
with mass lesions.
Table 5  �rognostic score chart for the probability of mortality in patients with severe or 
moderate TBI according to their CT characteristics
Predictor Value Score
Basal cisterns Normal �
Compresssed 1
Absent � 
Midline shift No shift or shift ≤ 5 mm �
 Shift > 5mm 1
Epidural mass lesion �resent � 
Absent 1
Intraventricular blood or tSAH Absent �
�resent 1
Sum score*�� add relevant scores ….. +1
* The sum score can be used to obtain the predicted probability of mortality from the formula below. 
We chose to add plus 1 to make the grading numerically consistent with the grading of the motor 
score of the GCS and with the Marshall CT-classification. The corresponding probabilities are calcu-
lated with the formula�� �robability (mortality) =  1/[1+ e –(-�.��+ �.��� *Sumscore)] 
Table 6  CT-classification by prediction score 
Score Nr of patients Actual mortality
 n %
1 �� � �
� ��� 41 �.��
� ��� 1�� 1�
4 4�5 1�1 ��
5 ��1 1��� 5�
� 114 �� �1
Table 7  Marshall CT-classification compared to the CT prediction score
 CT prediction score Marshall CT-classification
1 � � 4 5 � Total
1 � � � � �5 1 ��
� 1�� ��� � � �5 �� ���
� � 4�� 1�� 5 �5 �4 ���
4 � 5 �4� 1� 1�� 5� 4�5
5 � � �� �� 1�4 �� ��1
� � � � �� �4 1� 114
Total 1�� ���� 4�� ���� 5�� 1�� ��4�
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Discussion
We confirmed the predictive value of the Marshall CT-classification in a large series of patients 
(n=2249), but showed that a better discrimination can be obtained by making fuller use of the 
individual CT characteristics underlying the Marshall CT-classification. Discrimination could 
be further improved by adding intraventricular and traumatic subarachnoid hemorrhage and 
by a more detailed differentiation of mass lesions and basal cisterns (AUC = 0.77). We do not 
wish to detract from the general validity and appeal of the Marshall CT-classification when used 
for descriptive purposes. This classification however was not developed from the perspective 
of prognosis, and the question whether the categorization of variables in the Marshall CT-
classification is appropriate for predictive purpose is relevant. For instance in the Marshall CT-
classification, radiological signs of raised ICP (status of basal cisterns and presence of shift) are 
only used for further differentiation of patients with diffuse injuries whilst these parameters 
may also be expected to be of prognostic value particularly in patients with mass lesions. Indeed, 
Table 7 shows a better prognostic discrimination of the proposed prognostic CT score over the 
Marshall CT-classification, particularly in patients with mass lesions. 
The presence of tSAH has been shown to be a strong predictor both for outcome and mortality 
in TBI, but is not included in the Marshall CT-classification22-28. The predictive value of tSAH in 
TBI is confirmed in our study and we have additionally shown that including this parameter in a 
predictive model significantly increases discrimination; we also found IVH to be an independent 
predictor, in contrast to other studies in which the relation of IVH to poorer outcome was mainly 
caused by the association with other predictors22,29,30. Further, the Marshall CT-classification does 
not permit any distinction on type of mass lesion. Many studies have shown that prognosis in 
patients with an EDH is much better than in those with a subdural or intracerebral hematoma6,12. 
Bricolo et al.31 postulated that mortality should approach zero in patients with an uncomplicated 
EDH. As shown in Table 6 we found zero mortality in such patients (mass lesion with a prognostic 
score of 1). A further problem with the original CT-classification is that it differentiates between 
patients with evacuated versus non-evacuated mass lesions. Many have argued that this reflects 
a clinical decision and does not in itself constitute a CT-parameter, and in clinical practice this 
has led to confusion and it has been proposed not to include this differentiation11. Nevertheless 
we do note a 4% difference in mortality between patients with evacuated versus non-evacuated 
mass lesions. Further in depth adjusted analysis however will be required to determine whether 
the baseline characteristics of these two groups were similar or not.
Previous studies have shown that the Marshall CT-classification is a strong predictor in TBI3,9-12,25, 
with high inter- and intra observer reliability32. Wardlaw et al.33, however, found in a retrospective 
analysis of 425 patients of varying severity that the Marshall CT-classification did not remain 
a significant independent outcome predictor on multivariate analysis when clinical features 
were included, in contrast to tSAH and a newly suggested, ill-defined variable describing ‘overall 
appearance’. For the present study we did not include clinical characteristics in our models, but 
in a previous study describing a prediction model for TBI, we found that both the Marshall CT-
classification and tSAH remained as statistically significant predictors in multivariate analysis, 
following adjustment for clinical variables9.  
Consistent with other prediction studies in TBI34, we found that performance of the models 
was more dependent on the variables included than on the statistical approach. We found no 
clear statistical benefit in the use of a prediction tree compared to logistic regression models. 
We considered the use of a prediction tree in the current analysis appropriate as the Marshall 
CT-classification can be readily presented as prediction tree, which may be appealing for the 
clinician. Further, a tree can capture and correct easily for interaction, i.e. different relations 
between predictors in different subgroups. Interaction, if present, is easily detected by a 
better discriminative ability of the tree as compared to a logistic model. We did not observe 
such differences in our studies. The clinical appeal of a prediction tree method is however also 
dependent on the number of terminal nodes. The limited number of nodes (n=6) in the Marshall 
CT-classification and in the basic model makes this type of presentation appropriate. When 
additional variables were added to our model we found an optimal number of 15 terminal 
nodes, which significantly decreases the clinical appeal. For this reason we would prefer the 
logistic regression model, also as discriminative properties are similar. We realize that a logistic 
regression model may have less clinical appeal and therefore suggest to translate it into a score 
chart as proposed in table 6. Although this score chart performed well in our study population, 
assessment of its general applicability will require validation in other data sets. 
A number of limitations of our study should be recognized. First, our studies were performed 
on a large patient series including only patients with severe and moderate injury. Results can 
therefore not be extrapolated towards patients with mild injuries. Second, we focused our studies 
on analysis of data from the initial CT examination performed within 4 hours after injury. Other 
studies10,11 have shown that the ‘worst’ CT scan obtained during the clinical course has greater 
predictive value. Also within the current data set we found that the final CT-classification, based 
on the worst CT following admission, yielded better discrimination (AUC = 0.692 for Marshall CT-
classification and 0.716 for basic model). The intent of our studies, however, was to investigate 
the use of the CT-classification and CT predictors toward a prognostic classification of TBI on 
admission. Such classification is considered useful to establish the baseline characteristics 
and prognostic risk of TBI patients on admission. Third, the predictive analysis presented was 
conducted versus six-month mortality. For these studies we chose mortality rather than the 
GOS dichotomized into unfavorable versus favorable as this constitutes a hard and objective 
endpoint without any missing outcome data. As a sensitivity analysis we additionally calculated 
the discriminative properties of the Marshall CT-classification, the basic model in which the 
individual parameters of the CT-classification were rearranged and the extended model versus 
unfavorable outcome and found similar results. 
In summary, we conclude that the Marshall CT-classification has strong predictive power, but 
greater discrimination can be obtained if the individual CT parameters, underlying the CT-
classification are included in a prognostic model. Consequently for prognostic purposes we 
recommend the use of individual characteristics rather than the CT-classification. Performance 
of CT models for predicting outcome in TBI can be significantly improved by including more 
details of variables and by adding other variables to the model. We suggest that such models 
should include the following characteristics: status of basal cisterns, shift, tSAH and/or IVH and 
presence of mass lesions with differentiation between EDH versus intradural lesions. For more 
easy clinical application models can be translated into a score chart.
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Abstract
Context
Early prediction of outcome after traumatic brain injury (TBI) is important for several purposes, 
but no prognostic models have yet been developed with proven generalizability across different 
settings. 
Objective
To develop and validate prognostic models that use information available at admission to estimate 
six-month outcome after severe or moderate TBI. 
Main outcome measures
Mortality and unfavorable outcome, i.e. death, vegetative state or severe disability on the Glasgow 
Outcome Scale, at six months post-injury. 
Design, setting and patients
We used prospectively collected data on 2269 patients from two multi-center clinical trials to 
develop prognostic models for each outcome with logistic regression analysis. We included seven 
predictive characteristics, i.e. age, motor score, pupillary reactivity, hypoxia, hypotension, CT-
classification and traumatic subarachnoid hemorrhage. The models were validated internally with 
bootstrapping techniques. External validity was determined in prospectively collected data from 
two relatively unselected surveys in Europe (n=796) and in North America (n=746). We evaluated 
the discriminative ability, i.e. the ability to distinguish patients with different outcomes, with the 
area under the receiver operating characteristic curve (AUC). Further, we determined calibration, 
i.e. agreement between predicted and observed outcome, with the Hosmer-Lemeshow goodness-
of-fit test. 
Results
The models discriminated well in the development population (AUC 0.78 to 0.80). External validity 
was even better (AUC 0.83 to 0.89). Calibration was less satisfactory, with poor external validity 
in the North American survey (p<0.001). Especially, observed risks were higher than predicted for 
poor prognosis patients. A score chart was derived from the regression models to facilitate clinical 
application.
Conclusions
Relatively simple prognostic models using baseline characteristics can accurately predict six-
month outcome in patients with severe or moderate TBI. The high discriminative ability indicates 
the potential of this model for classifying patients according to prognostic risk.
Introduction
Traumatic brain injury (TBI) is a major cause of death and disability among a predominantly young 
population. In the USA each year about 52.000 people die and 80.000 remain severely disabled after 
TBI1. Early prediction of outcome may support clinical decision-making and resource allocation 
and may provide realistic and evidence-based expectations to relatives. Predictions may also be 
used to classify patients according to prognostic risk, which may be useful to compare outcome 
between different patient series, to study treatment results over time, or to stratify patients for 
randomized clinical trials (RCTs)2. 
Several prognostic models have been developed to predict long term outcome for patients with 
severe or moderate TBI3-16. Many of the models pre-date the general availability of Computed 
Tomography (CT) scans or include data obtained after admission. Also, the prognostic value of 
the commonly included eye- and verbal score of the Glasgow Coma Scale is nowadays restricted 
due to current management approaches such as early sedation and intubation17-19. Furthermore, 
many studies used relatively small sample sizes originating from a single center or region, which 
limits generalizability. The model may perform well in the development sample, but poorly when 
applied to other groups of patients, e.g. patients from another region. Validation of a prognostic 
model on another patient series should therefore be considered essential20. Unfortunately, such 
external validity has seldom been assessed in the field of TBI21. We can therefore only have limited 
confidence in previously developed prognostic models for outcome prediction in current patients 
with TBI.
We aimed to develop and validate prognostic models for six-month outcome, i.e. mortality and 
unfavorable outcome according to the Glasgow Outcome Scale (GOS)22. We used large patient 
series from a broad range of western countries. We consider a model based on easily accessible 
clinical features and CT scanning, available on admission.
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Patients and methods
Patients
Two selected patient populations were used for model development, i.e. the patients included in 
the International and in the North American multi-center (phase III) RCTs on the drug Tirilazad 
Mesylate in TBI23,24. These are the largest available data sets on severe and moderate TBI. The 
models were validated in two relatively unselected populations of patients consecutively admitted 
with severe or moderate TBI, i.e. the core data survey conducted by the European Brain Injury 
Consortium (EBIC)25 and the Traumatic Coma Data Bank (TCDB)26.
 
The protocols and the inclusion and exclusion criteria of the two Tirilazad trials were virtually 
identical. Both trials enrolled patients aged 15-65 years, with a severe (Glasgow Coma Scale27 (GCS) 
3-8) or moderate (GCS 9-12) closed TBI. Patients with an absent motor score or with a moderate 
TBI and a normal CT scan were excluded. All patients were admitted to a neurosurgical unit 
within four hours after injury. Recommendations for patient management were similar across 
the centers. The International Tirilazad trial (n=1120) was conducted in 40 centers in Europe, Israel 
and Australia from 1992 to 1994 and the North American Tirilazad trial (n=1149) in 36 centers in 
the USA and Canada from 1991 to 1994. By protocol, the proportion of patients with moderate 
TBI was lower in the International trial (14% versus 28% in the North American trial). Details on 
the Tirilazad trials have been reported23,24. Both Tirilazad trials studied the efficacy of Tirilazad 
Mesylate, an amino-steroid with anti-oxidant effect, against a placebo28. We combined data from 
placebo and treatment groups, since in both trials no statistically significant difference between 
the Tirilazad and the placebo treated group was shown for the primary outcome measure. 
The survey by the European Brain Injury Consortium (EBIC) included 796 patients with severe or 
moderate TBI25, consecutively collected between February and April 1995 from 55 European centers 
in which the six-month outcome assessment was routinely performed. The National Traumatic 
Coma Data Bank (TCDB) contained data on 746 patients with non penetrating severe TBI (GCS ≤ 8) 
admitted to four centers in the USA29. Data acquisition occurred from 1984 to 1988. In the surveys 
patients were included if they deteriorated to a condition meeting enrollment criteria within 24 
or 48 hours respectively.
Definitions of potential predictors and outcome 
We considered patient characteristics that were previously identified as important predictors30,31, 
and that could be determined easily and reliably within the first hours after injury. These 
included age, gender, cause of injury, motor score, pre-admission hypotension and hypoxia, 
pupillary reactivity, CT-classification32 and the presence of traumatic subarachnoid hemorrhage 
(tSAH). Cause of injury was categorized into traffic accidents, falls and other causes. Hypotension 
and hypoxia were considered present when documented by a systolic blood pressure below 
90 mm Hg or a pO2 below 60 mm Hg respectively, or if supported by strong clinical suspicion. 
Pupillary reactivity and motor score were measured on admission. For the motor score, we 
combined category ‘no response’ with ‘extensor response’ and category ‘localizing’ with ‘obeying 
commands’ to increase numbers per class. 
The CT-classification and the presence of tSAH were derived from the admission CT scan, obtained 
within the first four hours after the injury. The CT-classification32 systematically groups a spectrum 
of abnormalities on the CT scan, such as diffuse injury, midline shift, obliterated basal cisterns 
and mass lesions into six categories. Since only few patients were classified into category I (‘no 
visible abnormalities’), this category was combined with category II. The categories V (‘mass lesion 
evacuated’) and VI (‘mass lesion non-evacuated’) were joined to eliminate possible differences in 
decision-making concerning the evacuation of mass lesions. 
For several patients, values of some of the predictors were missing (4.8% of the required values). 
These values were statistically estimated with regression models including the other predictors, 
and subsequently imputed33,34. Such imputation is recommended as more efficient than dropping 
cases33. The true variability among predictor values is only slightly underestimated because of the 
small numbers of missing values. We also developed models with complete cases only, and found 
only minor differences in the model characteristics.
The two outcome measures were mortality and unfavorable outcome at six months post-injury. 
Data on mortality were available for all 2269 Tirilazad patients. Data on unfavorable outcome, 
derived from the GOS measurement, were available for 2137 patients, including 120 estimated 
outcomes based on GOS measurements at other points in time23. The EBIC survey contained data 
on six-month mortality and unfavorable outcome. In the TCDB the GOS assessment was frequently 
outside the window of six months +/- one month. We therefore chose to limit this analysis to 
mortality, since mortality generally occurs early and almost always within the first few months. 
Model development
We used logistic regression analysis to estimate the association between a predictor and outcome, 
expressed as an odds ratio (OR). Predictors have statistically significant effects (p < 0.05) if the 95% 
confidence interval (95% CI) of the OR does not include the value one. 
For both outcome measures (mortality and unfavorable outcome) a multivariable model was 
developed containing predictors that had a p-value < 0.20 in a backward stepwise procedure35. In a 
relatively large patient population, this liberal p-value will exclude only those characteristics with 
low predictive value36. 
Age was included as a linear and a squared term37. Regression coefficients of the clinical and CT 
predictors were similar across the two Tirilazad populations, as confirmed by statistically non-
significant interaction terms between predictors and population. Therefore, merging of the two 
populations was considered legitimate. 
Performance 
The performance of the models was assessed with respect to calibration and discrimination. 
Calibration is the ability of the model to produce unbiased estimates of the probability of the 
outcome. For example, if patients with certain characteristics are predicted to have a 10% chance of 
mortality, the actually observed mortality should also be 10%. Calibration was assessed graphically 
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by plotting observed outcome against the predicted probability. A smooth, non-parametric 
calibration line was created with the lowess algorithm36. Calibration was tested with the Hosmer-
Lemeshow goodness-of-fit test, which assesses agreement between predicted and observed risks 
over the full range of predicted probabilities. Patients were grouped per decile of predicted risk to 
perform the test, which means that each group contained 10% of the patients.
Discrimination is the model’s ability to separate patients with different outcomes. To quantify 
the discrimination we used the area under the receiver operating characteristic curve (AUC). The 
AUC evaluates whether those with higher predicted risk are more likely to have a poor outcome 
(mortality/unfavorable outcome) among all possible pairs of patients with different outcomes. A 
model with an AUC of 0.50 has no discriminative power at all (such as a coin flip), and an AUC of 
1.0 reflects perfect discrimination (such as a test without false-positive or false-negative results). 
Model validation
The performance of a prediction model is generally worse in new patients than initially expected. 
This optimism can be studied with internal validation techniques35. Internal validity of the models 
was assessed with standard bootstrapping procedures36,38. Bootstrapping involves drawing samples 
of patients with replacement from the development sample. Each sample can be considered as 
if one is repeating the data collection with the same number of patients and under identical 
circumstances as the original. Regression models were estimated in 200 bootstrap samples. These 
models were each evaluated on the original sample. The average difference in AUC was determined 
to indicate the optimism in the initially estimated discriminative ability33. In addition, we reduced 
the regression coefficients to provide better predictions for future patients33,35. The reduction was 
based on a shrinkage factor as estimated from the bootstrap validation procedure. 
We further assessed the external validity of the models. Predictions of outcome were generated 
with the internally validated Tirilazad models for patients in the EBIC and TCDB data sets. 
Discriminative ability and calibration were assessed to indicate the performance of the developed 
models in patients from another setting. As a secondary analysis, we adjusted the model intercepts 
so that the average predictions were correct for the EBIC and TCDB patients. This adjustment 
improves calibration, but does not influence discrimination. Calculations were performed using 
SAS software (version 6.12, SAS Institute INC., Cary, NC) and S-plus (version 2000, Insightful 
Corporation, Seattle, WA). 
Application in clinical practice
To facilitate application of the models in clinical practice, we created a score chart to estimate the 
outcome probability. The score chart was based on the values of the shrunk regression coefficients, 
which were re-scaled and rounded to whole numbers39. The re-scaling and rounding was such that 
the performance remained similar to that of the original model. We estimated 95% confidence 
intervals for predicted probabilities with each score, based on the average standard errors of 
predictions for patients with similar scores.
Table 1  �atient characteristics and outcome in the International and the North American 
Tirilazad trials, the survey of the European Brain Injury Consortium (EBIC) and the North Ameri-
can survey of the Traumatic Coma Data Bank (TCDB) 
Characteristics and outcome Development patients Validation patients
International 
Tirilazad trial  
(n = 11��)
North American 
Tirilazad trial  
(n = 114�)
European 
survey (EBIC)  
(n = ���)
North American 
survey (TCDB)  
(n = �4�)
n % n % n % n %
Potential predictors
Age Mean (SD) ��.� (14.�) ��.�� (1�.4) 4�.� (��.�) ��.1 (1�.4)
Gender Male ��5� ��% ��4 ��% 5�4 �5% 5�5 ��%
Missing � � 1 �
Cause of injury Traffic accidents ���� ��% �51 5�% 4�� 5�% 5�� �5%
Falls �15 1�% 1�1 15% ��# 1�%# 1�� 1��%
Other ��� �1% ��� ���% ���� �5% 45 �%
Motor score None/extensor 141 1�% 1�� 14% ��� �4% ��5 4�%
Abnormal flexion ��� �1% 1��� 1�% 4�� ��% ��� 1�%
Withdraws ��� ��% ��� ��% �� 1�% 14� ��%
Localizes/obeys 414 ��% 51� 45% �51 4�% 1�� �5%
Missing � � 1�� 4�
�upillary reactivity Both pupils reacted ��� ��% �41 ���% 4��� ��% ��� ��%
One pupil reacted 1��� 1�% 111 1�% �5 ��.�% �� �%
 No pupil reacted 1�� 1�% 1��� ��% 1��� �5% 1�� �1%
Missing �� �11 �� ����
Hypoxia Yes or suspected 14� 15% ���� ���% �1� ��% ��� 4��%
Missing 1�� 1�� 5 �
Hypotension Yes or suspected 155 14% �4� �1% 1��� ��% �1� 4�%
Missing �� �1 � �
CT-classification* I - II 4�� 4�% 5�� 4�% ��4 41% 1�� ��%
III �1� ��% ��� 1��% �� �% 145 �1%
IV 4� 4% 4� 4% 1� �% �� 5%
V - VI ��� ��% �5� ��% ��� 4�% ��� 45%
Missing �� 1� 14 5�
Traumatic subarach-
noid haemorrhage
Yes 5�5 5�% 515 4�% �14 41% 14�� ��%
Missing �� �4 �� 11�
Six-month outcome
Mortality Yes ��5 �5% ��5 ��% �44 �1% ��� 44%
Unfavorable Yes 45� 4�% 4�5  ���% ����� 4�% na‡ na‡ 
outcome Missing  �� ��� �
* CT-classification�� I = no visible intracranial pathology on CT scan, II = midline shift �-5 mm, III = 
cisterns compressed or absent with midline shift �-5 mm, IV = midline shift > 5 mm, V = any lesion 
surgically evacuated, VI = high- or mixed-density lesion > �5 mm, not surgically evacuated
# Only falls under influence of alcohol were registered as falls
‡ na = not applicable. 
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Results
Patient characteristics and outcome
The distribution of patient characteristics and outcome in the four patient populations is presented 
in Table 1. Poor outcome was lowest in the North American Tirilazad population (20% mortality and 
38% unfavorable outcome). In the International Tirilazad population more patients died (25%) or 
had an unfavorable outcome (42%). We observed the poorest outcomes in the relatively unselected 
populations: 31% mortality and 49% unfavorable outcome in the EBIC and 44% mortality in the 
TCDB data sets. 
The distribution of predictors differed between the four patient populations. The EBIC patients were 
generally older than the Tirilazad and TCDB patients (41, 34 and 33 years respectively). Regarding 
the motor score, the EBIC and TCDB populations were the most heterogeneous, containing both 
many severely (motor score ‘none’ and ‘extensor response’) and many less severely injured patients 
(motor score ‘localizing’ and ‘obeying commands’). The proportion of patients with hypoxia, 
hypotension and bilaterally absent pupillary reactivity was relatively low in the International 
Tirilazad population (15%, 14% and 12% respectively) and high in the TCDB (48%, 42% and 31% 
respectively). Overall, the Tirilazad populations had the most homogeneous case-mix, whereas the 
EBIC and TCDB populations were more heterogeneous.
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Table 3  Discrimination and calibration of the prognostic models. The models were developed 
on the pooled Tirilazad patients. Internal validation occurred on the pooled Tirilazad population 
and on the International and North American Tirilazad patients separately. External validation 
was performed in the unselected European Brain Injury Consortium (EBIC) survey and the North 
American survey of the Traumatic Coma Data Bank (TCDB)
Mortality Unfavorable outcome
Discrimination
AUC † (�5% CI) ‡
Calibration
�-value §
Discrimination
AUC† (�5% CI) ‡
Calibration
�-value §
Internal validation
�ooled Tirilazad �.��� (�.�� – �.��1) �.�� �.��� (�.��� – �.���) �.��
International Tirilazad �.��� (�.�5 – �.���) �.�� �.��� (�.��� – �.���) �.�1
North American Tirilazad �.�� (�.�5 – �.���) �.14 �.��� (�.��� – �.���) �.11
External validation
European survey (EBIC) �.��� (�.��4 – �.���) �.4� �.��� (�.��� – �.���) �.�5
North American survey (TCDB) �.��� (�.��� – �.�1) <�.��1 - -
† AUC = Area under the receiver operating curve
‡ �5% CI = �5% Confidence Interval of the AUC
§ Hosmer-Lemeshow goodness-of-fit test, low p-values indicate poor goodness-of-fit
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Univariable analysis showed a statistically significant relation to both outcome measures 
for age, motor score, pupillary reactivity, hypoxia, hypotension, and CT parameters (Table 2). 
Multivariable effects of these predictors were slightly smaller, but still substantial (ORs ≥ 1.4 and 
95% confidence intervals > 1, Table 2). Gender and cause of injury had no clear prognostic effects 
in the multivariable analysis and were therefore not included in further model development. Age, 
motor score and the CT parameters were the most important predictors. The CT-classification was 
more important to predict mortality, while age, motor score and pupillary reactivity had a slightly 
stronger association with unfavorable outcome. Details of the multivariable prognostic models for 
mortality and unfavorable outcome are described in the Appendix.
Performance of the models 
The discriminative ability of the two models was good in the Tirilazad patients (AUC 0.78 – 0.80, 
Table 3). Performance was even better in the EBIC and TCDB patients (external validation, AUC 0.83 
– 0.89). Internally, calibration of the models for mortality was satisfactory, with higher mortality 
for those with higher predictions (Figure 1). In the International and North American patients, 
the observed mortalities were 25% and 20%, while the average predicted risks were 21% and 
23% respectively. These deviations from the ideal calibration were close to statistical significance 
(Hosmer-Lemeshow test: p=0.06 and p=0.14). 
Externally, calibration was good for the EBIC patients. For the TCDB patients, the calibration curve 
was above the line representing identical predictions and observations. On average, the observed 
mortality was 44%, while 34% mortality was expected. The deviation was especially large for high 
predictions, e.g. patients with a predicted mortality risk of 50% actually had an observed mortality 
of around 70%.
The calibration curves for unfavorable outcome were similar to those shown in Figure 1. Despite 
this positive graphical impression of calibration, deviations reached statistical significance for 
the total and International Tirilazad patients (Hosmer-Lemeshow test p<0.05, Table 3). With 
adjustment of the model intercepts, the calibration for both mortality and unfavorable outcome 
improved. A significant deviation remained however for mortality predictions in the TCDB patients. 
This implies that the poor calibration was not only due to a problem in prediction of the average 
outcome for these patients.
Figure 1  Validation of the prognostic models in the pooled Tirilazad population (n=����), the 
International Tirilazad population (n=11��), the North American Tirilazad population (n=114�), 
the European Brain Injury Consortium Survey (n=���) and the Traumatic Coma Data Bank (n=�4�)
The dashed smooth curves reflect the 
relation between observed mortality 
and predicted probability of mortality. 
Perfect calibration is represented by the 
straight dotted line through the origin. 
Triangles indicate the incidence of poor 
outcome in quintiles of patients with 
similar predicted probabilities. Spikes at 
the bottom of each graph represent the 
distribution of predicted probabilities
H-L test = Hosmer Lemeshow goodness-of-
fit test
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Clinical application
We developed a score chart to estimate the probability of mortality and unfavorable outcome 
(Table 4). To predict outcome for an individual patient, the scores in the chart need to be added. 
The corresponding probability of a poor outcome can be read from figure 2. For example, consider 
a 30-year patient with motor score ‘withdrawal’, presence of pupillary reactivity, no hypoxia or 
hypotension, a CT classification of II, and no tSAH. This patient has a sum score of 1 point for 
mortality and 1 point for unfavorable outcome, which corresponds with a probability around 5% 
for mortality and 12% for unfavorable outcome (Figure 2). If additionally hypotension (add 2 points 
for mortality, 1 for unfavorable outcome) would have been present, and the CT showed both tSAH 
(add 2 points for mortality, 1 for unfavorable outcome) and signs of raised ICP (CT classification III) 
(add 2 points for mortality, 1 for unfavorable outcome), the probability of poor outcome increases 
to 32% for mortality (sum score: 7) and to 45% for unfavorable outcome (sum score: 4) (Table 4, 
Figure 2). 
We may apply the score chart for classifying patients, e.g. into five risk categories. Table 5 
demonstrates the considerable heterogeneity of patients with TBI, even within the setting of an RCT 
with strict enrollment criteria. Of the Tirilazad patients, 34% had a predicted risk of unfavorable 
outcome of less than 20% (14% observed), while 6% of patients had a predicted risk larger than 
80% (89% observed).  
Table 4  �rognostic score chart for the probability of mortality and unfavorable outcome in 
patients with severe or moderate TBI according to the prognostic models 
Predictor Value Mortality Unfavorable outcome
Age 15 – �� � � 
4� – 54 1 1 
55 – �4 � �
≥ �5 � �
Motor score None/extensor � � 
Abnormal flexion � �
Withdraws 1 1
Localizes/obeys � �
�upillary reactivity Both react � �
One reacts 1 1 
None reacts � � 
Hypoxia No � �
Yes 1 1
Hypotension No � �
Yes � 1
CT-classification# I or II � �
III � 1
IV 4 1
V or VI � 1
Traumatic subarachnoid  
haemorrhage
No � �
Yes � 1
Sum score*�� add relevant scores ….. …..
* The sum score can be used to obtain the predicted probability of mortality or unfavorable outcome 
from Figure � 
# CT-classification�� I = no visible intracranial pathology on CT scan, II = midline shift �-5 mm, III = 
cisterns compressed or absent with midline shift �-5 mm, IV = midline shift > 5 mm, V = any lesion 
surgically evacuated, VI = high- or mixed-density lesion > �5 mm, not surgically evacuated
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Discussion
We developed and validated prognostic models to predict the risk of six-month mortality and 
unfavorable outcome in individual patients after moderate or severe TBI. Predictions were based 
on characteristics that were readily available on admission to the neurosurgical unit. The models 
discriminated well between patients with poor and good outcome in the development population. 
External discrimination on relatively unselected North American (TCDB) and European (EBIC) 
patients was even better. This can be explained by the greater heterogeneity in case-mix in these 
surveys, enabling a clearer separation between patients with good from those with poor outcome.
The mortality in the North American TCDB patients was considerably higher than predicted (44% vs. 
34%). This poor calibration may be explained by the historic aspect of the data set, which originates 
from the 1980s, and the improvement of treatment standards, including trauma organization, 
diagnostic facilities such as CT scanning, and critical care management. Also, inclusion criteria 
were towards more severe conditions, e.g. patients with neurological worsening. In contrast, the 
observed frequency of poor outcome was slightly lower than predicted for the North American 
Tirilazad patients (20% vs. 23% for mortality, 38% vs. 41% for unfavorable outcome respectively). 
This systematic positive effect has been discussed before23. It may have resulted from chance, or 
be explained by an as yet unidentified regional factor, e.g. a clinical characteristic or a difference 
in trauma care. This observation also points to the desirability for updating a prognostic model 
according to specific population characteristics, such as calendar year, treatment setting or 
inadvertent selection influenced by local trauma organization40. 
In the past, several models have been derived to estimate the probability of hospital mortality of 
adult intensive care unit patients with physiological characteristics collected during the first day(s), 
including APACHE, SAPS and MPM41. Our models differ in several aspects, since we predicted six-month 
mortality or unfavorable outcome, only for TBI patients, and only with baseline characteristics. For 
comparison, we considered three TBI-specific models that were potentially useful for current clinical 
practice (Table 6). These were described in such detail that we could evaluate their discriminative 
ability5,6,16. Choi et al.5 predicted twelve-month mortality and unfavorable outcome using age, motor 
score, pupillary reactivity and the presence of intracerebral lesions at admission. Signorini et al.6 
predicted twelve-month survival with age, GCS, pupillary reactivity, injury severity score (ISS) and the 
presence of haematoma on the first CT scan. Andrews et al.16 predicted twelve-month unfavorable 
outcome with age, cause of injury, GCS and pupillary reactivity in a tree model. We found that the 
discriminative ability of these previous models was lower in the EBIC and TCDB populations than 
that of our models (Table 7). The AUC of the model of Choi et al.5 was 0.82 for mortality and 0.78 
for unfavorable outcome in the EBIC data and 0.78 for mortality in the TCDB. Signorini’s model6 
performed better, i.e. AUC equal to 0.85 and 0.81 in the EBIC and TCDB respectively. The AUC of the 
model by Andrews et al.16 was 0.75 in the EBIC population. On validation of Signorini’s model6 we 
excluded the effect of the ISS, as ISS was not consistently registered in the surveys. It is conceivable 
that the AUC would have been higher if this variable had been available, although the additional 
predictive value of extracranial injuries may be small42,43. 
The poorer discriminative ability of previously described models may have several reasons. 
The previously developed models were developed on patient samples originating from a single 
4DPSF
1S
FE
JD
UF
E
QS
PC
BC
JM
UZ

                





















NPOUINPSUBMJUZ
NPOUI
VOGBWPSBCMFPVUDPNF
Figure 2  �redicted probability of mortality and unfavorable outcome corresponding to the sum 
scores from Table 5
After calculating a sum score for a patient with moderate or severe TBI, this graph can be used to 
determine the corresponding predicted probability with the �5% confidence interval. The exact 
probability of mortality or unfavorable outcome can be calculated with the formulas shown in 
the appendix
Table 5  Classification of Tirilazad patients (n=�14�) according to their severity and prognosis 
into five risk categories. Categories were defined according to risk of unfavorable outcome, as 
estimated by the prognostic models
Classification Risk of unfavo-
rable outcome
Score* n (%) Mean mortality 
(%)
Mean unfavorable 
outcome (%)
Good � - ��% �-� �41 (�4%) �% 14%
Relatively good �1 - 4�% � 5��1 (��%) 15% �4%
Intermediate 41 - ��% 4-5 ��4 (1�%) ��% 55%
�oor �1 - ���% �-� ��1 (15%) 4�% ��%
Very poor ��1 - 1��% ≥ �� 1�� (�%) ���% ���%
* Score according to the score chart in Table 4
124
Chapter 6
125
Predicting outcome
institute or the same region5,6,16, which may limit their generalizability. Further, patient samples 
were all much smaller than the 2200 patients used for our models. Thus, the precision to quantify 
a prognostic model was smaller and ‘overfitting’ may have occurred. This is the phenomenon 
that a model predicts outcomes well in the development population but tends to predict too 
extreme probabilities in new patients. On the other hand, ‘underfitting’ – i.e. the erroneous 
omission of predictors with weaker effects – may also have occurred in small samples by lack of 
power. Finally, the previously developed models included at most five predictors, compared to 
the seven predictors in our models. It is hence quite plausible that our proposed models truly 
have a higher predictive accuracy6,21,33,35,36. 
The presented score chart may support clinicians in their initial assessment of the severity and 
prognosis of a TBI patient. This is for example important for informing relatives. Although it is 
unlikely that any clinician has the equivalent and systematic experience of treating the 2200 
patients underlying our models, statistical models can never replace the clinician. A prediction for 
an individual TBI patient always has uncertainty, as shown in Figure 2. The model makes certain 
structural assumptions and statistical interaction terms were not included. It is hence possible 
that specific patterns of risk factors are inadequately reflected in the model predictions. Therefore, 
predictions should be regarded with care and not directly be applied for treatment limiting 
decisions. However in specific circumstances, such as multiple casualty situations or in settings 
where treatment facilities are very limited it may provide guidance to resource allocation.
We propose that the prime application of the prognostic models is towards a more accurate 
classification of TBI than is currently possible with the GCS or CT-classification alone. Considerable 
heterogeneity may still exist between patients classified by the GCS as severe (GCS 3-8) or moderate 
(GCS 9-12) TBI. This heterogeneity makes it difficult to compare different series and treatment 
results. Classification of patients according to baseline prognostic risk will facilitate a more 
accurate comparison of series over time and place. The risk estimate may also be used as a quality 
control instrument to evaluate the efficacy of health care in TBI. It may be considered a challenge 
for clinicians to obtain better results than predicted. 
Classification of TBI patients according to prognostic risk estimate can play an important role 
for more efficient design and conduct of RCTs2. Until now RCTs have included TBI patients who 
may do poorly no matter how good the treatment or patients who may do well no matter what 
treatment is given. Inclusion of patients with such an extreme prognosis in a RCT will decrease 
statistical power44. Restricting the inclusion of patients within the Tirilazad trials to those with 
an intermediate risk, e.g. between 20 and 80% of unfavorable outcome, would for instance have 
excluded 40% of the patients (Table 5). Accordingly, costs and efforts would have been decreased, 
while maintaining nearly the same power to detect a treatment effect. Similar reductions (30%) in 
sample size have been suggested before2. 
Several limitations of our analyses should be acknowledged. First, the Tirilazad studies, on which we 
developed our models, concern selected trial populations. Thus, specific subgroups were relatively 
infrequent, such as patients with absent motor score, those obeying commands, and those with 
a normal CT scan or age above 65 years. Discrimination was higher in populations that included 
more patients from these subgroups, such as the relatively unselected EBIC and TCDB surveys.
Table 7  Comparison of the discriminative ability of three previously described models and the 
Tirilazad model  
Model Discriminative ability (AUC*)#
�ooled Tirilazad
population (n=����)
European survey
(n=���)
North American 
survey (n=�4�)
Choi et al.5 �.��� / �.�� �.��� / �.��� �.��� / -
Signorini et al.� �.�1/ - �.��5 / - �.��1 / -
Andrews et al.1� - / �.�� - / �.�5 - / -
This study �.��� / �.��� �.��� / �.��� �.��� / - 
* AUC = Area under the receiver operating curve 
# First AUC refers to the model predicting mortality, second AUC to the model predicting unfavorable 
outcome. 
Table 6  Characteristics of three previously developed TBI-specific models considered for com-
parison to the Tirilazad model
Model Outcome Predictors Model Comment
Choi et al., 1��1 1�-month 
mortality and 
unfavorable 
outcome
Age, motor score, 
pupillary reactivity, 
intracerebral 
lesions
Tree model Reasonable number of 
patients (n=555), only 
major predictors (4 out 
of �� considered), only 
internal validation 
Signorini et al., 1��� 1�-month 
survival
Age, GCS, pupillary 
reactivity, ISS, 
hematoma
Logistic 
regression
Reasonable number 
of patients (n=���), 
reasonable number of 
predictors (n=5), limited 
external validation
Andrews et al., ���� 1�-month 
mortality and 
unfavorable 
outcome
Age, cause of injury, 
GCS, pupillary 
reactivity
Tree model Small number of patients 
(n=1�1), only major 
predictors (n=4), only 
internal validation 
This study �-month 
mortality and 
unfavorable 
outcome
Age, motor score, 
pupillary reactivity, 
hypoxia, hypoten-
sion, CT classifica-
tion, tSAH
Logistic 
regression
Large number of patients 
(n=����), larger num-
ber of predictors (n=�), 
internal and external 
validation
GCS = Glasgow Coma Scale, ISS = Injury Severity Score, CT = Computerized Tomograph, tSAH = trau-
matic subarachnoid haemorrhage
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Second, limitations in assessing the full GCS, which forms an integral part of the Revised Trauma 
Score, the Trauma and Injury Severity Score and the APACHE scores in the intensive care settings, 
are well recognized17,19. It has been proposed to impute pre-sedation GCS values for calculation 
of the APACHE scores45. Nevertheless, in current clinical practice the motor score is not always 
available due to effects of early sedation/ paralysis and artificial ventilation46. Substituting the 
admission motor score by earlier observations, such as the motor score at the site of the accident, 
may alter the prognostic value of the models, and is therefore not advised. Further studies are 
needed to elucidate this important issue.
Although the performance of the presented models was satisfactory, it might potentially be 
improved by including CT parameters other than the CT-classification or tSAH. Performance may 
also be improved by inclusion of subsequent information obtained after admission, including 
temporal course, MRI scans at later time points, and other parameters such as raised ICP47. In a 
secondary analysis we found that substituting the admission CT-classification by the worst CT in 
the models significantly improved the performance. The objective of the present study, however, 
was to investigate prognostic models that predict long-term outcome with baseline predictors 
only. 
In conclusion, prediction models were developed which provide high discrimination between 
patients with good and poor six-month outcome. Using large patient populations originating 
from many countries increased the generalizability of the models. These models may be useful 
for providing realistic information to relatives on expectations of outcome, for quantifying 
and classifying the severity of brain injury, for stratification of patients in clinical trials, or as a 
reference for evaluating quality of care. 
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Appendix
Details of the prognostic models
The probability of a poor outcome (mortality or unfavorable outcome according to the GOS) is 
calculated according to the logistic formula: 1/(1 + exp-LP). 
The linear predictor (LP) takes the form of LP=intercept + regression coefficients × predictor 
values. 
LP for mortality = –3.267 – (0.0198 × age) + (0.000528 × age2) + (1.126 × motor score 1 or 2) + (0.918 
× motor score 3) + (0.494 × motor score 4) + (0.364 × one pupil reacts) + (0.648 × no pupil reacts) + 
(0.745 × hypotension) + (0.377 × hypoxia) + (0.808 × CT classification III) + (1.354 × CT classification 
IV) + (0.860 × CT classification V or VI) + (0.694 × traumatic subarachnoid haemorrhage). 
LP for unfavorable outcome = –2.842 + (0.00106 × age) + (0.000391 × age2) + (1.690 × motor score 
1 or 2) + (1.275 × motor score 3) + (0.675 × motor score 4) + (0.440 × one pupil reacts) + (0.938 
× no pupil reacts) + (0.740 × hypotension) + (0.449 × hypoxia) + (0.637 × CT classification III) + 
(0.628 × CT classification IV) + (0.619 × CT classification V or VI) + (0.657 × traumatic subarachnoid 
haemorrhage). 
Coding of the predictors: 
Age and age2: age in years; 
All other predictors: 1 if true and 0 if false.
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Abstract
Objective
Various prognostic models have been developed to predict outcome after traumatic brain 
injury (TBI). We aimed to determine the validity of six models that used baseline clinical and CT 
characteristics to predict mortality or unfavorable outcome at six months or later after severe 
or moderate TBI. 
Study design and setting
The validity was studied in two selected series of TBI patients enrolled in clinical trials (Tirilazad 
trials: n=2269; International Selfotel trial: n=409) and in two unselected series of patients 
consecutively admitted to participating centers (EBIC survey: n=796; Traumatic Coma Data 
Bank: n=746). Validity was indicated by discriminative ability (AUC) and calibration (Hosmer-
Lemeshow goodness-of-fit test). 
Results
The models varied in number of predictors (four to seven) and in development technique (two 
prediction trees and four logistic regression models). Discriminative ability varied widely (AUC: 
0.61-0.89), but calibration was poor for most models. Better discrimination was observed for 
logistic regression models and for models including more predictors. Further, discrimination 
was better when tested on unselected series that contained more heterogeneous populations. 
Conclusion
Our findings emphasize the need for external validation of prognostic models. The satisfactory 
discrimination indicates that logistic regression models, developed on large samples, can be 
used for classifying TBI patients according to prognostic risk.  
Introduction
Traumatic brain injury (TBI) carries a high mortality and is a major cause of life long disability in 
a predominantly young population.  Many studies have investigated the value of baseline clinical 
and CT characteristics for early prediction of long-term outcome. International guidelines 
contain a section dedicated to prognosis1,2. This section summarizes existing knowledge on the 
predictive value of age, Glasgow Coma Scale (GCS), pupils, hypoxia and hypotension as well 
as individual CT characteristics (status of basal cisterns, shift, and traumatic subarachnoid 
hemorrhage). A number of studies in TBI have focused on the development of prognostic models, 
with which the risk for mortality or morbidity after TBI can be assessed using multiple patient 
characteristics. Early attempts showed that risk prediction was difficult on admission, but more 
recent studies have shown better results3-10.
Risk assessment is important for various purposes: to inform relatives on realistic expectations, 
to support clinical decision-making and resource allocation, or to classify patients according to 
prognostic risk. The latter may be useful to compare different patient series, to study treatment 
results over time or to stratify patients for randomized clinical trials (RCTs)11. The different 
aims of models pose different requirements to performance. For purposes of classification, a 
high discriminative ability is most relevant, while reliable support for clinical decision-making 
requires well-calibrated predictions. Whatever the purpose, external validation of models is 
essential to support general applicability12. When simply tested on data that were used for model 
development, the apparent performance may be excellent, but when tested on new patients, or 
on a different patient series, the performance may be considerably poorer13. Surprisingly, only 
few of the published models in the field of TBI have been subjected to extensive validation, 
assessing both internal and external validity5,6,10. Internal validity (or reproducibility) indicates 
how a model performs in patients similar to those used for model development. External validity 
(or generalizability) evaluates how a model performs for new patients, e.g. more recent patients 
or patients from different centers12.
The aim of the present study was to identify models that use baseline characteristics to predict 
outcome after moderate (Glasgow Coma Scale 9 to 12) or severe (Glasgow Coma Scale 3 to 8) 
TBI14, and to determine the validity of predictions from these models on external data sets. 
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Materials and methods
Models
We conducted a systematic literature search in PubMed for prognostic models in TBI published after 
1990; keywords for the search were ‘head injury’, ‘traumatic brain injury’, ‘prognosis’, ‘prediction’, 
‘models’, ‘Glasgow Outcome Scale’, ‘mortality’ and ‘unfavorable outcome’. We first checked all 
abstracts for studies that used baseline characteristics to predict long term (≥ 6 months) mortality 
or unfavorable outcome15 after severe or moderate TBI. We then performed a detailed study of 
selected papers, and checked cross-references for other potentially relevant publications.
Validation populations
For validation, we used two series of patients included in randomized controlled trials (RCTs) in 
TBI: the Tirilazad studies (N=2269) and the International Selfotel trial (N=427). Further, we used 
two relatively unselected series of patients with severe or moderate TBI consecutively admitted 
to participating centers: the European Brain Injury Consortium (EBIC) survey (N=796) and the 
Traumatic Coma Data Bank (TCDB) (N=746).
The Tirilazad trials were two phase III RCTs, investigating efficacy and safety of the drug Tirilazad 
Mesylate in TBI. The International trial (N=1120) was conducted from 1992 until 1994 in Europe, 
Israel and Australia and the North-American trial (N=1149) from 1991 until 1994 in the USA and 
Canada16,17. The trials included patients between 15 and 65 years of age, with severe (GCS 3-8) or 
moderate (GCS 9-12) TBI. Patients with an absent motor score or penetrating head injury were 
excluded. For the present study we considered patients from both trials as originating from one 
population. Data on six-month mortality were present for all 2269 patients, data on six-month 
unfavorable outcome for 2149 patients17. 
The International Selfotel trial was a phase III RCT, investigating the competitive NMDA-
glutamate antagonist Selfotel18. The trial was conducted in Europe, Canada, Australia and 
Argentina between 1994 and 1995. Enrollment criteria were: age 16 - 65 years, severe (GCS 3-8) 
TBI, presence of abnormalities on the CT scan, at least one reactive pupil and non penetrating 
TBI. Data on six-months outcome were available for 409 patients. 
The EBIC survey included patients admitted to 104 centers in 12 European countries between 
February and April 199519. In this series, data were prospectively collected in all adult (> 16 years) 
patients suffering a moderate or severe TBI, consecutively admitted to participating centers. For 
the present study we selected patients from centers routinely reporting six-months outcome 
data (N=796). 
The TCDB included patients with severe (GCS 3- 8) TBI admitted to four centers in the USA 
between 1984 and 198720. For our analyses, we selected all adult (age > 15 years) patients 
admitted with non-penetrating TBI (N=746). In the TCDB the six-month GOS was assessed with 
a broad time window. We therefore chose to limit our analysis to mortality, since deviations in 
time windows for outcome assessment are less relevant for mortality.  
For several patients, values of predictors were missing (4.9% of the required values, Table 3). 
These values were statistically estimated, based on the regression models including the other 
predictors, and subsequently imputed21,22. The imputation method (function ‘transcan’ from the 
Hmisc library for S-plus) transformed continuous and categorical predictor variables to have 
maximum correlation with the best linear combination of the other variables. Subsequently, 
missing values were imputed with best guess expected values of the transformed variables, and 
transformed back to the original scale. Such imputation is recommended as more efficient than 
dropping cases. This procedure assumes that values are ‘missing at random’, i.e. random after 
conditioning on the other predictors21,23. After imputation, all values of predictors were present 
for the development of the prognostic models.
Performance of models
We calculated the predicted outcome (mortality or unfavorable outcome) for each population 
according to the prognostic equations, with statistical imputation of missing values for 
predictors24. The performance of the models was assessed with respect to discrimination and 
calibration. Discrimination is the model’s ability to separate patients with different outcomes. 
To quantify the discrimination we calculated the area under the receiver-operating characteristic 
curve (AUC)25. A model with an AUC of 0.50 has no discriminative power, while an AUC of 1.0 
reflects perfect discrimination. Ninety-five percent confidence intervals around this AUC were 
calculated by AUC +/- 1.96*SE, where SE was half the standard error of the Somer’s D, as estimated 
by the rcorr.sens function in S-plus (version 2000, Insightful Corporation, Seattle, WA). 
Calibration is the ability of a model to produce unbiased estimates of the probability of outcome, e.g. 
if patients with certain characteristics are predicted to have a 10% chance of mortality, the actually 
observed mortality should also be 10%. Calibration was assessed graphically by plotting observed 
outcome against the predicted probability (0-100%). Calibration was further tested with the Hosmer-
Lemeshow goodness-of-fit test, which assesses agreement between predicted and observed risks. In 
our analyses, predicted risk was grouped into deciles for the regression models. For the tree models 
we used the predicted groups for the comparison of observed outcome versus predicted risks.  
In a secondary analysis, we refitted the original models on the Tirilazad population, updating 
the regression coefficient (weights) of the predictors to best fit this population. This was done 
in order to better assess the ‘pure’ predictive value of the different combinations of risk factors, 
excluding influences of differences in the development population (e.g. selected or unselected) 
or statistical methodology (e.g. use of bootstrapping in model development). For prediction trees 
we refitted two variants: one with the tree structure as published before, and another with the 
risk factors considered in the tree as main effects in logistic regression models. Internal validity 
of the refitted models was assessed with bootstrapping procedures for which we used a standard 
algorithm25-28. Bootstrapping involved drawing samples of patients with replacement from the 
development sample. Each sample can be considered as if one is repeating the data collection 
with the same number of patients and under identical circumstances as the original. Regression 
models were estimated in 200 bootstrap samples. These models were each evaluated on the 
original sample. The average difference in AUC was determined to indicate the optimism in the 
initially estimated discriminative ability25. In addition, we reduced the regression coefficients 
to provide better predictions for future patients21,28. The reduction was based on the mean of 
the slope of the linear predictor (shrinkage factor)27,29. The external validity of these models was 
evaluated on the other three series, with calculation of discriminative ability and calibration.
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Results
Models
We identified 10 papers published after 1990 that described prognostic models (Table 1). 
Four of these studies used early end points (24 hours, 48 hours, 21 days, discharge)5,7,8,30. Two 
studies included data obtained during the clinical course after admission in the model9,31. 
Consequently, only four studies provided prediction models that used baseline clinical and/or 
CT characteristics obtained on admission to predict long term outcome4,6,10,32. These included 
two papers that presented prediction trees4,10 and two presenting logistic regression models6,32. 
One of these describes two models that were previously developed by us on the Tirilazad studies. 
The tree developed by Choi et al.4 and the models developed by us predicted both mortality and 
unfavorable outcome. Thus, the four studies described six models in total.
The tree developed by Choi et al.4 selected four characteristics from 23 candidate variables, where 
the optimum number of splits of the tree (and thus the selected characteristics) were statistically 
determined in the dataset using recursive partitioning33. Signorini et al.  6 developed a logistic 
regression model and used a forward selection algorithm (p<0.05), with eight candidate variables. 
Andrews et al.10 developed a tree, using 10-fold cross-validation to determine the optimal tree 
size using recursive partitioning33. The number of candidate variables was not mentioned. For 
the logistic regression models by Hukkelhoven et al.32, a backward stepwise selection procedure 
(p<0.20) was used to select 7 predictors from 9 candidate variables. More information about the 
models is shown in Table 1.
 
All six prediction models included age, pupillary reactivity and either the GCS or the Motor Score 
(Table 2). Some models included cause of injury, hypotension, hypoxia, injury severity score (ISS), 
and various CT scan characteristics (Table 2). The tree models included four predictors4,10, and the 
logistic regression models five6 and seven32. The ISS, used in Signorini’s model6, and intracerebral 
lesion, used in Choi’s tree4, were not available in (some of) the validation populations. Therefore, 
we considered the mean ISS in the population used to develop Signorini’s model6 in all validation 
patients. Since Choi’s tree used intracerebral lesion to split two tree branches from each other4,10, 
we could combine these branches and further validate the remaining seven branches of the tree.  
Validation populations
Characteristics of the validation populations are described in Table 3. Although the populations 
showed comparable distributions for most variables, some differences were noted. The 
unselected series (EBIC and TCDB) showed more heterogeneity, both in clinical severity (motor 
score and pupillary abnormalities) as well as in CT characteristics (e.g. mass lesions, obliteration 
of cisterns). The EBIC patients were generally older (mean 41 years) than the Tirilazad, Selfotel 
and TCDB patients (32 to 33 years). The occurrence of road traffic accidents as cause of injury was 
highest in the Selfotel and TCDB patients (80% and 75% respectively, compared to approximately 
55% in the other two populations). 
Table 2  �redictors included in the models that were validated in the present study
Predictors Choi 4 Signorini 6 Andrews 10 Hukkelhoven 32
Tree* LR# Tree* LR#
Age X X X X
Cause of injury X
GCS X X
Motor Score X X
�upillary reactivity X X X X
Hypotension X
Hypoxia X
CT-classification X
TSAH X
Intracerebral lesion X
Lesion X
Injury Severity Score X
* Tree = tree model
# LR = logistic regression model
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With respect to outcome measures, both trial populations showed lower percentages for 
mortality and unfavorable outcome (22% and 23% for mortality and 40% and 43% for unfavorable 
outcome in the Tirilazad and Selfotel populations respectively), compared to 31% (EBIC) and 44% 
(TCDB) for mortality and 49% (EBIC) for unfavorable outcome.
External validation
The models selected from the literature showed a wide variability in discrimination in most series 
(Table 4). Signorini et al. reported an apparent AUC of 0.90, while we found an AUC of 0.61 to 0.85 
at external validation of this model. Discriminative performance was not only dependent on 
the model, but also on the validation population, with better results in the more heterogeneous 
series of EBIC and TCDB patients, and poorer in the selected trial populations (Table 4). 
Performance was also associated with the number of risk factors in the model. The seven 
predictor models developed earlier by us showed a maximum AUC of 0.89, the five predictor 
model of Signorini et al. a maximum AUC of 0.85 and the four predictor models of Andrews et 
al. and Choi et al. a maximum AUC of 0.75 and 0.82 respectively.
The calibration of four of the six models was poor, as demonstrated by the low p-values of the 
Hosmer-Lemershow goodness of fit test (p < 0.01). Figure 1 shows the poor external calibration of 
these models in more detail, demonstrating that calibration curves often differed considerably 
from the dotted line representing perfect agreement between predictions and observations. 
For example, the calibration curve for mortality as predicted by the four-predictor tree4 was 
considerably below the dotted ideal line for the Tirilazad, Selfotel and EBIC patients. This implies 
that most predicted mortalities were systematically too high, e.g. Tirilazad patients with a 
predicted mortality of 60% actually had an observed mortality of around 35% (Figure 1). The 
calibration curves of the prediction trees showed several twists, resulting from the inherent 
structure of the tree, which divides patients into only seven categories. The seven-predictor 
models showed good calibration in the EBIC and Selfotel series, but performed more poorly in 
the TCDB patients.
Most refitted models discriminated somewhat better than the original models (Table 5). Several 
similarities with the original models were however observed; discriminative abilities were 
mainly dependent on the number of risk factors in the model and on the validation population. 
Compared to the original models, calibration was considerably better for most refitted models, 
except for one of the prediction trees4. For the prediction trees discrimination was better when 
refitting the individual risk factors from the tree than when refitting the original tree structure. 
Remarkably, the refitted models for mortality still showed poor calibration on external validation 
on the TCDB series. 
– continues on page 147 –
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Figure 1  Validation of the previously developed prognostic models in the pooled Tirilazad 
population (n=����), the Selfotel population (n=4��), the European Brain Injury Consortium 
(n=���) and the Traumatic Coma Data Bank (n=�4�).
The tree by Choi et al.4 predicts both mortality and unfavorable outcome, as indicated in the first 
and second rows in the figure respectively. Signorini’s model predicts mortality, Andrews’ model1� 
predicts unfavorable outcome. Hukkelhoven et al.�� developed two models on the Tirilazad data�� 
one predicting mortality (fifth row) and one predicting unfavorable outcome (sixth row).
The dashed smooth curves reflect the relationship between observed frequency and predicted 
probability of poor outcome. �erfect calibration is represented by the straight dotted line through 
the origin. Triangles indicate the incidence of poor outcome in quintiles of patients with 
similar predicted probabilities. Spikes at the bottom of each graph represent the distribution 
of predicted probabilities.  
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Discussion
The external validity varied considerably for previously developed models that aim to predict long 
term outcome after severe or moderate TBI with baseline characteristics available at admission. 
We found only a moderate discriminative ability for prediction trees described by Choi et al.4 and 
by Andrews et al.10 (AUC around 0.70), reasonable discrimination for the five-predictor logistic 
regression model described by Signorini et al.6 (AUC around 0.75) and better discrimination 
in the seven-predictor models described earlier by us32 (AUC around 0.80). Calibration of most 
models was relatively poor, but improved when models were refitted on the same data set with 
the same, modern, statistical techniques.
It was difficult to directly compare the performance of models as reported by the authors with the 
results of our validation studies. Only the model by Signorini et al. reported discriminative ability, 
with an apparent AUC of 0.906 as compared to values of 0.61 – 0.85 in our validation study. In the 
past, performance of published models has often been expressed in the accuracy rate, which is the 
proportion of patients with a certain outcome that was predicted correctly. The tree by Choi et al. 
had an accuracy rate of 78% in the development population4 and the tree by Andrews et al. had 
accuracy rates of 96% (development set) and 60% (training set)10. We do not consider accuracy rates 
for validation purposes appropriate. For instance, this rate is greatly influenced by the outcome 
distribution of the population. In a representative TBI population with an average mortality of 
20%, the accuracy rate will already be 80% if all patients would be labeled as survivors. 
External validation of prognostic models is essential to assess generalizability, and for fair 
comparisons of alternative models. Models often perform less well at external validation12,13 and 
this has several reasons. First, prognostic modeling on small samples provides limited power 
to identify predictive variables and to quantify a model with sufficient precision. Therefore, 
models based on small samples may often have biased and imprecise regression coefficients34. 
Larger samples are required for reliable statistical modeling25,35. The present study confirms 
this: the model developed on the largest series discriminated best in new patients32, while the 
model developed on the smallest sample (121 patients) from a single center discriminated 
poorly10. Further, a clear increase in performance was achieved by refitting the models that were 
developed from single centers with the large, multi-center Tirilazad patient population.
In general, a small development population may induce “overfitting”. Overfitting is the 
phenomenon that a model predicts outcome well in the development population, but tends 
to predict too extreme probabilities for new patients. Indeed, overfitting was noted before for 
the logistic regression model developed by Signorini et al.6,36. The risk of overfitting can best 
be limited by increasing the sample sizes for predictive modeling studies. This can be achieved 
by multi-center collaborations, which has the advantage that generalizability may also be 
increased12. Alternatively, more advanced statistical approaches may be useful, e.g. bootstrapping 
techniques to determine a shrinkage factor25,27,28. Shrinkage of regression coefficients improves 
the calibration of predictions in new patients. Bootstrapping is a relatively new technique, 
which was only used in the development of the seven predictor models32. We recommend that 
such techniques should be more generally applied12,25. The need for such modeling techniques is 
well recognized in other fields, such as genetic profiling in cancer research, where the number 
of patients is often small in relation to the number of candidate predictors37,38.Ta
bl
e 
5 
 �
er
fo
rm
an
ce
 o
f 
th
e 
pr
ev
io
u
sl
y 
de
ve
lo
pe
d 
pr
og
n
os
ti
c 
m
od
el
s 
af
te
r 
re
fi
tt
in
g 
on
 t
h
e 
Ti
ri
la
za
d 
pa
ti
en
ts
. E
xt
er
n
al
 v
al
id
at
io
n
 o
f 
th
e 
re
fi
t-
te
d 
m
od
el
s 
w
as
 p
er
fo
rm
ed
 o
n
 t
h
e 
pa
ti
en
ts
 in
cl
u
de
d 
in
 t
h
e 
Se
lf
ot
el
 t
ri
al
, t
h
e 
Eu
ro
pe
an
 B
ra
in
 I
n
ju
ry
 C
on
so
rt
iu
m
 (E
BI
C
) s
u
rv
ey
 a
n
d 
th
e 
N
or
th
 
A
m
er
ic
an
 s
u
rv
ey
 o
f 
th
e 
Tr
au
m
at
ic
 C
om
a 
D
at
a 
Ba
n
k 
(T
C
D
B)
 
Ev
al
u
a-
 
te
d 
ou
t-
co
m
e
M
od
el
Ti
ri
la
za
d 
(n
=2
26
)
Se
lf
ot
el
 (n
=4
0
)
EB
IC
 (n
=7
6
)
TC
D
B
 (n
=7
46
)
D
is
cr
im
in
at
io
n
 
C
al
ib
ra
ti
on
(p
-v
al
u
e‡
)
D
is
cr
im
in
at
io
n
 
C
al
ib
ra
ti
on
(p
-v
al
u
e‡
)
D
is
cr
im
in
at
io
n
 
C
al
ib
ra
ti
on
D
is
cr
im
in
at
io
n
 
C
al
ib
ra
ti
on
(p
-v
al
u
e‡
)
A
U
C
*
�5
%
 C
I#
A
U
C
*
�5
%
 C
I#
A
U
C
*
�5
%
 C
I#
(p
-v
al
u
e‡
)
A
U
C
*
�5
%
 C
I#
M
or
ta
lit
y
C
h
oi
 –
 t
re
e
0.
69
0.
66
-0
.7
1
< 
0.
01
0.
65
0.
58
-0
.7
1
< 
0.
01
0.
81
0.
78
-0
.8
4
< 
0.
01
0.
72
0.
68
-0
.7
6
< 
0.
01
C
h
oi
 –
 L
R
0.
72
0.
70
-0
.7
5
0.
43
0.
67
0.
60
-0
.7
4
0.
04
0.
84
0.
82
-0
.8
7
0.
41
0.
82
0.
78
-0
.8
5
< 
0.
01
Si
gn
or
in
i -
  L
R
0.
72
0.
70
-0
.7
5
0.
75
0.
65
0.
58
-0
.7
2
0.
16
0.
86
0.
83
-0
.8
8
0.
05
0.
83
0.
80
-0
.8
6
< 
0.
01
H
u
kk
el
h
ov
en
 –
 L
R
0.
78
0.
76
-0
.8
0
0.
06
0.
74
0.
68
-0
.8
0
0.
49
0.
87
0.
84
-0
.8
9
0.
44
0.
89
0.
86
-0
.9
1
< 
0.
01
U
nf
av
o-
ra
bl
e 
ou
tc
om
e
C
h
oi
 –
 t
re
e
0.
72
0.
70
-0
.7
5
< 
0.
01
0.
71
0.
66
-0
.7
5
< 
0.
01
0.
78
0.
75
-0
.8
1
< 
0.
01
-
-
C
h
oi
 –
 L
R
0.
77
0.
75
-0
.7
9
0.
78
0.
72
0.
67
-0
.7
7
< 
0.
01
0.
80
0.
77
-0
.8
3
< 
0.
01
-
-
A
n
dr
ew
s 
– 
tr
ee
0.
68
0.
66
-0
.7
0
0.
05
0.
66
0.
61
-0
.7
0
0.
08
0.
76
0.
73
-0
.7
9
< 
0.
01
-
-
A
n
dr
ew
s 
– 
LR
0.
77
0.
75
-0
.7
9
0.
03
0.
72
0.
67
-0
.7
6
0.
61
0.
79
0.
76
-0
.8
2
< 
0.
01
-
-
H
u
kk
el
h
ov
en
 –
 L
R
0.
80
0.
78
-0
.8
2
0.
02
0.
74
0.
69
-0
.7
9
0.
95
0.
83
0.
80
-0
.8
6
0.
05
-
-
* 
A
U
C
 =
 A
re
a 
u
n
de
r 
th
e 
re
ce
iv
er
 o
pe
ra
ti
n
g 
cu
rv
e 
(in
 t
h
e 
Ti
ri
la
za
d 
da
ta
 w
it
h
 o
pt
im
is
m
-c
or
re
ct
io
n
 b
y 
bo
ot
st
ra
pp
in
g)
, 
#
 9
5%
 C
I =
 9
5%
 C
on
fi
de
n
ce
 In
te
rv
al
 o
f t
h
e 
A
U
C
‡  
H
os
m
er
-L
em
es
h
ow
 g
oo
dn
es
s-
of
-fi
t 
te
st
, l
ow
 p
-v
al
u
es
 in
di
ca
te
 p
oo
r 
go
od
n
es
s-
of
-fi
t
Tr
ee
 =
 a
 lo
gi
st
ic
 r
eg
re
ss
io
n
 m
od
el
 w
as
 c
on
st
ru
ct
ed
 w
it
h
 t
h
e 
tr
ee
 s
tr
u
ct
u
re
LR
 =
 a
 lo
gi
st
ic
 r
eg
re
ss
io
n
 m
od
el
 w
as
 c
on
st
ru
ct
ed
 w
it
h
 t
h
e 
ri
sk
 fa
ct
or
s 
in
cl
u
de
d 
as
 m
ai
n
 e
ff
ec
ts
 
14
Chapter 7
14
Model validation
Discrimination was clearly related to the number of predictors included in the model, with 
better discrimination in models using seven predictors than in the four- or five-predictor 
models. This is caused by the inclusion of additional and statistically independent information 
in the models, which permits a more detailed differentiation of risks between patients.  We note 
that the seven predictors included in our previously developed models are well-known from 
previous research2 and are readily available in clinical practice. The number of predictors that 
can potentially increase discriminative abilities of a model is however not infinite, and including 
larger numbers of predictors may increase the risk of overfitting. As a rule of thumb, the number 
of predictors should be less that 1/10 of the number of events (e.g. number of patients with a 
particular outcome)25,35. We further observed a higher discrimination of all models at validation 
in the unselected series (EBIC and TCDB) as compared to results obtained on validation on the 
more selected trial population (Tirilazad and Selfotel populations). This is explained by the 
greater heterogeneity of the unselected series, which include both more severe and less severely 
injured patients (e.g. the extremes). This permits better discrimination between patients at low 
and high risks. Consequently, the interpretation of the results of external validation studies 
requires insight into the characteristics of the validation population. If a validation population 
is more heterogeneous than the development population, the expected discriminative ability is 
higher than that of the development population.
Calibration of most models was relatively poor (Figure 1). The substantial differences between 
predicted and observed outcomes may have been caused by several factors, including influences 
of regional trauma organization and referral policy on composition of populations, center 
differences in therapeutic approaches or changes in treatment over time. From a methodological 
point of view, the poor calibration points to the desirability for updating a prognostic model 
according to specific patient characteristics13,39. This was further confirmed by the improvement 
in performance following refitting (Table 4 and 5). No improvement was observed in calibration 
of the refitted models for the TCDB population, which suggests that a different factor overrides 
the benefits of refitting. As the TCDB data set is the oldest data set included in our analysis 
plausible explanations include improvements in trauma organization and standards of care. 
From a clinical perspective the poor calibration suggests a significant limitation for application 
of most models to support clinical decision-making and resource allocation.
We found no advantage of the tree models over logistic regression models. In fact, the refitted 
tree structures4,10 performed more poorly than refitted logistic regression models containing 
the same predictors (Table 5). As found in earlier methodological studies, the selection and 
number of predictor variables was however more important than the particular methodology 
applied40. Further improvement in performance may hence come from including more (and 
more powerful) predictor variables in future prediction models.
Several limitations of the present study should be acknowledged. First, we only selected 
prognostic models based on admission clinical and CT characteristics, as it was our primary 
intent to focus on the baseline situation, without influences of subsequent clinical treatment. 
Conclusions can therefore only be drawn concerning models using baseline characteristics; it is 
likely that prognostic models including information from later time periods will perform better. 
Secondly, some models were developed for predicting twelve-months outcome, while in the 
validation populations outcome was determined at six months post injury. This may have biased 
results in favor of the seven predictor model, which was developed on the six-month GOS32. 
However the GOS is considered fairly stable at six months post injury41 and we therefore do not 
consider this a significant confounding factor. The injury severity score (ISS), included in the 
model by Signorini et al.6 and intracerebral lesion, included in the model by Choi et al.4 were not 
used in the validations. It is conceivable that the performance of these models could have been 
better if it had been possible to include these risk factors, although the improvement would 
likely have been small8,42. Another limitation of our study was that calibration was assessed 
with standard statistical procedures, which group patients with similar predictions. Therefore, 
no information was available about the performance of specific clinical groups, e.g. how well 
the model predicted the outcome for individuals who are male, 75 years old, with one reactive 
pupil and involved in traffic accidents. Further, two of the four validation populations were 
patients from RCTs. Although such populations are somewhat selected, they had the advantage 
to be relatively large, to originate from various Western countries, and to contain prospectively 
collected and carefully verified data. Three of the four validation populations used were collected 
between 1992 and 1995. Although these populations cannot directly be considered old or 
outdated, some factors affecting external validation may have changed since this data collection. 
We therefore advise to validate prognostic models repeatedly on new patient series.
We conclude that models developed with baseline characteristics available on admission may 
provide satisfactory discrimination, but often suffer from poor calibration. This implies that 
these models can best be applied for discriminative purposes, such as ranking or classifying 
patients. Generally the clinical severity of patients with TBI is classified into severe/moderate/
mild according to the GCS. This however provides only a very rough classification, and we 
contend that the classification can be much more detailed if based on a prognostic model, 
that includes more characteristics. Caution should be applied when using prognostic models 
for supporting clinical decision-making and resource allocation, for which good calibration is 
essential. The better calibration, observed in the refitted models, confirms the desirability for 
updating a model on more recent patient populations.
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Abstract
Objective
To investigate whether triage for direct admission of patients with traumatic brain injury to 
a trauma center is facilitated by predicting the risk of potentially removable lesions or raised 
intracranial pressure (ICP).
Design and setting
Cohort study in a level I university trauma center.
Patients and participants
A prospective cohort of primarily (n=200) and secondarily (n=75) referred patients with moderate 
or severe traumatic brain injury.
Measurements and results
Predictive characteristics for the risk of surgically removable lesions and the risk of raised ICP 
(repeatedly ≥ 20 mm Hg) were identified and included in prognostic models. These models         
were validated internally with bootstrapping techniques and externally on a historic sample 
(n=205) regarding discriminative ability (AUC). Among the cohort patients, 67% had raised ICP 
and 54% had surgically removable lesions. Both outcomes occurred more frequently in patients 
secondarily referred, but the incidence in patients primarily referred was also high (62% and 
33% respectively). No strong predictors of raised ICP were identified. Age and pupillary reactivity 
were significant predictors of surgically removable lesions. The models discriminated reasonably 
for surgically removable lesions (AUC=0.78 at development and AUC=0.67 at external validation) 
but not for raised ICP (AUC=0.59 at development and AUC=0.50 at external validation). 
Conclusions
It is difficult to accurately identify patients in need of specialized intensive care using baseline 
characteristics. The high incidence of both outcomes in patients primarily referred support 
direct admission of more and particularly older patients with severe or moderate brain trauma 
to level I trauma centers.
Introduction
Traumatic brain injury (TBI) is one of the most important causes of death in young adults1. 
Survivors are often confronted with severe limitations in their daily life. In patients with severe 
or moderate TBI therapeutic principles aim at early detection and evacuation of mass lesions 
and treatment of raised intracranial pressure (ICP). Raised ICP is reportedly the leading cause of 
inhospital deaths after TBI2. Invasive monitoring of ICP and surgical treatment of mass lesions 
requires admission to a level I trauma center with specialized intensive care and neurosurgical 
facilities. 
In many European countries capacity problems in level I trauma centers prohibit direct admission 
of all patients with severe or moderate TBI, and many patients are secondarily referred. The 
European Brain Injury Consortium (EBIC) data survey reported a national proportion of 35% 
- 75% secondarily referred patients3. In European countries participating in a large trial in TBI 
24% - 57% of the patients were secondarily referred4. Secondary referral may delay the initiation 
of appropriate therapy, increase the risk of adverse events and systemic insults during inter-
hospital transport, and be disadvantageous for the recovery of the patient5. On the other hand, 
some patients admitted primarily to the level I trauma center may have less severe injuries 
than initially suspected and do not require specialized facilities. Currently these patients occupy 
scarce beds and absorb care and medical resources. A more efficient triage may be aided by early 
identification of patients in need of specialized intensive care. 
The objective of our study was to analyze differences in baseline characteristics between primarily 
and secondarily referred patients with TBI and to investigate the feasibility for predicting the 
need of specialized intensive care, i.e. the risk of (a) potentially operable lesions or (b) raised 
intractranial pressure (ICP) within 7 days after TBI with simple baseline characteristics. To 
estimate these risks more precisely we developed prognostic models. 
Patients and methods
Patients
We collected data from 275 patients (‘cohort’) with severe TBI (Glasgow Coma Scale, GCS, 3-8) or 
moderate TBI (GCS 9-12) admitted to the trauma center of Erasmus Medical Center, Rotterdam, 
The Netherlands, between 1 January 2000 and 31 March 2003. Erasmus Medical Center functions 
as a primary care facility for Rotterdam and its immediate surroundings (population 500.000) 
and as tertiary care facility for a wide region in the southwest of The Netherlands (population 
1.5000.000 – 2.000.000). Consequently the cohort represents a mix of primarily referred (directly 
admitted) and secondarily referred (from other centers) patients (Table 1). For validation of the 
models developed we selected 205 patients with severe or moderate TBI who had been enrolled in 
randomized clinical trials at Erasmus Medical Center between 1989 and 1997 (historic sample). 
Data from treatment and placebo groups were combined for the present analysis, as none of 
these studies had shown any significant difference between treatment groups. 
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Table 1. �atient characteristics and outcome measures in patients with traumatic brain injury 
(n = ��5)
Clinical characteristics Directly admitted (n=���) Secondary referral (n=�5)
Age, mean ± SD (years) 4�  ±�� 5� ±�1
Male gender 15� ���% 54 ��%
Cause of injury*
Traffic accidents 11� 55% �� ��%
Domestic/Falls �4 1�% �4 ��%
Other# 5� ���% �1 ���%
Missing � 1
Motor score^*
No response 4� ��% � 4%
Extension �� 11% 5 �%
Abnormal flexion �4 1�% 5 �%
Flexion withdrawal ��� ��% � 1�%
Localizing �� ��% �1 ��%
Obeying commands �� 14% �� 44%
Missing 1�^ �
Eye score^*
No reaction 11�� ��% �1 ��%
To pain �� 11% � 1�%
To speech/spontaneous 5� ��% 4� 5��%
Missing 1�^ �
Verbal score^*
None 1�4 5�% 1�� �5%
Incomprehensible �� ��% 1� 1��%
Inappropriate/confused/oriented 44 �4% 4� 5��%
Missing 1� �
GCS^*
�-�� 1�5 ���% �� ��%
≥ � 5� ��% 4� �4%
Missing 1� �
Pupillary reactivity
Both pupils reacted 1�� ��% 4� ��%
One pupil reacted 1� �% � 1�%
No pupil reacted 4� �5% 1� 1��%
Missing � �
Table 1  (continued)
Pupillary size
Both wide �� 14%  �� 11%
One wide �5 1�% 1� 1�%
Both normal 14�� �4% 55 ��%
Missing � �
Hypoxia*
Yes or suspected �� ���% 1� 14%
Missing 11 �
Hypotension*
Yes or suspected �� 14% � 4%
Missing 11 �
Hypothermia*
Yes or suspected 4� �5% � �%
Missing ��� 11
Injury Severity Score*, mean ± SD 4� ±14 �� ±1�
Time to definitive treatment, mean ± SD 
(min)
��� ±1�5 4�� ±���
Outcome measures Directly admitted (n=���) Secondary referral (n=�5)
Raised intracranial pressure (ICP)‡
Yes �� ��% �� ��%
Missing �� 4�
Surgically removable lesion*
Yes �� ��% 4� ��%
Missing 1 1
* p < �.�5
# Includes accidents at work, during sports, falls under the influence of alcohol , assaults, and other
^ Score at or, if missing, before admission to the neurosurgical unit
‡ IC� ≥ �� mm Hg
15
Chapter 8
15
Predicting the need of specialized intensive care
Predictors and outcome
As potential predictors for the need of specialized intensive care we considered age, gender, 
cause of injury, motor score, hypotension, hypoxia, pupillary response, and Injury Severity Score 
(ISS). These patient characteristics have been previously identified as important predictors of 
poor outcome6-11 and are easy to assess with high interobserver agreement. Other potentially 
important predictors such as the duration and degree of hypotension, duration of hypoxia, time 
from injury to referral, and time to definitive therapy were not considered for analysis since 
these characteristics would not be available at the site of injury. Age and ISS were included 
as continuous variables. Cause of injury was categorized into traffic accidents, falls, and other 
causes, including work related injuries, sports injuries, and assaults. Hypotension and hypoxia 
were defined by systolic blood pressure below 90 mmHg and pO2 below 60 mmHg or if supported 
by strong clinical suspicion. The pupils were defined as wide if their size was 5 mm or larger. All 
characteristics were measured before or on admission to the neurosurgical unit. 
The two outcome measures were: (a) development of a large hematoma, potentially eligible for 
surgery (volume hematoma ≥ 25 ml and/or size hematoma > 1 cm and/or mass effect) within the 
first 7 days after the injury and (b) occurrence of raised ICP (repeatedly ≥ 20 mm Hg) within the 
first 7 days after the injury. If monitored, the ICP was assessed each hour. To determine raised 
ICP two persons (C.H., F.S.) evaluated all hourly measured ICP-values (‘eye-ball’ assessment), 
while blinded to the values of the potential predictors of a patient. ICP values were weighted 
according to their deviance of the limit of 20 mmHg, for example, three consecutive values of 
21 mmHg were not considered as raised ICP, while two values of 40 mmHg were. In the case of 
any doubt the two evaluators conferred to reach consensus. The historic sample contained daily 
ICP measurements. If any of these daily measurements was 20 mmHg or higher, the patient was 
categorized as having raised ICP.
Since the ICP was monitored only for a limited number of the patients (134 patients of the 
cohort and 180 patients of the historic sample) we examined whether radiological signs 
of raised ICP, i.e. midline shift of 5 mm or more and compressed or absent basal cisterns on 
computed tomography within the first 7 days, could be used as an alternative outcome measure 
for monitored raised ICP. Unfortunately, a poor correlation was observed between documented 
raised ICP and radiological signs of raised ICP (only 65% of the cohort patients and 46% of the 
historic patients had matching outcomes). We therefore limited our further analysis to patients 
in whom ICP had been monitored invasively. 
Values of measured predictors were missing in some patients (3.1% in the development sample, 
1.5% in the historic sample). These values were estimated statistically based on regression models 
including the other predictors, and subsequently imputed12,13. Such imputation is recommended 
as more efficient than dropping cases12. Thus, all patients contributed to the development of the 
prognostic models. In the historic sample the ISS was not assessed. We followed a conservative 
approach by assigning the median ISS of the cohort as the ISS for all historic patients. We chose  
a 7-day window for the outcome measures as the vast majority of problems related to the 
development of operable lesions and raised ICP occurs within this time period. Age was quantified 
in years, ISS in points; all other predictors were coded as ‘1’ if true and ‘0’ if false.
Development and validation of the prognostic models
From the group of nine potential predictors we selected those that had a p-value < 0.50 in a 
backward stepwise logistic regression procedure14,15. Subsequently, we developed a prognostic 
model for each outcome measure using logistic regression analysis. Internal validity was 
assessed with standard bootstrapping procedures15,16. Bootstrapping involved drawing samples 
with replacement from the development sample. Each sample can be seen as if one is repeating 
the data collection with the same number of patients and under identical circumstances as the 
original. Multivariable prediction models were estimated in 200 bootstrap samples and each 
evaluated on the original sample. The average difference in performance indicates the optimism 
(overfitting)12. This is the phenomenon that a model predicted outcome well in the development 
sample, but tends to predict too extreme probabilities in new patients. Subsequently the 
coefficients were corrected (decreased) to provide better predictions for future patients12,14. 
External validity, that is, whether the models perform well for patients from another setting, 
was assessed on the historic sample. 
Performance 
Performance of the models was assessed with regard to calibration and discrimination. Calibration 
was assessed graphically by plotting observed outcome against the predicted probability. A 
smooth, non-parametric calibration line was created with the lowess algorithm15. Calibration 
was tested with the Hosmer-Lemeshow goodness-of-fit test. Discrimination is defined as the 
model’s ability to differentiate patients with different outcomes. To quantify the discrimination 
we used the area under the receiver operating characteristic curve (AUC), which considers pairs 
of sensitivity and specificity for consecutive cutoff points of the predicted probabilities from a 
model (0-100%). The AUC indicates among all possible pairs of patients with different outcomes, 
the likelihood that those with higher predictive risk indeed are more likely to have a poor 
outcome (raised ICP or surgically removable lesions). The higher the AUC, the better the model 
discriminates. A model with an AUC of 0.50 has no discriminative power at all, while an AUC of 
1.0 reflects perfect discrimination. 
The robustness of the prognostic models was examined by performing sensitivity analyses. We 
repeated the analyses for those patients with a direct (primary) referral to the Erasmus Medical 
Center. Calculations were performed using SAS version 6.12 (SAS Institute INC., Cary, NC, USA) 
and S-plus version 2000 (Insightful Corporation, Seattle, Wash., USA).  
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Table 2. Associations between predictors and monitored raised IC� in patients with moderate 
or severe traumatic brain injury (n=1�4)
Predictors Raised ICP OR uni (5% CI*) OR multi (5% CI*)
Age#
�� years na - § - §
�1 years na 1.� (�.� – �.�) 1.� (�.� – �.4)
Gender
Male �� (�4%) - § -
Female 1� (�5%) 1.1 (�.4 – �.�) -
Cause of injury
Traffic accident 4� (�4%) 1.� (�.4 – �.�) -
Domestic/falls 15 (��%) �.� (�.� – �.�) -
Other causes �� (�5%) - § -
Motor score 
No reaction/extension �� (��%) �.�� (�.� – 1.��) �.� (�.� – 1.��)
Abnormal flexion/flexion withdrawal �� (��%) �.� (�.4 – �.�) 1.� (�.4 – �.4)
Localizing/obeying �1 (�5%) - § - § 
Pupillary reactivity
Both pupils reacted 5� (��%) - § - §
One pupil reacted 1� (��%) 1.� (�.� – �.1) �.�� (�.� – �.��)
No pupil reacted �4 (��%) 1.� (�.� – �.1) 1.5 (�.5 – 4.�)
Pupillary size
None wide 55 (��%) - § - §
One wide 1� (�1%) 1.5 (�.� – �.��) 1.� (�.� – 4.��)
Both wide 11 (�1%) �.� (�.� – �.�) �.� (�.� – �.�)
Hypoxia
No 55 (�5%) - § -
Yes or suspected �� (��%) �.� (�.4 – �.�) -
Hypotension
No �4 (�5%) - § - §
Yes or suspected � (5�%) �.� (�.� – 1.� ) �.�� (�.� – �.�)
ISS‡
�� na - § - §
45 na �.� (�.� – 1.5) 1.� (�.� – 1.�)
* If this interval does not include the value 1, the factor has a statistically significant effect on the 
outcome 
# �1 years is the �5th percentile and 4� years the �5th percentile, including age as a continuous linear 
term 
‡ �� is the �5th percentile and 45 the �5th percentile, including ISS as a continuous linear term
§ Reference 
 OR = odds ratio, uni = univariable logistic regression analysis, multi = multivariable logistic 
regression analysis, na = not applicable since percentiles were used for describing the association 
between age and outcome or ISS and outcome, CI = confidence interval*
Table 3. Associations between predictors and surgically removable lesions in patients with 
moderate or severe traumatic brain injury (n=��5) 
Predictors Removable lesions OR uni (5% CI*) OR multi (5% CI*)
Age#
�� years na - § - §
�1 years na �.4 (�.� – 5.4) �.� (�.� – 5.�)
Gender
Male ��5 (41%) - § -
Female �� (4��%) 1.� (�.�� – �.4) -
Cause of injury
Traffic accident 45 (��%) �.� (�.� – 1.1) �.� (�.4 – 1.�)
Domestic/falls �5 (�1%) �.� (1.� – 4.1) 1.1 (�.5 – �.4)
Other causes �4 (44%) - § - §
Motor score
No reaction/extension ��� (4�%) �.� (�.4 – 1.�) -
Abnormal flexion/flexion withdrawal �� (�5%) �.� (�.� – 1.1) -
Localizing/obeying 55 (4�%) - § -
Pupillary reactivity
Both pupils reacted �� (��%) - § - §
One or no pupil reacted 4� (55%) �.1 (1.� – �.�) �.� (1.1 – 4.5)
Pupillary size
None wide �� (��%) - § - §
One or both wide �� (5�%) 1.5 (�.� – �.�) 1.� (�.�� – �.5)
Hypoxia
No �� (4�%) - § -
Yes or suspected �1 (���%) �.�� (�.4 – 1.�) -
Hypotension
No �� (4�%) - § - §
Yes or suspected � (�1%) �.� (�.� – 1.� ) 1.� (�.4 – �.�)
ISS‡
�� na - § - §
45 na �.5 (�.� – �.�) �.5 (�.� – �.�)
* If this interval does not include the value 1, the factor has a statistically significant effect on the 
outcome 
# �1 years is the �5th percentile and 4� years the �5th percentile, including age as a continuous linear term 
‡ �� is the �5th percentile and 45 the �5th percentile, including ISS as a continuous linear term
§ Reference 
 OR = odds ratio, uni = univariable logistic regression analysis, multi = multivariable logistic regres-
sion analysis, na = not applicable since percentiles were used for describing the association between 
age and outcome or ISS and outcome, CI = confidence interval*
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Results
Patient characteristics and outcome
The characteristics and outcome of the cohort patients are presented in Table 1, differentiated 
into primary (73%) and secondary (27%) referrals. Most patients were male, both in the primarily 
(78%) and the secondarily referred group (72%). The distribution of many baseline characteristics 
differed between the two groups. In general, secondarily referred patients were older (52 vs. 42 
years), were more frequently injured in the domestic setting or by a fall (32% vs. 17%), and had 
initially less severe clinical characteristics (higher GCS, fewer secondary insults). 
If monitored, raised ICP was observed frequently, both in directly admitted (62%) and secondarily 
referred patients (70%). Potentially operable lesions were observed in 42% of the patients in 
the cohort, more frequently in those secondary referred (66% vs. 33% in the directly admitted 
patients). When including only ICP monitored patients, the need for specialized intensive care 
(i.e. the presence of one or both outcome measures) was present in 97% of patients secondarily 
referred and in 68% of patients directly admitted. 
The historic sample was more homogeneous with respect to the baseline clinical characteristics 
the historic sample was more homogeneous, with fewer patients in the motor score categories 
‘no response’ and ‘obeying command’ (8% and 3% respectively). A large proportion of the patients 
in the historic sample (84%) was classified as having a severe TBI. Gender and the occurrence of 
hypotension were similar to the cohort study. Raised ICP was noted in 54% of the ICP monitored 
patients in the historic sample (88% monitored) and potentially operable lesions were present 
in 49%. 
Predictors
Both univariable and multivariable analyses showed small effects of most potential predictors on 
the two outcome measures. No strong predictors of raised ICP were identified, and only age and 
pupillary reactivity were statistically significant (p-value < 0.05) predictors of potentially operable 
lesions (Table 2 and 3). Multivariable analyses with a high p-value (p-value < 0.50) included age, 
motor score, pupillary reactivity, pupillary size, hypotension, and ISS as potential predictors of 
raised ICP and age, cause of injury, pupillary reactivity, pupillary size, hypotension and ISS as 
potential predictors of surgically removable lesions. Details of the developed prognostic models 
are presented in the Appendix.
Performance of the models 
Patients with and without raised ICP could not be distinguished; AUC was 0.59 in the cohort 
with the 95% confidence interval (CI) of the AUC including the value 0.50, and AUC was 0.50 
in the historic sample (Table 4). Surgically removable lesions were predicted with reasonable 
discrimination (AUC = 0.78, 95% CI 0.72 – 0.83 in the cohort; AUC = 0.67, 95% CI 0.60 – 0.75 
in the historic sample, a decrease of 0.11), also if the model included only those patients who 
were primarily referred to the trauma center (AUC = 0.73, 95% CI 0.66 – 0.81). When the model 
excluded ISS, the decrease in performance was only slightly smaller (AUC = 0.74 in the cohort; 
AUC = 0.67 in the historic sample, a decrease of 0.07). Discriminative ability of the model 
predicting surgically removable lesions is also demonstrated in Table 5; 82% of the directly 
admitted and 69% of the secondarily referred cohort patients were categorized in one of the 
two extreme categories. Calibration of the model predicting surgically removable lesions was 
satisfactory in the cohort, but poor in the historic sample (p-value = 0.01, Hosmer-Lemeshow 
goodness-of-fit test). Figure 1 shows discrimination and calibration of the model predicting 
surgically removable lesions in more detail. 
Table 4. Discrimination and calibration of the prediction rules. The rules were developed in 
patients at the Erasmus Medical Center in ���� – ���� (cohort, n = ��5) and externally vali-
dated in patients there in 1���� – 1��� (historic sample, n = ��5) 
Outcome measures Cohort (n=275) Historic sample (n=205)
Discrimination Calibration
�-value *
Discrimination Calibration
�-value * AUC (�5% CI) AUC (�5% CI)
Monitored raised IC� �.5� (�.4�� – �.��) �.4� �.5� (�.41 – �.5��) �.1��
Surgically removable lesions �.��� (�.�� – �.���) �.�� �.�� (�.�� – �.�5) �.�1
* Hosmer-Lemeshow goodness-of-fit test, low p-values indicate poor goodness-of-fit
AUC = area under the receiver operating curve, CI = confidence interval
Table 5. Classification of patients into three risk categories, according to their predicted risk 
of surgically removable lesions, as estimated by the prognostic model (n=��5)
Risk of surgically
removable lesions
Direct admission (n=1) Secondary referral (n=74)
n % n %
< �.4� 1�� �1 �� ��
�.4� – < �.�� �� 1�� �� �1
≥ �.�� 41 �1 �1 4�
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Discussion
Various studies have reported prognostic models of baseline characteristics for predicting 
outcome after TBI6-10,17-20, but to our knowledge no previous studies have attempted to predict 
the need of specialized intensive care for patients with TBI. We observed that several baseline 
characteristics were associated with this need, with age and pupillary reactivity showing 
statistical significance when predicting surgically removable lesions. Our results, however, 
indicate that it is not possible to predict the need for specialized intensive care in patients with 
severe or moderate TBI with sufficient confidence to use such predictions for refining triage 
criteria. 
Several factors may have contributed to the poor discriminative ability of the model predicting 
raised ICP. We only investigated a threshold value of 20 mm Hg for raised ICP by eyeball 
assessment, and the relatively small sample size of the development population (134 patients 
with monitored ICP) may have hampered the identification of predictors and the assessment of 
the regression coefficients of the model. The relatively poor calibration of the model predicting 
surgically removable lesions at external validation may be explained by the selection of patients 
in the historic sample according to more rigorous criteria, as well as by the different (earlier) 
period of data collection. Limited calibration during external validation is, however, observed 
often for prognostic models and indicates that the model may require adjustment for specific 
circumstances before it can be used in new populations21,22. 
Several limitations of our study should be acknowledged. First, we only collected data from 
patients who were admitted to the trauma center of the Erasmus Medical Center. Consequently, 
we do not know how many other patients may have needed specialized intensive care. This 
may have caused some selection bias. However, since the local trauma policy is that all patients 
having sustained severe or moderate traumatic injury within the Rotterdam area are primarily 
referred to the level I trauma center of the Erasmus Medical Center, this subpopulation of patients 
referred may be considered representative of the overall population of severe and moderate TBI. 
Second, the models might be improved by including other patient characteristics or information 
obtained at later time periods. Further, predictors were measured at or, occasionally, before 
baseline. Before a model like this can actually be implemented for optimizing the initial triage 
of TBI patients, its validity needs to be confirmed with pre-hospital data.  
 
Although we were not able to predict the need of intensive care after TBI, we observed that the 
rates of both outcome measures in patients primarily referred were high: 33% of the patients 
had potentially operable lesions and in 62% had raised ICP among those with ICP monitored. 
Even if we would consider raised ICP to be absent in patients not monitored, the rate of one 
or both outcomes occurring in the population studied was 48%. This high incidence indicates 
that the triage criteria, according to which all patients with a Revised Trauma Score23 lower 
than 11 and/or a GCS below 12 are referred, are relatively specific, i.e., relatively successful in 
selecting patients at risk for intracranial complications. On the other hand, the triage criteria 
are less sensitive since the proportion of secondarily referred patients, who almost all needed 
specialized intensive care, was substantial (27%). 
Figure 1. Validation of the model predicting surgically removable lesions in the cohort (n = 
��5) and the historic sample (n = ��5). Dashed smooth curves reflect the relationship between 
observed and predicted probability of surgically removable lesions�� straight dotted line through 
the origin perfect calibration�� triangles incidence of poor outcome in deciles of patients with 
similar predicted probabilities�� spikes at the bottom of each graph distribution of predicted 
probabilities 
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Secondary referral may delay initiation of appropriate monitoring and surgical intervention and 
incurs the additional risk of adverse events during interhospital transport24-26. Studies on adult 
and pediatric populations have shown initial treatment at a local hospital with subsequent 
transfer to a trauma center to be associated with a doubling of mortality27. A general approach 
to prevent secondary referral is to get the right patient to the right facility at the right time. 
Definitions of the right facility and the right time have been proposed in the international 
guidelines28 as a center with 24 h computed tomography service and neurosurgical facilities 
and expertise in the treatment of TBI, which should be reached as soon as possible. Defining the 
right patient, however, is complex. The high incidence of both outcomes in patients primarily 
referred, together with the substantial proportion of patients secondarily referred may support 
more liberal triage criteria, for example, admitting more patients with moderate TBI directly to 
a level I trauma center. Since secondarily referred patients were generally older, and age was 
identified as a significant predictor, especially older patients may be suitable for such a policy. 
The final answer to whether such a more liberal admission policy is appropriate can be answered 
definitively only following a population-based study. Alternatively, the risk of secondary referral 
may be reduced by using a specialist retrieval team29.    
Expanding the triage criteria of the trauma centers to older, moderately injured TBI patients 
would have considerable consequences for local trauma organization and capacity of tertiary 
referral centers. The majority of patients primarily admitted to our center originate from the 
immediate surroundings of Rotterdam. If we extrapolate the expected number of admissions 
to the wider region for tertiary referral, a two- to threefold increase in the number of admitted 
patients might be expected. Nevertheless, such a liberal admission policy, if cost effective, may 
be considered preferable to the current approach in which patients are only secondarily referred 
after intracranial complications have developed and the neurological condition deteriorated. The 
negative consequences on capacity may in part be compensated by early transferral to a regional 
hospital of those patients in whom intracranial complications do not develop after a couple of 
days. Such a policy may limit the risks of additional interhospital transport in the acute phase, 
offer facilities for prompt initiation of specialized management, and is in accordance with the 
concept of concentration of care within trauma centers.
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Appendix
Details of the prognostic models.
The probability of a poor outcome (raised ICP or surgically removable lesions) is calculated as 
1/(1 + exp-LP). 
The linear predictor (LP) takes the form of LP=intercept + regression coefficients × predictor 
values. 
LP# for monitored raised ICP = 0.55 + (0.00089   × age) - (0.062 × motor score equal to ‘no response’ 
or ‘extension’) + (0.00091 × motor score equal to ‘abnormal flexion’ or ‘flexion withdrawal’) 
- (0.049 × one pupil reacts) + (0.076 × no pupil reacts) + (0.098 × one pupil wide) - (0.033 × both 
pupils wide) - (0.059 × hypotension) - (0.00013 × injury severity score). 
LP# for radiological signs of raised ICP = - 0.64 + (0.025   × age) + (0.22 × motor score equal to ‘no 
reponse’ or ‘extension’) + (0.48 × motor score equal to ‘abnormal flexion’ or ‘flexion withdrawal’) 
+ (0.52 × one pupil reacts) + (1.20 × no pupil reacts) + (1.0068 × one pupil wide) + (1.17 × both 
pupils wide) + (0.50 × hypotension) - (0.027 × injury severity score). 
LP# for surgically removable mass lesions = - 0.60 + (0.031    × age) - (0.33 × traffic accident) + (0.062 
× accident at home or fall) + (0.72 × one or none pupil react) + (0.44 × one or both pupils wide) 
- (0.036 × injury severity score). 
Coding of the predictors: 
Age in years; ISS in points; All other predictors: 1 if true and 0 if false.
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Discussion
This thesis addresses three research questions regarding prognosis for patients with severe or 
moderate TBI. The focus is on developing and validating prognostic models that use baseline 
patient characteristics to predict long-term outcome and the need for specialized intensive care. 
In this chapter the findings of our studies are first discussed in the light of the research questions 
as formulated in Chapter 1. Furthermore, implications of the results for clinical practice are 
presented. Finally, conclusions are drawn and suggestions for further research are given.  
Study findings
1. Methodological developments in prognostic modeling in TBI.
The review of 26 prognostic modeling studies highlighted important deficiencies in the methods 
used to develop and validate prognostic models in TBI. Many previously developed models were 
limited by old, small and relatively homogeneous study populations for their development and 
by the way predictors were chosen. Furthermore, rather crude statistical methods were used 
and patients with missing predictor values were often omitted from the study population. 
Additionally, models were seldom validated on more recent patients from the same place, and 
never on patients from another place. 
Based on the observed deficiencies we proposed guidelines to develop and validate prognostic 
models. The guidelines concern five subjects, i.e. study population, predictors, outcome, model 
development and model validation. We hope that our guidelines contribute to improve the 
quality of prognostic modeling and validation in future TBI studies. 
2. Construction and validation of prognostic models that predict long-term 
outcome for patients with severe or moderate TBI
We first examined the characteristics of the study population (the Tirilazad cohort). The cohort 
was relatively heterogeneous, which was partly explained by regional differences. Remarkably, 
outcome was better in patients treated in the United States than those treated in Europe or 
other countries. We found that age should be included in a prognostic model as a continuous 
predictor, and that various combinations of CT characteristics could well predict outcome. We 
developed two logistic regression models that predict six-month mortality and unfavorable 
outcome. Both models included the same seven predictors, measured at baseline. The models 
provided high discrimination between patients with good and poor six-month outcome (AUC 
0.78 to 0.80 in the development series and AUC 0.83 to 0.89 at external validation). The models 
showed satisfactory calibration in most patient series. We compared the performance of our 
seven-predictor models with several other models, including prediction trees and logistic 
regression models. Better discrimination was observed for the logistic regression models and 
for the models including more predictors. 
Overall, we consider our seven-predictor models suitable for clinical practice, especially to classify 
patients according to prognostic risk. Carefulness is however required, because an adjustment 
for possible poor calibration may be necessary. 
3. Predict the need of specialized intensive care.
We developed two prognostic models, one predicting the risk of surgically removable lesions and 
one predicting the risk of raised ICP, using baseline characteristics. Both outcome measures are 
indicators of the need of specialized intensive care. The models could reasonably discriminate 
patients with and without surgically removable lesions (AUC = 0.78 at development and AUC = 
0.67 at external validation in a historic sample of 205 patients from the Erasmus MC), but could 
– unfortunately – not discriminate patients with and without raised ICP. Overall, the models 
were not considered suitable for implementation in clinical practice. 
Methodological considerations 
Below, we discuss the different steps we have taken to construct and validate the models and we 
relate these steps to the methodological guidelines for model development and validation (Table 
1), as proposed in Chapter 2. 
Models predicting six-month mortality and unfavorable outcome
Study population
We intended to use the Tirilazad patients for model development since we regarded it as close 
to ideal: with more than 2200 – consecutively admitted – patients it is the largest available data 
set on severe and moderate TBI. The cohort originated from multiple centers, i.e. 76 centers 
from 17 countries in North America, Europe, Australia and Israel. In Chapter 3 we observed 
that the Tirilazad cohort was relatively heterogeneous. Thus, the first two guidelines for model 
development were met (Table 1). A limitation of the series, however, was that data were collected 
more than 10 years ago (from 1991 to 1994). Although no major diagnostic or therapeutic 
changes have taken place since that time, the validity of the models in current clinical practice 
requires further study. 
In the studies described in this thesis treatment and placebo-groups were combined, since in 
neither trial a statistically significant difference between the treatment and placebo group was 
shown for the primary outcome (GOS at 6 months after the injury). Nevertheless, we realize 
that some (even negative) treatment effect may be present. In the North American Tirilazad trial 
mortality was significantly higher in treatment group. However, this effect was considerably less 
than the prognostic effects of the predictors. Moreover, the Tirilazad patients were randomized 
between the treatment and the placebo group, which guaranteed balance with respect to 
observed and unobserved characteristics. Consequently, we considered it legitimate to combine 
treatment and placebo groups in addressing our research questions. 
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Table 1. Guidelines for developing and validating prognostic models in TBI
Guidelines Model for outcome Model for need of care
Study population
• Large, well-defined cohort + -
• Heterogeneous  +/- +/-
• Representative for current clinical practice +/- +
Predictors
• �lausible + +
• �recisely defined + +
• Readily available or easily obtainable + +
Outcome
• Relevant for clinical practice + + and +/-*
• �recisely defined + and +/-# +
• Measurable with minor observer variability +/- +
Model development
• Use of appropriate statistical techniques + +
• Use of sensible performance measures,
    evaluating calibration and discrimination
+ +
• �resentation in a readily applicable format + na
Model validation
• Internal validation + +
• External validation + -
* + for the model predicting surgically removable lesions, +/- for the model predicting raised IC�
# + for the model predicting mortality, +/- for the model predicting unfavorable outcome�� 
na = not applicable
Predictors
After identifying the association between age and outcome, we studied the literature to determine 
which predictors might be eligible for inclusion in the models. Nine predictors were considered, 
i.e. age, gender, cause of injury, motor score, hypotension, hypoxia, pupillary reactivity, the 
Marshall CT-classification and the presence of traumatic subarachnoid hemorrhage (tSAH). 
All nine candidate predictors were previously identified as important1,2 and are thus plausible. 
Additionally, they are precisely defined and can be obtained easily and reliably within the first 
four hours after the injury. Consequently, the candidate predictors fulfill the guidelines for 
predictors, as proposed in Chapter 2 (Table 1).
The observed value of the predictors may be affected by several factors, such as treatment. For 
instance, the motor score may become untestable by paralysis and – to a lesser extent – sedation. 
Deep sedation may also affect pupillary reactivity. The influence of such treatments on the 
prognostic value of these predictors needs further study in more recent data sets.
Some potential predictors were not considered for inclusion in the models. For example, the 
verbal and the eye score of the GCS were dropped because they are not testable for patients in 
coma. Consequently, their discriminating ability will be limited and only relevant for patients 
with moderate TBI. In Chapter 3 we identified a difference in outcome between patients in North 
America and patients in Europe, which could not be explained by adjustment for a large set of 
potential confounders. Confounders included clinical characteristics, management and referral 
policy. Consequently, one might suggest that ‘continent’ (as a proxy for one or more unknown 
underlying characteristics) is a potential predictor for outcome. Nevertheless, we did not consider 
this suggestion since no plausible explanation could be found and the difference may be caused 
by coincidence. Furthermore, including ‘continent’ as predictor may have resulted in a lack of 
‘face-validity’ of the model, thus hampering implementation of the models in clinical practice. 
The observed outcome difference between continents requires further thorough study. 
In Chapter 5 we observed that a combination of several individual CT characteristics 
discriminates better than the Marshall CT-classification. In our models, however, we included 
only the Marshall CT-classification and tSAH, because the models were developed before the 
predictive ability of various combinations of CT characteristics had been explored. Although 
the Marshall CT-classification is well known, which may enhance implementation of the model 
in clinical practice, a new model in which the Marshall CT-classification is replaced by several 
individual CT characteristics may perform better. This subject requires further study.   
In this thesis we focused on characteristics that were previously identified as important 
predictors. It may however be possible that other – less generally accepted – characteristics 
add prognostic value. For instance, blood parameters, such as glucose or hemoglobin, are easy 
to assess shortly after admission. Also, extracranial injuries may be important in outcome 
prediction3-6. Their potential predictive power needs to be examined further. 
Outcome
Only few patients with an unfavorable outcome are expected to become favorable after six 
months post-injury7. Both outcome measures (mortality and unfavorable outcome) are relevant 
for clinical practice, since they assess overall outcome after TBI (Table 1).
The developed models predicted six-month mortality and six-month unfavorable outcome. 
Mortality was derived from the presence of a date of death and could be assessed very accurately 
with a time-window of maximally 24 hours. For unfavorable outcome a much broader time-
window of two months was used. Moreover, if patients had no GOS measurements within this 
time-window (12%), GOS was estimated according to a weighting algorithm, based on values at 
other points in time. This algorithm was developed specifically for our studies (see appendix of 
Chapter 3). Patients with missing GOS, for whom the GOS could also not reasonably be imputed 
(5%), were omitted from the study population. Omission of these patients may have caused 
selection bias, because patients with a good outcome may have been more likely to withdraw 
from follow-up. However, this bias would have been larger if all patients with missing outcome 
were simply deleted from the data set. Also imputing missing outcome values with the last 
known outcome value (Last Value Carried Forward), a generally applied approach for missing 
outcome values, is expected to create more bias than our algorithm, as outcomes usually 
176
Chapter 9
177
Discussion
improve over time. Consequently, we consider mortality as precisely defined and unfavorable 
outcome as defined with satisfactory precision (Table 1). 
The third proposed guideline for outcome, i.e. measurable with a low degree of observer 
variability, is partially fulfilled for unfavorable outcome. For the GOS some degree of inter-
observer variability has been observed8, although this may be diminished by using a structured 
interview during GOS assessment9. 
Model development
In Chapter 6 of this thesis, we developed prognostic models to predict mortality and unfavorable 
outcome for TBI patients, using logistic regression analysis. Out of nine potential predictors, we 
selected seven predictors (age, motor score, pupillary reactivity, hypotension, hypoxia, Marshall 
CT classification and tSAH), which were included in a multivariable logistic regression model. 
Predictors were selected with backward stepwise selection, using a p-value of 0.20. Such a liberal 
p-value balances simplicity of the model and predictive information and it may be preferable 
to the usually applied p-value of 0.0510,11. Bootstrapping techniques were used for internal 
validation of the model10. 
Most predictors were included in such a way that the relation with outcome was adequately 
described. For instance, age was included as a quadratic and linear term, as identified in Chapter 
4. The other predictors were dichotomous or categorical. For motor score some categories were 
combined to increase numbers per class, although it may have caused loss of information. 
Further loss of information may have been caused by the fact that we included motor score as 
‘dummy’-variables, thus ignoring its ordinal scale. However, before motor score can be included 
as an ordinal scale, further study is needed, e.g. on the size of the steps between the different 
scores. For the Marshall CT-classification the categories ‘mass lesion evacuated’ and ‘mass lesion 
non-evacuated’ were combined, since the distinction between these is artificial.
For several patients, values of some predictors were missing (5% of the required values). These 
values were statistically estimated with logistic regression, including the other predictors, and 
subsequently imputed in a single imputation procedure10,12. Such imputation is considered valid 
for patient series with a relatively small proportion of missing values. For data sets with a larger 
proportion of missing values multiple imputation is recommended13. 
Overall, we consider the statistical techniques used to develop our models satisfactory (Table 1).
The second and third guideline for model development were ‘the use of sensible performance 
measures’ and ‘presentation in a readily applicable format’. These were well accomplished (Table 
1). A score chart was presented to facilitate the quick estimation of the predicted probability (see 
Chapter 6). In this chart, each clinical characteristic is assigned a score. These scores can be 
easily added into a sum score that, through the logistic formula, corresponds with the predicted 
probability of mortality or unfavorable outcome. 
To develop prognostic models for TBI patients various statistical techniques have previously 
been used, such as logistic regression analysis, recursive partitioning and neural networks. In 
Chapter 7 we observed a slightly better performance for the logistic regression models, compared 
to the models developed with recursive partitioning, while both considered the same predictors. 
Chapter 7 also showed that the performance of a model depended more on the selection and 
number of predictor variables than on the applied analysis technique. The same phenomenon 
has been observed earlier by others14. Various studies observed that the performance of various 
statistical techniques is similar when the same set of predictors is considered 15-17. Therefore, 
it is not plausible that further improvement in model performance may come from other 
qualified statistical techniques. Further improvement should come from inclusion of more –
both independent and more powerful – predictors. 
Model validation
The methods used for validation largely met the proposed guidelines (Table 1). The models were 
validated internally by bootstrapping techniques and externally on three different patient series. These 
validation populations were all relatively large and were collected at different time points in different 
parts of the Western world. Validity was assessed regarding calibration and discrimination. 
Performance was good with respect to discrimination. Calibration according to the Hosmer-
Lemeshow statistic was sometimes disappointing. However, in large samples, such as the 
Tirilazad cohort, even small disagreements between observed frequencies and predicted 
probabilities might result in a significant Hosmer-Lemeshow statistic. 
Models predicting the need for specialized intensive care
The models predicting the risk of surgically removable lesions and the risk of raised ICP (ICP ≥ 20 
mmHg) fulfilled only part of the proposed guidelines for model development and validation (Table 
1). Although the study population was recent and relatively heterogeneous (as shown in Table 1 of 
Chapter 8), the population was also relatively small and originated from one center only. 
Age, motor score, pupillary reactivity, hypotension, hypoxia, gender, cause of injury and injury 
severity score (ISS) were considered as candidate predictors. The first five were already discussed 
in the paragraph above. Gender, cause of injury and ISS complied with the guidelines; they were 
all plausible predictors, precisely defined and readily available. 
The outcome measures were both easy to define and could be obtained with a low degree of 
intra- and inter-observer variation. Raised ICP, however, has as disadvantage that we may debate 
whether the used threshold value of 20 mmHg is appropriate. 
Model development occurred with reliable statistical techniques. The predictors age and ISS were 
included as continuous linear characteristics. Values of missing predictors were statistically 
estimated with logistic regression, including the other predictors, and subsequently imputed12,18.
The models were internally validated with bootstrapping techniques. External validation was 
also performed, but on a small and rather old dataset from the same center. To be relevant for 
clinical practice, both models needed to perform well, since both outcomes are indicators for the 
need for specialized intensive care. Unfortunately, the model predicting raised ICP performed 
poorly, both on the development and the validation population. Consequently, we decided to 
create no format to facilitate applicability of the model in clinical practice.   
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Practical considerations 
This paragraph discusses strengths and limitations regarding generalizability of our models to 
predict six-month outcome, and the applicability in clinical practice. 
Population
Patients with TBI constitute a heterogeneous population, including patients with widely varying 
severity of the injury, patients with different pathophysiology, e.g. focal versus diffuse injuries, 
and also patients in whom basic management may differ between centers. The models developed 
in this thesis are suitable for patients with severe or moderate closed TBI. Consequently, 
extrapolation of the models to patients with penetrating TBI is not advised, since this type of 
injury is pathofysiologically different from a closed TBI.
Furthermore, the cohorts used in this thesis originated from various centers all over the world. 
All centers are well-known trauma units with specialized intensive care and neurosurgical 
facilities and the management techniques in such units are generally of high professional level. 
Consequently, performance of the models in centers with less highly qualified personnel and 
instruments may be poorer. It is always advisable to validate the models before implementation 
in clinical practice, and especially so for such centers. 
Outcome
Both mortality and unfavorable outcome were derived from the GOS. The GOS, however, has 
been criticized for being insensitive, especially in patients with more favorable outcomes, an 
insensitivity which was even further increased by the dichotomization applied in this thesis. 
We therefore realize that the dichotomized GOS may not catch relatively small differences in 
morbidity. Our models are especially suitable for providing an overall indication of outcome. 
More sensitive predictions may be provided with a model that predicts, for instance, the Barthel 
Index19 or the Disability Rating Scale20, both used to quantify the degree of functional outcome, 
or the EuroQoL, used for assessing health-related quality of life21.
Application of the models in clinical practice 
Before a prognostic model can be used in clinical practice, it needs to be validated to support 
generalizability. A minimum of 200 patients has been suggested for such validation studies22. If 
validity is confirmed the model can be safely applied, although monitoring is still needed. 
At validation, however, also a structural difference in calibration may be observed. We found 
this for instance at validation of our models in the International Tirilazad patients. A structural 
difference in calibration implies a difference in the average predicted outcome between patient 
series, but similar odds ratios for the predictors in the development and validation patients. This 
is in agreement with the more general idea that biological associations between predictors and 
outcome do not change much over time or between centers. For example, it is plausible that age 
will affect outcome after TBI similarly in patient series collected at different places or different 
time periods. If such a structural difference in calibration is observed, the model can simply 
be adjusted by re-estimating the model intercept23,24. This was done in Chapter 6 and with re-
estimation of the model intercept; calibration improved in the International Tirilazad patients. 
At validation, also a difference in the odds ratios for the predictors in the model and the odds 
ratios in the validation population may be observed. This was for instance found at validation of 
our model for mortality in the TCDB cohort. Such differences in odds ratios may, for instance, 
be caused by differences in definitions of the data in the development and validation patients, 
or by subgroup effects (e.g. a new treatment which is effective in part of the population) that 
influence the individual regression coefficient of a predictor. Then, more complex strategies 
may be needed, such as re-estimating the individual model parameters (e.g. fitting of the 
regression coefficients of a pre-specified set of predictors) and model revision (assessment of the 
relevance of predictors plus estimation of their parameters)23,24. Such strategies are, however, 
only recommended if the quality and size of the validation data are substantial. Furthermore, 
attention should be paid to the modeling guidelines as proposed in Chapter 2.
In some circumstances, however, validation of the models is not feasible. For instance, a small 
center may not be able to collect the required minimum of 200 patients needed for reliable 
validation. In that case, we should be more conservative in the application of the model25. For 
instance, if the aim of the model is to classify patients according to prognostic risk or to compare 
patient series and treatment results over time and place, application of the model may be valid. 
If the aim of the model is towards treatment limiting decisions, however, application may not 
be advised. 
Application of the models in clinical research
The proposed seven-predictor models may serve various purposes in research, including case-mix 
adjustment in comparisons between centers, and over time within centers. An attractive role 
is in improving the efficiency of randomized clinical trials in TBI. A large-scale NIH sponsored 
project currently addresses this issue. The developed models can be used for covariate adjustment 
of the treatment effects in a RCT. This will increase the interpretability of the treatment effect 
(corrected for any imbalance at randomization, and conditional on predictive effects) as well as 
the statistical power of tests for the treatment effect. Hence, smaller sample sizes can be used 
for the same power as an analysis which ignores predictive effects26-28. Another application of 
the models is in an analysis of treatment effect according to a ‘sliding dichotomy’29. Here, the 
dichotomization of the GOS is determined by prognosis, rather than defined the same point for 
all patients. The sliding dichotomy may also lead to better interpretation and to more statistical 
power for treatment effects in TBI patients.
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Discussion
Conclusions and recommendations
Conclusions and recommendations with regard to methods developing prognostic models 
A sensible development and validation strategy for prognostic models in TBI should pay attention to:
• The size, heterogeneity, origin and time of data collection of the study population
• The plausibility, definition and availability of the predictors
• The definition, clinical relevance and observer variability of the predicted outcome measure
• The procedures used for model development and presentation. These include type of 
model, handling of missing predictor values, selection and coding of predictors, validity of 
performance measures, and applicability of the model presentation
• The procedures used for model validation. These include internal and external validation in 
new patients.
Conclusions and recommendations with regard to predicting six-month mortality and 
unfavorable outcome after severe or moderate TBI 
• An older age is continuously associated with a worsening outcome after TBI. Hence, it is 
disadvantageous to define the effect of age on outcome in a discrete manner when aiming to 
estimate prognosis of adjust for confounding variables. 
• To predict outcome after TBI the often-used Marshall CT-classification might be replaced by 
a combination of individual CT characteristics, including the status of basal cisterns, midline 
shift, traumatic subarachnoid or intraventricular hemorrhage, and the presence of different 
types of mass lesions.
• Possible improvements of the developed models may come from less generally accepted 
predictors. Among them are blood parameters, extracranial injuries and region of treatment, 
where the latter may be a proxy for one or more unknown underlying characteristics.
• The developed prognostic models can be used reliably to classify patients according to 
prognostic risk. 
• The developed prognostic models can serve important roles in research, especially in increasing 
the efficiency of randomized clinical trials.
• When implementing the models in clinical practice, it is recommended to repeatedly assess 
the validity of predictions, and perform updating if needed. 
Conclusions and recommendations with regard to the need of specialized intensive care 
after severe or moderate TBI 
• It is difficult to accurately identify patients in need of specialized intensive care using baseline 
characteristics. Current guidelines, used for triage of TBI patients, are relatively specific in 
selecting patients in need of such care. On the other hand, these guidelines are less sensitive, 
and direct admission of more, and especially older, patients with severe or moderate TBI to 
level I trauma centers may be supported.
References
1. Chesnut R, Ghajar ��, Maas AIR, et al. Management and prognosis of severe traumatic brain       
injury. �art ��� early indicators of prognosis in severe traumatic brain injury. �� Neurotrauma  
������1���55�-���.
�. Bullock R, Chesnut R, Clifton G, et al. Management and prognosis of severe traumatic brain       
injury. �art 1�� Guidleines for the management of severe traumatic brain injury. �� Neurotrauma 
������1���451-55�.
�. Gibson RM, Stephenson GC. Aggressive management of severe closed head trauma�� time for 
reappraisal. Lancet 1�������(���5�)�����-�1. 
4. Andrews ���, Sleeman DH, Statham �F, et al. �redicting recovery in patients suffering from      
traumatic brain injury by using admission variables and physiological data�� a comparison 
between decision tree analysis and logistic regression. �� Neurosurg ��������(�)�����-��.
5. Sakellaropoulos GC, Nikiforidis GC. Development of a Bayesian Network for the prognosis of 
head injuries using graphical model selection techniques. Methods Inf Med 1��������(1)����-4�.
�. Signorini DF, Andrews ���, ��ones �A, Wardlaw ��M, Miller ��D. �redicting survival using simple 
clinical variables�� a case study in traumatic brain injury. �� Neurol Neurosurg �sychiatry 
1�������(1)����-5.
�. Choi SC, Barnes TY, Bullock R, Germanson TA, Marmarou A, Young HF. Temporal profile of 
outcomes in severe head injury. �� Neurosurg 1��4����1(�)��1��-��.  
��. Maas AIR, Braakman R, Schouten H��, Minderhoud ��M, van Zomeren AH. Agreement between  
physicians on assessment of outcome following severe head injury. �� Neurosurg 1������5��(�)����1-5.
�. Wilson ��T, �ettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and 
the extended Glasgow Outcome Scale�� guidelines for their use. �� Neurotrauma 1������15(��)��5��-��5.
1�. Harrell FE, ��r. Regression modeling strategies�� with applications to linear models, logistic 
regression and survival analysis. New York�� Springer, ���1.
11. Steyerberg EW, Eijkemans M��C, Harrell FE, ��r., Habbema ��DF. �rognostic modelling with logistic 
regression analysis�� a comparison of selection and estimation methods in small data sets. Stat 
Med ������1�(��)��1�5�-��.
1�. Little R. Regression with missing X’s�� a review. �� Am Stat Assoc 1����������1���-1���.
1�. Rubin D. Multiple Imputation for Nonresponse in Surveys. New York�� ��ohn Wiley and Sons, 
1����.
14. Titterington DM, Murray GD, Murray LS, et al. Comparison of discrimination techniques applied 
to a compex data set of head injured patients. �� Roy Stat Soc, Series A 1���1��144��145-1�5.
15. Ennis M, Hinton G, Naylor D, Revow M, Tibshirani R. A comparison of statistical learning 
methods on the Gusto database. Stat Med 1������1�(�1)���5�1-��.
1�. Clermont G, Angus DC, DiRusso SM, Griffin M, Linde-Zwirble WT. �redicting hospital mortality 
for patients in the intensive care unit�� a comparison of artificial neural networks with logistic 
regression models. Crit Care Med ���1����(�)����1-�.
1�. Borque A, Sanz G, Allepuz C, �laza L, Gil �, Rioja LA. The use of neural networks and logistic       
regression analysis for predicting pathological stage in men undergoing radical prostatectomy�� 
a population based study. �� Urol ���1��1��(5)��1���-��.
12
Chapter 9
1��. Harrell FE, ��r., Lee KL, Mark DB. Multivariable prognostic models�� issues in developing 
models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 
1�����15(4)����1-���.
1�. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index�� a reliability study. Int Disabil Stud 
1�������1�(�)���1-�.
��. Rappaport M, Hall KM, Hopkins K, Belleza T, Cope DN. Disability rating scale for severe head 
trauma�� coma to community. Arch �hys Med Rehabil 1��������(�)��11��-��.
�1. EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol 
Group. Health �olicy 1�����1�(�)��1��-����.
��. Vergouwe Y, Steyerberg EW, Eijkemans M��C, Habbema ��DF. Substantial effective sample sizes 
were required for external validation studies of predictive logistic regression models. �� Clin  
Epidemiol ���5��5��(5)��4�5-���.
��. van Houwelingen HC. Validation, calibration, revision and combination of prognostic survival        
models. Stat Med ������1�(�4)���4�1-15.  
�4. Steyerberg EW, Borsboom G��, van Houwelingen HC, Eijkemans M��C, Habbema ��DF. Validation 
and updating of predictive logistic regression models�� a study on sample size and shrinkage. 
Stat Med ���4����(1�)���5��-���.
�5. ��ustice AC, Covinsky KE, Berlin ��A. Assessing the generalizability of prognostic information. Ann 
Intern Med 1�����1��(�)��515-�4.
��. Steyerberg EW, Bossuyt �M, Lee KL. Clinical trials in acute myocardial infarction�� should we 
adjust for baseline characteristics? Am Heart �� ������1��(5)���45-51.
��. Hauck WW, Anderson S, Marcus SM. Should we adjust for covariates in nonlinear regression 
analyses of randomized trials? Control Clin Trials 1������1�(�)���4�-5�.
���. Hernandez AV, Steyerberg EW, Habbema ��DF. Covariate adjustment in randomized controlled 
trials with dichotomous outcomes increases statistical power and reduces sample size 
requirements. �� Clin Epidemiol ���4��5�(5)��454-��.   
��. Murray GD, Barer D, Choi SC, et al. Design and analysis of phase III trials with ordered outcome          
scales�� the concept of the sliding dichotomy. �� Neurotrauma ���5����(5)��511-�.
Summary
Samenvatting
Dankwoord
Curriculum vitae
14 15
Summary
Summary
This thesis describes studies on prognosis after severe or moderate traumatic brain injury (TBI). 
In Chapter 1, the clinical problem of TBI is discussed. TBI is generally defined as an injury to the 
brain caused by an external physical force, such as a traffic accident, a fall or a gunshot. TBI is 
an important public health care problem in the western world. It is one of the most common 
causes of death in young adults and it can affect people’s lives enormously. 
The focus of this thesis is on developing and validating prognostic models: statistical models that 
combine individual patient characteristics to predict the probability of a particular outcome or 
disease state. The objectives of this thesis were: (1) to study methodological developments in 
prognostic modeling in TBI; (2) to develop and validate prognostic models that predict long-
term outcome for patients with severe or moderate TBI an (3) to predict the need of specialized 
intensive care to aid a more efficient triage of patients.
Methodological developments in prognostic modeling in TBI
In Chapter 2, we systematically review 26 previously developed TBI models with the purpose 
to gain insight into methodological developments in prognostic modeling in TBI. We observed 
several shortcomings. For instance, many models were developed on old and relatively small 
patient series, originating from one single place or region. This makes the generalizability of 
these models to new patients or patients from another region questionable. Furthermore, rather 
crude statistical methods were used and the handling of missing values was often not reported 
or – if reported – patients with missing values were simply omitted from the study population. 
Before a prognostic model can reliably be applied in clinical practice, the performance of the 
model in new patients, e.g. more recent patients or patients from another region, needs to be 
studied (‘external validition’). However, the 26 models were seldom validated on more recent 
patients from the same place, and never on patients from another place. In this chapter, we 
propose guidelines to develop and validate future prognostic models in TBI (the first research 
question). These guidelines include five subjects, i.e. study population, predictors (characteristics 
that predict the outcome), outcome, model development and model validation.
Prediction of long-term outcome for patients with severe or moderate TBI
Accurate prediction of long-term outcome at baseline (in our studies: within 4 hours after 
injury) is important for several purposes. It may support clinical decision-making and provide 
realistic and evidence-based expectations to relatives (counseling) and caregivers. Outcome 
predictions may also be applied to classify patients according to prognostic risk, which may be 
useful to compare outcome between patient series from different centers or to study treatment 
results over time. Furthermore, the design and analysis of randomized clinical trials (RCTs) 
may be improved; prognostic models may be used for defining enrollment criteria and for risk-
stratification, such that covariate-adjusted treatment effects are estimated.
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Chapter 3 till 7 of this thesis describe the development and validation of prognostic models that 
predict long-term outcome after a severe or moderate TBI. Long-term outcome is often evaluated 
with the ‘Glasgow Outcome Scale’ (GOS), a five level classification scale that assesses overall 
outcome. The five categories are: ‘good recovery’ (resumption to normal life, even though there 
may be deficits), ‘moderate disability’ (disabled, but independent), ‘severe disability’ (conscious, 
but disabled), ‘vegetative state’ (awake, but not aware) and ‘death’. The GOS is often dichotomized 
into two groups: favorable and unfavorable outcome, with favorable outcome including ‘good 
recovery’ and ‘moderate disability’, and unfavorable outcome including the remaining three 
categories. Our models predict death and unfavorable outcome at six months after the injury. 
After six months, most patients are stable with respect to outcome category. 
In Chapter 3, we describe the patient characteristics of our main study population: the Tirilazad 
cohort. This cohort consists of 2269 patients with severe and moderate TBI, who were included 
in the International and North American Tirilazad trials. Despite the strict enrolment criteria, 
used to select patients for the trials, the cohort was rather heterogeneous, containing both many 
severely and many less severely injured patients. The heterogeneity in patient characteristics was 
associated with region. Furthermore, we also observed regional differences in case management. 
The variation in patient characteristics and case management may partly be explained by 
regional differences, such as differences in demography and culture or variation in local policies 
regarding trauma. Remarkably, outcome was better in patients treated in the United States than 
those treated in Europe or other countries. This difference could not be explained by differences 
in demographical and clinical patient characteristics or differences in case management.
Next, we describe the association between important predictors and long-term outcome 
(mortality and unfavorable outcome). In Chapter 4 we examine the optimal way to include age in 
a prognostic model and in Chapter 5 we consider Computed Tomography (CT) characteristics.
In Chapter 4, we perform a meta-analysis to study the association between age and outcome 
(mortality and unfavorable outcome) and observed that an older age is continuously associated with a 
worsening outcome after TBI. Hence, it is disadvantageous to define the effect of age on outcome in a 
discrete manner (using a cut-off point) when we aim to estimate prognosis or adjust for confounding 
variables. The association between age and both mortality and unfavorable outcome could be 
described adequately by a linear trem or – statistically even better – by a linear and a squared term. 
These descriptions fit the association well and are also simple to apply in clinical practice.
In Chapter 5 we study the association between different combinations of CT characteristics and 
mortality. First, we examined the Marshall CT-classification – which groups patients with TBI 
according to multiple CT characteristics, i.e. presence of intracranial abnormalities, presence of 
mass lesions, CT signs of raised intracranial pressure (status of basal cisterns, midline shift) and 
planned evacuation of mass lesions –, since this classification is often used for prognostic purposes. 
Although the Marshall CT-classification performed reasonably, performance could be improved by 
rearranging the underlying individual CT characteristics of the Marshall CT-classification. Best 
predictions may be obtained by replacing the Marshall CT-classification by an alternative set of 
CT characteristics, including the states of basal cisterns, midline shift, traumatic subarachnoid or 
intraventricular hemorrhage, and the presence of different types of mass lesions.
In Chapters 6 and 7, we address research objective 2. We assess the performance of prognostic      
models with regard to discrimination and calibration. Discrimination is the ability to distinguish 
a patient with a good outcome from a patient with a poor outcome. Perfect discrimination 
is reached if patients who die have predicted probabilities of mortality close to 100%, while 
patients who survive have predictions close to 0%. To quantify the discrimination we calculated 
the area under the receiver operating characteristic curve (AUC). A model with an AUC of 0.50 
has no discriminative power, while an AUC of 1.0 reflects perfect discrimination. Calibration 
refers to the agreement between the observed outcome frequencies (e.g. the proportion of TBI 
patients who die) in the data and the predicted probabilities that patients have the outcome (e.g. 
the predicted probability that TBI patients die) of the model. For instance, if a group of patients 
are predicted to have a 10% chance of mortality, then approximately 10 out of 100 patients 
should actually die. 
In Chapter 6, two prognostic models that predict mortality and unfavorable outcome are 
developed. Both models included the same seven predictors: i.e. age, motor score, pupillary 
reactivity, hypotension, hypoxia, the Marshall CT-classification and the presence of a traumatic 
subarachnoid haemorrhage. The models provided high discrimination between patients with 
good and poor six-month outcome (AUC=0.78 for the model predicting mortality and AUC=0.80 
for the model predicting unfavorable outcome). Calibration of both models was satisfactory. 
Before the models can reliably be used in clinical practice, they have to be validated in other 
clinical settings. Such external validation studies were performed in Chapter 6 and Chapter 7, 
using three multi-center cohorts; the EBIC (n=796), TCDB (n=746) and Selfotel cohort (n=427). 
Discrimination of the models was satisfactory in the Selfotel cohort (AUC=0.74 for both models) 
and even better in the other cohorts (AUC 0.83 to 0.89). Calibration was satisfactory in all cohorts, 
except in the TCDB cohort: in this historic cohort predicted probabilities were lower than 
observed frequencies. The poor calibration may be explained by the improvement of treatment 
standards, including trauma organization and critical care management, since the TCDB data 
collection (1984-1988). Overall, we consider the developed seven-predictor models suitable   
for clinical practice. Caution is however required, because recalibration may be necessary. To 
facilitate implementation of the models in clinical practice, we developed score charts. With 
these charts the physician can calculate the risk of a poor long-term outcome using baseline 
characteristics. 
In Chapter 7, we also assess the performance of four other models that use baseline clinical 
and CT characteristics to predict long-term mortality or unfavorable outcome after severe or 
moderate TBI. All models were externally validated on the EBIC, TCDB and Selfotel cohorts. 
The seven-predictor models had the highest discriminative abilities and best calibration. In 
a secondary analysis, we refitted the other models on the Tirilazad population, updating the 
regression coefficients (weights) of the predictors to best fit this population. This was done to 
better assess the ‘pure’ predictive value of the different combinations of predictors, excluding 
the influences of differences in study population or statistical methodology. External validation 
of the refitted models on the EBIC, TCDB and Selfotel cohort showed that performance was 
better for logistic regression models than for classification trees, and for models with more 
predictors than models with only a few predictors. 
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Need of specialized intensive care
Nowadays a high proportion of the severe and moderate TBI patients are first transported to 
a general hospital and later to a level I trauma center (secondary referral). Secondary referral, 
however, may delay the institution of appropriate therapy and increase the risk of adverse events 
and systemic insults during inter-hospital transport. 
In Chapter 8, we study whether a more efficient triage may be aided by early identification 
of patients in need of specialized intensive care (research objective 3). These patients have a 
high risk of developing surgically removable lesions or raised intracranial pressure (ICP). In a 
prospective cohort of 275 patients admitted to the neurosurgical unit of the ErasmusMC, we 
developed two prognostic models; one predicting the risk of surgically removable lesions and 
one predicting the risk of raised ICP, using baseline characteristics. We observed, however, that 
the models could only reasonably discriminate patients with and without surgically removable 
lesions (AUC=0.78 at development and AUC=0.67 at external validation in a historic sample 
of 205 patients from the Erasmus MC), and could not discriminate patients with and without 
raised ICP. Therefore, these models are not considered suitable for implementation in clinical 
practice. 
In this chapter we also compare patients primarily (73%) and secondarily referred (27%) to the 
neurosurgical unit. We observe that patients secondarily referred were older, more frequently 
injured in the domestic setting or a fall, had initially less severe clinical characteristics and 
a high incidence of both outcomes (66% surgically removable lesions and 70% raised ICP, if 
monitored). The high proportion of secondarily referred patients and the high incidence of both 
outcomes in this group of patients may support direct admission of more, and especially older, 
patients with severe or moderate TBI to specialized neurosurgical units.
This thesis ends with a general discussion of the findings of the presented studies (Chapter 9). 
Conclusions and recommendations are presented. With respect to predicting long-term 
outcome, we conclude that the developed models can be used to classify TBI patients according 
to prognostic risk. The models can serve important roles in research, especially in increasing the 
efficiency of randomized clinical trials. When implementing the models in clinical practice, it is 
recommended to repeatedly assess the validity of predictors, and perform updating if needed. 
Furthermore, we conclude that it is difficult to accurately identify patients in need of specialized 
intensive care. Current criteria, used for triage of TBI patients, are relatively specific but also 
less sensitive in selecting patients in need of such care. The latter may support direct admission 
of more patients with severe or moderate TBI to specialized neurosurgical units. For future 
model development and validation, we recommend the guidelines presented in Chapter 2, such 
that more accurate and evidence-based prognostic estimates become available for physicians 
treating individual patients with TBI. 
Samenvatting
Dit proefschrift beschrijft een aantal studies op het gebied van prognose na matig ernstig 
of ernstig traumatisch hersenletsel (THL). In hoofdstuk 1 wordt het klinische probleem van 
traumatisch hersenletsel besproken. Traumatisch hersenletsel wordt gedefinieerd als elk 
hersenletsel dat is ontstaan door een oorzaak van buitenaf, zoals een ongeval, een val of een 
schotwond. THL vormt een belangrijk volksgezondheidsprobleem in de Westerse wereld; het is 
één van de meest voorkomende doodsoorzaken bij jong volwassenen en het kan het leven en het 
functioneren van jonge mensen enorm beïnvloeden. 
De nadruk van dit proefschrift ligt op de ontwikkeling en validatie van prognostische modellen; 
statistische modellen waarin individuele patiëntkenmerken worden gecombineerd om de kans 
op een bepaalde uitkomst of ziekte status te kunnen voorspellen. De doelstellingen betroffen: 
(1) het beschrijven van methodologische ontwikkelingen ten aanzien van eerder ontwikkelde 
prognostische modellen voor THL patiënten; (2) de ontwikkeling en validatie van nieuwe 
prognostische modellen die de lange termijn gevolgen voorspellen voor patiënten met matig 
ernstig of ernstig traumatisch hersenletsel en (3) het voorspellen van de behoefte van een THL 
patiënt aan behandeling in een gespecialiseerd traumacentrum om zo de triage criteria (al dan 
niet transporteren naar een gespecialiseerd trauma centrum) te kunnen verbeteren.    
Methodologische ontwikkelingen ten aanzien van eerder ontwikkelde 
prognostische modellen
In hoofdstuk 2 wordt een overzicht (systematic review) gegeven van eerder gebruikte methodes 
voor de ontwikkeling en validatie van prognostische modellen voor THL patiënten. Hiertoe is de 
methodologie van 26 eerder ontwikkelde modellen systematisch beoordeeld. Wij constateerden 
verschillende methodologische beperkingen. Zo zijn veel modellen ontwikkeld op gegevens van 
een oud en relatief klein cohort met patiënten afkomstig uit één enkele plaats of gebied. Hierdoor 
is de validiteit van deze modellen voor nieuwe patiënten of voor patiënten uit een ander gebied 
twijfelachtig. Verder werd meestal niet aangegeven hoe is omgegaan met missende waardes 
of werden patiënten met missende waardes simpelweg verwijderd uit het cohort. Voordat een 
prognostisch model gebruikt kan worden in de klinische praktijk, dient de prestatie van het model 
te worden bestudeerd in nieuwe patiënten (externe validatie), bijvoorbeeld recentere patiënten of 
patiënten uit een ander gebied. Echter, uit de review bleek dat de eerder ontwikkelde modellen 
slechts zelden zijn gevalideerd op recentere patiënten uit hetzelfde gebied en nooit op patiënten uit 
een ander gebied. In hoofdstuk 2 worden richtlijnen voorgesteld ten aanzien van de ontwikkeling 
en validatie van toekomstige prognostische modellen. Deze richtlijnen hebben betrekking op vijf 
onderwerpen, te weten: ontwikkelpopulatie, predictoren (patiëntkarakteristieken die de uitkomst 
voorspellen), voorspelde uitkomst, model ontwikkeling en model validatie.
Het voorspellen van de lange termijn gevolgen 
Het accuraat kunnen voorspellen van de lange termijn uitkomst is van belang voor verschillende 
toepassingen, waaronder het informeren van familieleden en zorgverleners en het classificeren 
van patiënten op basis van hun prognostisch risico. Een dergelijke classificatie is bruikbaar 
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voor verschillende doeleinden, zoals het vergelijken van de uitkomst tussen verscheidene 
patiëntenseries of voor het bestuderen van behandelingsresultaten door de tijd heen, waarbij 
wordt gestratificeerd voor prognostisch risico. Daarnaast kan de opzet en analyse van 
gerandomiseerde klinische trials worden verbeterd; prognostische modellen kunnen worden 
gebruikt voor de verfijning van in- en exclusiecriteria, voor risico-stratificatie, en voor covariaat 
correctie in de statistische analyse. 
De hoofdstukken 3 tot en met 7 van dit proefschrift beschrijven de ontwikkeling en validatie van 
modellen voor het voorspellen van de lange termijn gevolgen na een traumatisch hersenletsel. 
Vaak worden de lange termijn gevolgen geëvalueerd met behulp van de ‘Glasgow Outcome Scale’ 
(GOS). Deze schaal kent vijf categorieën: ‘goed herstel’ (terugkeer naar het gewone leven, ondanks 
eventuele tekorten), ‘matige handicap’ (gehandicapt, maar onafhankelijk), ‘ernstige handicap’ 
(bewust, maar gehandicapt en afhankelijk), ‘vegetatieve status’ (geen contact met de omgeving) 
en ‘overlijden’. De GOS wordt vaak gedichotomiseerd, waarbij de eerste twee categorieën 
worden samengevoegd tot ‘gunstige uitkomst’ en de laatste drie tot ‘ongunstige uitkomst’. De 
modellen die door ons zijn ontwikkeld, voorspellen het overlijden en de ‘ongunstige uitkomst’ 
na zes maanden herstel. Na deze herstelperiode is de toestand van de meeste THL patiënten 
gestabiliseerd. 
In hoofdstuk 3 worden de patiëntkarakteristieken van ons belangrijkste studiepopulatie, 
het Tirilazad cohort, beschreven. Dit cohort bestaat uit 2269 patiënten met matig tot ernstig 
THL, geselecteerd voor de Noord-Amerikaanse en Internationale Tirilazad trials. De gebruikte 
selectiecriteria en het voorgeschreven behandelprotocol waren relatief streng. Desondanks 
bestond het cohort uit een relatief heterogene patiëntenpopulatie, met zowel zeer ernstig als 
minder ernstige patiënten. Ook werden de patiënten aanzienlijk verschillend behandeld. De 
verschillen in patiëntkarakteristieken en behandeling konden deels worden verklaard door 
regionale verschillen in demografische opbouw, cultuur en patiëntenmanagement. Opvallend is 
dat we ook een verschil in de uitkomst vonden: patiënten die werden behandeld in de Verenigde 
Staten hadden een betere uitkomst dan de patiënten behandeld in Europa. Dit uitkomstverschil 
kon niet worden verklaard door verschillen in demografische of klinische patiëntkarakteristieken 
en ook niet door verschillen in behandeling. 
In hoofdstuk 4 en 5 wordt de associatie tussen enkele belangrijke predictoren en de lange 
termijn gevolgen na traumatisch hersenletsel bestudeerd. De predictoren betreffen leeftijd 
(hoofdstuk 4) en afwijkingen op de CT-scan (hoofdstuk 5). 
In hoofdstuk 4 beschouwen we verschillende studies (meta-analyse), en vinden we een continue 
associatie tussen de leeftijd en de 6-maands uitkomst (mortaliteit en ‘ongunstige uitkomst’): hoe 
ouder de patiënt, hoe slechter de uitkomst. Door leeftijd als een continue lineaire term of als een 
continue lineaire plus een kwadratische term op te nemen, wordt de associatie op een optimale 
manier beschreven. Optimaal houdt in dat de geobserveerde data goed worden benaderd, maar 
dat de termen tevens makkelijk toepasbaar zijn in de klinische praktijk. 
Hoofdstuk 5 heeft als doel het bestuderen van de associatie tussen verschillende combinaties 
van afwijkingen op de CT-scan en de mortaliteit. Allereerst onderzochten we de Marshall 
CT-classificatie – een classificatie die patiënten met hersenletsel groepeert aan de hand van 
verschillende CT afwijkingen, zoals de aanwezigheid van grote hematomen (bloedingen > 25 cc) 
– aangezien deze classificatie vaker wordt gebruikt voor prognostische doeleinden. Alhoewel de 
Marshall CT-classificatie een redelijk goed onderscheid maakte tussen patiënten die al dan niet 
overleden, kon de discriminatie worden verbeterd door de individuele CT-afwijkingen uit de 
Marshall CT-classificatie een andere weging te geven. De mortaliteit van patiënten met matig tot 
ernstig THL werd het best voorspeld door een combinatie van de volgende afwijkingen op de CT-
scan: compressie van de basale cisternen, aanwezigheid van een ‘midline shift’, aanwezigheid 
van een subarachnoïdale en/of intraventriculaire bloedingen en verschillende typen grote 
hematomen. 
 
Hoofdstuk 6 en 7 behandelt doelstelling 2. Vanaf hoofdstuk 6 worden prognostische modellen 
ontwikkeld en gevalideerd. De kwaliteit van deze modellen bepalen we aan de hand van het 
discriminerend vermogen en de calibratie. Discriminatie heeft betrekking op het vermogen van 
het model om een patiënt met een goede uitkomst (bijvoorbeeld een patiënt die overleeft) te 
onderscheiden van een patiënt met een slechte uitkomst (een patiënt die overlijdt). In het ideale 
geval liggen de voorspelde kansen voor sterfte voor patiënten die daadwerkelijk overlijden dicht 
bij de 100% en voor patiënten die overleven dicht bij de 0%. Het discriminerend vermogen wordt 
over het algemeen gekwantificeerd met de ‘area under the receiver operating charateristics 
curve’, de AUC. Een model met een AUC van 0.50 heeft geen discriminerend vermogen, terwijl 
een AUC van 1.00 perfect discrimineert. Calibratie vergelijkt de geobserveerde uitkomst 
frequentie met de gemiddelde voorspelde kans op die uitkomst per categorie voorspelde kansen. 
Bijvoorbeeld, van een groep patiënten met gemiddeld voorspelde kans van 10% op overlijden 
zou – bij een model met goede calibratie – ongeveer 10 van de 100 patiënten daadwerkelijk 
moeten overlijden. 
In hoofdstuk 6 worden twee prognostische modellen ontwikkeld: het eerste model voorspelt 
de mortaliteit en het tweede de ‘ongunstige uitkomst’ na zes maanden herstel. Beide modellen 
gebruiken dezelfde zeven predictoren, te weten: leeftijd, motor score, pupilreactiviteit, hypotensie, 
de Marshall CT-classificatie en de aanwezigheid van een traumatische subarachnoïdale bloeding. 
De predictoren zijn allen voor of vlak na binnenkomst in het traumacentrum bepaald. Beide 
modellen presteren goed: AUC=0.78 voor het model dat de mortaliteit voorspelt en AUC=0.80 
voor het model dat de ongunstige uitkomst voorspelt. De calibratie is voldoende. Hoofdstuk 6 en 
7 beschrijft de externe validatie van de ontwikkelde modellen in drie cohorten: het EBIC (n=796), 
TCDB (n=746) en Selfotel cohort (n=427). Het discriminerend vermogen van de modellen was 
voldoende in het Selfotel cohort (AUC=0.74 voor beide modellen) en goed in de andere cohorten 
(AUC=0.83 tot 0.89). De calibratie was voldoende in alle cohorten, behalve in het TCDB cohort: 
het voorspelde risico op een slechte uitkomst was voor deze patiënten lager dan het werkelijke 
risico. Dit laatste zou verklaard kunnen worden door de periode van dataverzameling voor het 
TCDB cohort, namelijk tussen 1984 en 1988. Sinds die tijd is de behandeling van THL patiënten 
verbeterd, hetgeen het risico van een slechte uitkomst verlaagt. 
Concluderend beschouwen we de ontwikkelde zeven-predictor modellen als toepasbaar in de 
klinische praktijk. Om deze toepasbaarheid te vergemakkelijken zijn scorekaarten ontwikkeld, 
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waarmee de arts het risico op een slechte uitkomst kan berekenen. Voorzichtigheid is echter 
geboden, aangezien hercalibreren van de modellen nodig kan zijn voor een nieuwe populatie. 
In hoofdstuk 7 vergeleken we tevens de prestatie van onze zeven-predictor modellen met dat 
van vier andere eerder ontwikkelde modellen (logistische modellen en beslisbomen) die ook, 
met behulp van patiëntkarakteristieken die voor of vlak na aankomst in het traumacentrum 
zijn bepaald, de lange termijn gevolgen na een matig tot ernstig traumatisch hersenletsel 
voorspellen. Alle modellen werden extern gevalideerd in het EBIC, TCDB en Selfotel cohort. 
De zeven-predictor modellen presteerden het best, zowel wat betreft de discriminatie als 
de calibratie. In een tweede analyse werden de vier eerder ontwikkelde modellen opnieuw 
geschat op het Tirilazad cohort. Bij deze nieuwe schatting werden aan de predictoren uit het 
desbetreffende model andere wegingsfactoren toegekend op basis van het Tirilazad cohort. Het 
doel hiervan was het bepalen van de ‘werkelijke’ voorspellende waarde van de verschillende 
combinaties van predictoren, zonder verstorende invloed van verschillen in ontwikkelpopulatie 
of de gebruikte statistische methoden. Externe validatie van de opnieuw geschatte  modellen op 
het EBIC, TCDB en Selfotel cohort liet zien dat logistische regressiemodellen beter presteerden 
dan classificatiebomen (‘trees’). Modellen met meer predictoren presteerden eveneens beter dan 
modellen met slechts enkele predictoren. 
Behoefte aan behandeling in een gespecialiseerd traumacentrum
Tegenwoordig worden relatief veel patiënten met een matig tot ernstig hersenletsel eerst naar 
een perifeer ziekenhuis getransporteerd en pas later naar een neurochirurgisch traumacentrum 
(secundaire verwijzing). Secundaire verwijzing kan echter de start van een adequate behandeling 
vertragen en het risico op bijwerkingen en systemische letsels tijdens het transport tussen 
ziekenhuizen verhogen.  
In hoofdstuk 8 wordt bestudeerd of de triage efficiënter kan worden door een vroegtijdige 
identificatie van patiënten die behoefte hebben aan behandeling in een neurochirurgisch 
traumacentrum (doelstelling 3 van dit proefschrift). Deze patiënten hebben een hoog risico 
op de ontwikkeling van een operabele bloeding of een verhoogde intracraniële druk (ICP). De 
onderzoekspopulatie bestond uit 275 THL patiënten die zijn opgenomen in het gespecialiseerde 
traumacentrum van het ErasmusMC. Patiëntgegevens werden prospectief verzameld. We 
ontwikkelden twee prognostische modellen: het eerste model voorspelt het risico op operabele 
bloedingen en het tweede model het risico op verhoogde intracraniële druk. Het eerste model 
kon patiënten met en zonder operabele bloeding redelijk goed onderscheiden (AUC = 0. 78 en 
AUC = 0.67 tijdens externe validatie op een cohort van 205 THL patiënten die lang geleden in 
het traumacentrum van het ErasmusMC zijn opgenomen). Het tweede model kon echter geen 
onderscheid maken tussen patiënten met en zonder verhoogde intracraniële druk. Om de triage 
te kunnen verbeteren, dienen beide modellen goed te presteren. Aangezien dit slechts voor één 
model niet het geval is, vinden we de modellen niet geschikt voor implementatie in de klinische 
praktijk.  
In hoofdstuk 8 vergelijken we tevens de karakteristieken van de direct (73%) en secundair (27%) 
verwezen patiënten. De secundair verwezen patiënten zijn in het algemeen iets ouder, vaker 
gewond geraakt in een huiselijke omgeving of door een val en hebben bij aanvang iets minder 
ernstig letsel. De incidentie van beide uitkomstmaten is echter hoog: 66% heeft een operabele 
bloeding en 70% een verhoogde intracraniële druk (indien druk bepaald). De hoge proportie 
van secundair verwezen patiënten en de hoge incidentie van beide uitkomsten in deze groep 
patiënten zou directe verwijzing van meer, en speciaal oudere, patiënten met matig tot ernstig 
hersenletsel naar een neurochirurgisch traumacentrum kunnen ondersteunen. 
Dit proefschrift eindigt met een algemene discussie van de resultaten en het geven van conclusies 
en aanbevelingen voor toekomstig onderzoek (hoofdstuk 9). Met betrekking tot het voorspellen 
van de lange termijn gevolgen wordt geconcludeerd dat de ontwikkelde zeven-predictor modellen 
kunnen worden gebruikt voor het classificeren van THL patiënten op basis van hun prognostisch 
risico. De modellen kunnen bijvoorbeeld worden toegepast in wetenschappelijk onderzoek om 
de opzet en analyse van gerandomiseerde klinische trials te verbeteren. Bij implementatie van 
de modellen in de klinische praktijk wordt geadviseerd om regelmatig de validiteit te testen, en 
– indien nodig – de modellen aan te passen. Het voorspellen van de behoefte aan behandeling in 
een gespecialiseerd traumacentrum blijkt moeilijk te zijn. De huidige criteria voor de triage van 
THL patiënten zijn relatief specifiek. Ze zijn echter minder sensitief, hetgeen de directe verwijzing 
van meer THL patiënten zou kunnen ondersteunen. Voor toekomstig onderzoek ten aanzien van 
de ontwikkeling en validatie van prognostische modellen, wordt aanbevolen om de richtlijn uit 
hoofdstuk 2 te volgen, zodat meer nauwkeurige, door degelijk empirisch onderzoek ondersteunde, 
prognostische schattingen beschikbaar komen voor artsen en hun patiënten met THL .  
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Dankwoord
Het zit er bijna op. Jaren van data ordenen en analyseren, nieuwe technieken leren, patiëntgegevens 
verzamelen, overleg, theepauzes, bij 30∞C in fleecejack op het werk zitten vanwege de goed 
werkende airco en schrijven, schrijven en nog meer schrijven. Uiteindelijk heeft al dat werk 
geresulteerd in dit ‘boekje’. Dit proefschrift had nooit tot stand kunnen komen zonder de bijdrage 
van een groot aantal mensen die hebben meegedacht, uitgelegd en geadviseerd. Aan iedereen die 
heeft meegeholpen: bedankt! 
Een aantal mensen wil ik specifiek noemen. In de eerste plaats wil ik mijn co-promotoren, Ewout 
Steyerberg en Andrew Maas, en mijn promotor, Dik Habbema, bedanken. Ewout, jij was als 
dagelijks begeleider mijn belangrijkste aanspreekpunt en vraagbaak. Bedankt voor je scherpe 
inzichten en je kritische maar altijd waardevolle commentaar. Ik heb ongelooflijk veel van je 
geleerd! Andrew, je creativiteit en enthousiasme voor de wetenschap zijn groot. Dank voor het 
geduld dat je hebt gehad met deze niet-clinicus die telkens wilde weten hoe het ook alweer zat met 
die CT-scan en die Glasgow Coma Scale. Dik, ook al had je de rol van ‘persoon-op-de-achtergrond’, 
toch heb jij op een aantal momenten een belangrijke rol gespeeld. Bedankt voor je vriendelijke en 
doortastende begeleiding.    
Naast Ewout, Andrew en Dik wil ik ook de collega’s van MGZ bedanken voor de bereidheid om met 
mij mee te denken over allerlei inhoudelijke, methodologische en praktische zaken, maar vooral 
ook voor de leuke contacten. In het bijzonder denk ik aan mijn kamergenoten Claudine Hunault, 
Yvonne Vergouwe en Laetitia Veerbeek. Ik kijk met veel plezier terug! Bij René Eijkemans, Caspar 
Looman en Gerard Bosboom kon ik altijd binnenlopen voor een doortimmerd statistisch advies. 
Ook bij de afdeling automatisering en het secretariaat van MGZ en de afdeling neurochirurgie kon 
ik altijd terecht. Dank jullie wel! 
Anneke Rampen heeft als afstudeerstudent meegewerkt aan het onderzoek. Anneke, dank 
voor je bijdrage. De medewerkers van het neurochirurgische traumacentrum van het Erasmus 
MC, en Tineke Landman in het bijzonder, wil ik bedanken voor hun inspanningen bij de 
dataverzameling. 
I am grateful to my co-authors for the time and effort they have put in reading the manuscripts, 
and for their useful suggestions. Furthermore, I would like to thank Rodrigo Labouriau for the 
stimulating discussions. Rodrigo, it was nice to see that a Brazilian man living in Denmark liked 
a typical Dutch ‘stoofpotje’ with gingerbread so much! 
Prof.dr. C.J.J. Avezaat heeft het hele manuscript van constructief en nuttig commentaar voorzien. 
Dank hiervoor!
Het CBO, waaronder Kitty Rosenbrand en Teus van Barneveld, wil ik bedanken voor de mogelijkheid 
die ze me gaven om de laatste loodjes van dit proefschrift sneller af te ronden. Jan Wille heeft met 
behulp van een teiltje water, een pipet en vooral heel veel geduld de foto op de voorkant van dit 
proefschrift gemaakt en Albert Epping heeft met veel aandacht de lay-out van dit proefschrift 
verzorgd. Dank jullie wel! 
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Tot slot enkele woorden voor mijn (schoon)familie en vrienden, waaronder mijn paranimfen 
Dirk en Liesbeth: dank jullie wel voor de belangstelling en voor al die leuke momenten. Papa, dit 
is een mooie gelegenheid om je te bedanken voor je onvoorwaardelijke steun op alle gebieden. 
Helaas kan mama mijn promotie niet meer meemaken, maar in gedachten zal zij er ook bij zijn. 
Carl, bedankt voor al het goeds dat we samen hebben. Dat er nog maar veel moois mag volgen! 
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